var title_f40_13_41168="Bell's palsy";
var content_f40_13_41168=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bell's palsy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/13/41168/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41168/contributors\" id=\"au5042\">",
"       Michael Ronthal, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/13/41168/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41168/contributors\" id=\"se5269\">",
"       Jeremy M Shefner, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/13/41168/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41168/contributors\" id=\"de6967\">",
"       John F Dashe, MD, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/13/41168?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BELL'S PALSY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Bell's palsy is a condition in which the nerve that controls the muscles of the face becomes injured or even stops working altogether. This causes the facial muscles to become weak or paralyzed. Common signs of Bell's palsy are weakness of muscles on one side of the face, drooping eyelid or mouth on one side, or drooling from one side of the mouth (",
"     <a class=\"graphic graphic_picture graphicRef59425 \" href=\"mobipreview.htm?40/14/41189\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Bell's palsy affects about 40,000 people each year in the United States, affecting all races and both genders equally. Diabetes and pregnancy increase the risk of developing Bell's palsy.",
"    </p>",
"    <p>",
"     Most people with Bell's palsy recover completely. A minority of people continue to have some symptoms for life. If you have any signs of Bell's palsy, you should see a doctor or nurse because treatment is available. More detailed information about Bell's palsy is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36216?source=see_link\">",
"      \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=see_link\">",
"      \"Bell's palsy: Prognosis and treatment in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      BELL'S PALSY CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Bell&rsquo;s palsy is caused by an inflammation of the facial nerve. This inflammation may be caused by a virus. There is some evidence that the virus is often herpes simplex virus (HSV), the same virus that causes cold sores and genital herpes. Other viruses may also cause the condition, including herpes zoster virus, cytomegalovirus, and Epstein Barr virus. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/3/36916?source=see_link\">",
"      \"Patient information: Genital herpes (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13507?source=see_link\">",
"      \"Patient information: Shingles (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The inflammation causes swelling of a nerve that controls movement of one side of the face. The nerve, as well as tiny blood vessels near the nerve, must travel through a tight area surrounded by bone. As the nerve swells, it becomes compressed (pinched) and its protective covering breaks down, interfering with the nerve's ability to communicate with the muscles. This causes weakness or paralysis of the muscles in one side of the face. Weakness of these muscles can make it difficult to smile or close the eye.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BELL'S PALSY SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Bell's palsy causes one side of the face to be partly or completely paralyzed. This may cause:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Eyebrow sagging",
"      </li>",
"      <li>",
"       Drooping of the eye and corner of the mouth",
"      </li>",
"      <li>",
"       One eye will not close completely (",
"       <a class=\"graphic graphic_picture graphicRef59425 \" href=\"mobipreview.htm?40/14/41189\">",
"        picture 1",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In some cases, you may lose the normal ability to close one eye, which can lead to drying of the surface of the eye (the cornea). Loud noises may cause discomfort in the ear on the affected side &mdash; a condition called dysacusis. In addition, some people lose the sense of taste on the front of the tongue.",
"    </p>",
"    <p>",
"     The changes caused by Bell's palsy will affect the appearance of your face, including how you smile. These changes are often obvious to others, and can cause people with Bell's palsy to feel distressed and to avoid social activities.",
"    </p>",
"    <p>",
"     The symptoms of Bell's palsy usually appear over a period of a day or two. Most patients begin to improve within three weeks after the first symptoms begin. Improvement may continue for three to six months.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      BELL'S PALSY TESTS",
"     </span>",
"    </p>",
"    <p>",
"     Bell's palsy is usually diagnosed based on your symptoms and a physical examination. Blood and other tests are not usually needed, but doctors do sometimes test for Lyme disease, an infection that can cause weakness of the face.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      BELL'S PALSY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no cure for Bell's palsy, but treatment can help you to get better faster, especially if you can start treatment within the first few days. However, you may not have to be treated for Bell's palsy if your symptoms are mild. Talk to your doctor or nurse to ask if you should be treated.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Eye care",
"     </span>",
"     &nbsp;&mdash;&nbsp;You will need eye treatments if you cannot close your eye. If the cornea, which is the clear protective covering of the eye, becomes overly dry, there is a risk of permanent eye damage. You can use artificial tears (eye drops) as often as every hour during the day to keep the eye moist. A moisturizing ointment is usually better at night. You can use the ointment during the day, although it will make your vision blurry.",
"    </p>",
"    <p>",
"     If your eye does not close completely, you should protect it during the day with glasses or goggles. Use a patch over your eye at night, but be sure not to use tape on your eyelid since the patch could slip and scratch the cornea.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people who are diagnosed with Bell's palsy quickly (within 2 to 3 days of the first symptoms) are treated with steroids (eg, prednisone) for one week. Steroids, also called glucocorticoids, can reduce swelling and improve your chances of recovering completely [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/13/41168/abstract/1\">",
"      1",
"     </a>",
"     ]. These medicines work best when started early (within three days of the first symptoms). Antiviral medicines (eg, valacyclovir, Valtrex&reg;) are sometimes used in conjunction with glucocorticoids, but controlled trials have not found an added benefit from the use of these agents.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;You will need a follow up visit with your doctor or nurse after you start treatment. At this visit, you will have an examination and you can discuss any questions or problems.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      RECOVERY FROM BELL'S PALSY",
"     </span>",
"    </p>",
"    <p>",
"     In general, people whose paralysis is less severe tend to recover more completely. If symptoms begin to improve within the first 21 days, the chances are also good that you will recover and have little or no remaining weakness in the muscles of the face. However, a small number of people are left with moderate to severe muscle weakness that is permanent. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=see_link\">",
"      \"Bell's palsy: Prognosis and treatment in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If the damage to the nerve is severe, it may heal and grow back in a disorganized fashion. When this happens, your ability to control separate facial movements may be lost. For example:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       When you blink your mouth may twitch",
"      </li>",
"      <li>",
"       Smiling may cause your eye to close",
"      </li>",
"      <li>",
"       When you salivate (eg, before eating), tears may flow from one eye",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A second or third attack of Bell's palsy is uncommon, but has been reported in 7 to 15 percent of people [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/13/41168/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804564440\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23445352\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/13/32977?source=see_link\">",
"      Patient information: Bell's palsy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/14/14562?source=see_link\">",
"      Patient information: Myasthenia gravis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23445369\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/3/36916?source=see_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13507?source=see_link\">",
"      Patient information: Shingles (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36216?source=see_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=see_link\">",
"      Bell's palsy: Prognosis and treatment in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/bellspalsy.html\">",
"      www.nlm.nih.gov/medlineplus/bellspalsy.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/bells/detail_bells.htm\">",
"      www.ninds.nih.gov/disorders/bells/detail_bells.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       AAO-HNS American Academy of Otolaryngology&ndash;Head and Neck Surgery",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.entnet.org/HealthInformation/bellsPalsy.cfm\">",
"      www.entnet.org/HealthInformation/bellsPalsy.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/13/41168/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/13/41168?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41168/abstract/1\">",
"      Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007; 357:1598.",
"     </a>",
"    </li>",
"    <li>",
"     May, M. The Facial Nerve, Thieme, New York 1986..",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41168/abstract/3\">",
"      Peitersen E. The natural history of Bell's palsy. Am J Otol 1982; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41168/abstract/4\">",
"      Allen D, Dunn L. Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2004; :CD001869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41168/abstract/5\">",
"      Holland NJ, Weiner GM. Recent developments in Bell's palsy. BMJ 2004; 329:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41168/abstract/6\">",
"      Ruckenstein MJ. Evaluating facial paralysis. Expensive diagnostic tests are often unnecessary. Postgrad Med 1998; 103:187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_13_41168=[""].join("\n");
var outline_f40_13_41168=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BELL'S PALSY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           BELL'S PALSY CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BELL'S PALSY SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           BELL'S PALSY TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           BELL'S PALSY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           RECOVERY FROM BELL'S PALSY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/14/41189\" title=\"picture 1\">",
"           Bells palsy photos PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_13_41169="Acute dysphagia child";
var content_f40_13_41169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Acute dysphagia in children and no fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 789px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system.",
"     <br>",
"      * Conditions include botulism, mayasthenia gravis, cerebral palsy, and Miller Fisher syndrome.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41169=[""].join("\n");
var outline_f40_13_41169=null;
var title_f40_13_41170="Phase contrast micrograph showing dysmorphic red cells in urine";
var content_f40_13_41170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79440%7ENEPH%2F62064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79440%7ENEPH%2F62064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phase contrast micrograph showing dysmorphic red cells in urine sediment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Phase contrast microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hans K&ouml;hler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scanning electron micrograph showing dysmorphic red cells in urine sediment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scanning microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hans K&ouml;hler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41170=[""].join("\n");
var outline_f40_13_41170=null;
var title_f40_13_41171="WHO weight for length boys 0 to 24 months";
var content_f40_13_41171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Weight-for-length percentiles, boys 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 508px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41171=[""].join("\n");
var outline_f40_13_41171=null;
var title_f40_13_41172="Ezogabine: Drug information";
var content_f40_13_41172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ezogabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/59/43956?source=see_link\">",
"    see \"Ezogabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13365445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Potiga&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12915691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Neuronal Potassium Channel Opener",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13371903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Partial-onset seizures, adjunct:",
"     </b>",
"     Oral: Initial: 100 mg 3 times/day; may increase at weekly intervals in increments of &le;150 mg/day to a maintenance dose of 200-400 mg 3 times/day (maximum: 1200 mg/day). In clinical trials, no additional benefit and an increase in adverse effects was observed with doses &gt;900 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13371899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Partial-onset seizures, adjunct:",
"     </b>",
"     Oral: Initial: 50 mg 3 times/day; may increase at weekly intervals in increments of &le;150 mg/day to a maximum daily dose of 750 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13371901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Initial: 50 mg 3 times/day; may increase at weekly intervals in increments of &le;150 mg/day to a maximum daily dose of 600 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ESRD requiring hemodialysis: Initial: 50 mg 3 times/ day; may increase at weekly intervals in increments of &le;150 mg/day to a maximum daily dose of 600 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13371900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment (Child-Pugh &le;7): No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment (Child-Pugh 7-9): Initial: 50 mg 3 times/day; may increase at weekly intervals in increments of &le;150 mg/day to a maximum daily dose of 750 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh &gt;9): Initial: 50 mg 3 times/day; may increase at weekly intervals in increment of &le;150 mg/day to a maximum daily dose of 600 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14266245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Potiga&trade;: 50 mg, 200 mg, 300 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14274793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F14263398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13365443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM259619.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM259619.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13371904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered with or without food; swallow tablets whole. If therapy is discontinued, gradually reduce dose over &ge;3 weeks unless safety concerns require abrupt withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12915694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjuvant treatment of partial-onset seizures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13365441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ezogabine may be confused with ezetimibe.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potiga&trade; may be confused with Portia&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13365507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Dizziness (dose related; 23%), somnolence (dose related; 22%), fatigue (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Confusion (dose related; 9%), vertigo (8%), coordination impaired (dose related; 7%), attention disturbance (6%), memory impairment (dose related; 6%), aphasia (dose related; 4%), balance disorder (dose related; 4%), anxiety (3%), amnesia (2%), disorientation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (7%), constipation (dose related; 3%), weight gain (dose related; 3%), dysphagia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Diplopia (7%), blurred vision (dose related; 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tremor (dose related; 8%), weakness (5%), abnormal gait (dose related; 4%), dysarthria (4%), paresthesia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Chromaturia (dose related; 2%), dysuria (dose related; 2%), hematuria (2%), urinary hesitation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Alopecia, appetite increased, coma, dyspnea, encephalopathy, euphoria, hallucinations, hydronephrosis, hyperhidrosis, hypokinesia, leukopenia, liver enzymes increased, malaise , muscle spasms, myoclonus, nephrolithiasis, neutropenia, nystagmus, peripheral edema, psychotic disorder, rash, renal colic, syncope, thrombocytopenia, urinary retention, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13365450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13365451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Dose-related dizziness and somnolence (generally mild-to-moderate) have been reported; effects generally occur during dose titration and appear to diminish with continued use.  Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders: Dose-related neuropsychiatric disorders, including confusion, psychotic symptoms, and hallucinations, have been reported, generally within the first 8 weeks of treatment; some patients required hospitalization. Symptoms resolved in most patients within 7 days of discontinuation of ezogabine. The risk appears to be greatest with rapid titration at greater than the recommended doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: QT prolongation has been observed; monitor ECG in patients with electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), hypothyroidism, familial long QT syndrome, concomitant medications which may augment QT prolongation, or any underlying cardiac abnormality which may also potentiate risk (eg, congestive heart failure, ventricular hypertrophy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary retention: Urinary retention, including retention requiring catheterization, has been reported, generally within the first 6 months of treatment. All patients should be monitored for urologic symptoms; close monitoring is recommended in patients with other risk factors for urinary retention (eg, benign prostatic hyperplasia), patients unable to communicate clinical symptoms, or patients who use concomitant medications that may affect voiding (eg, anticholinergics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Dosage adjustment recommended in hepatic impairment; ezogabine exposure increases in moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dosage adjustment recommended in renal impairment; ezogabine undergoes significant renal elimination.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly due to potential for urinary retention, particularly in older men with symptomatic BPH. Systemic exposure is increased in the elderly; dosage adjustment is recommended in patients &ge;65 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually over a period of &ge;3 weeks to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13365446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13365447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Patients exposed to ezogabine during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13365448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13365449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13365536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Potiga Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (90): $356.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (90): $712.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (90): $712.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (90): $712.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13371907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizures; electrolytes, bilirubin, ALT, AST, serum creatinine, QT interval; urinary retention; observe patient for excessive sedation, confusion, psychotic symptoms, and hallucinations; suicidality (eg, suicidal thoughts, depression, behavioral changes); evaluate for signs/symptoms of ezogabine toxicity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13365970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ezogabine binds the KCNQ (Kv7.2-7.5) voltage-gated potassium channels, thereby stabilizing the channels in the open formation and enhancing the M-current.  As a result, neuronal excitability is regulated and epileptiform activity is suppressed. In addition, ezogabine may also exert therapeutic effects through augmentation of GABA-mediated currents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13371878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 2-3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Ezogabine: 80%; N-acetyl active metabolite (NAMR): 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Glucuronidation via UGT1A4, UGT1A1, UGT1A3, and UGT1A9 and acetylation via NAT2 to an N-acetyl active metabolite (NAMR) and other inactive metabolites (eg, N-glucuronides, N-glucoside)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Ezogabine and NAMR: 7-11 hours; increased by ~30% in elderly patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 0.5-2 hours; delayed by 0.75 hours when administered with high-fat food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (85%, 36% of total dose as unchanged drug, 18% of total dose as NAMR); feces (14%, 3% of total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brodie MJ, Lerche H, Gil-Nagel A, et al, &ldquo;Efficacy and Safety of Adjunctive Ezogabine (Retigabine) In Refractory Partial Epilepsy,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2010, 75(20:1817-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41172/abstract-text/20944074/pubmed\" id=\"20944074\" target=\"_blank\">",
"        20944074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferron GM, Paul J, Fruncillo R, et al, &ldquo;Multiple-Dose, Linear, Dose-Proportional Pharmacokinetics of Retigabine in Healthy Volunteers,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2002, 42(2):175-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41172/abstract-text/11831540/pubmed\" id=\"11831540\" target=\"_blank\">",
"        11831540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French JA, Abou-Khalil BW, Leroy RF, et al, &ldquo;Randomized, Double-Blind, Placebo-Controlled Trial of Ezogabine (Retigabine) in Partial Epilepsy,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(18):1555-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41172/abstract-text/21451152/pubmed\" id=\"21451152\" target=\"_blank\">",
"        21451152",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stephen LJ and Brodie MJ, &ldquo;Pharmacotherapy of Epilepsy: Newly Approved and Developmental Agents,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2011, 25(2):89-107.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41172/abstract-text/21254787/pubmed\" id=\"21254787\" target=\"_blank\">",
"        21254787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16789 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41172=[""].join("\n");
var outline_f40_13_41172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365445\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12915691\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371903\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371899\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371901\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371900\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14266245\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14274793\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14263398\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365443\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371904\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12915694\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365441\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365507\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365450\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365451\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365446\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365447\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365448\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365449\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365536\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322905\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371907\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365970\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371878\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16789|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/59/43956?source=related_link\">",
"      Ezogabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_13_41173="Pelvis PI";
var content_f40_13_41173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 660px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the location of the pelvis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41173=[""].join("\n");
var outline_f40_13_41173=null;
var title_f40_13_41174="Neuroendocrine cancer of unknown primary site";
var content_f40_13_41174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuroendocrine cancer of unknown primary site",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     John D Hainsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     F Anthony Greco, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     Jonathan R Strosberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41174/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/13/41174/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of unknown primary site (CUP) is a relatively common clinical entity, accounting for 4 to 5 percent of all invasive cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/1\">",
"     1",
"    </a>",
"    ]. Within this category, tumors from many primary sites with varying biology are represented. Neuroendocrine tumors constitute less than 5 percent of all CUPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14758?source=see_link\">",
"     \"Overview of the classification and management of cancers of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that differ in biologic behavior, histologic appearance, and response to treatment (",
"    <a class=\"graphic graphic_table graphicRef76723 \" href=\"mobipreview.htm?11/46/12011\">",
"     table 1",
"    </a>",
"    ). Several types of NETs (eg, carcinoid tumors, pancreatic neuroendocrine tumors, medullary thyroid cancers, pheochromocytomas) are characterized by slow growth and frequent secretion of hormones or vasoactive substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In most cases, these tumors also have typical histologic appearance and are accurately diagnosed with standard pathologic methods (light microscopy and immunohistochemical staining). Other NETs, typified by small cell carcinoma of the lung, are highly aggressive neoplasms, and are usually advanced when diagnosed.",
"   </p>",
"   <p>",
"    NETs of unknown primary site are relatively uncommon, accounting for 10 to 13 percent of all NETs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of over 35,000 patients diagnosed with neuroendocrine tumors over a 31-year period (most had well differentiated tumors arising from the gastrointestinal tract), a primary site could not be found or classified in only 13 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 750 patients with NET seen over a 24-year period at a single institution, 82 (10 percent) were of unknown primary site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When NETs are recognized histologically in patients with CUP (usually due to the presence of carcinoid-type features), the majority are well differentiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/7\">",
"     7",
"    </a>",
"    ]. However, additional NETs presenting as CUP are recognized histologically only as small cell undifferentiated or poorly differentiated carcinoma, and the definitive diagnosis of NET is made only after immunohistochemical (IHC) stains are performed.&nbsp;These poorly differentiated cancers are characterized by multiple sites of metastases and rarely produce symptoms related to secretion of bioactive substances. Accurate distinction of well differentiated, indolent tumors from poorly differentiated, aggressive tumors is important, since treatment approaches are different.",
"   </p>",
"   <p>",
"    This review will cover the evaluation and treatment of patients with biopsy-proven metastatic NETs of unknown primary. The diagnostic workup of rare patients who present with symptoms suggestive of an underlying neuroendocrine hormonal syndrome (eg flushing, diarrhea, hypoglycemia, hyperglycemia) is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=see_link&amp;anchor=H6984431#H6984431\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Functionality and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systems for the histologic and anatomic classification of NETs at various body sites have been proposed. Although differences exist, all systems separate NETs on the basis of tumor grade (assessed by mitotic rate and Ki67 index) and differentiation into two broad categories: well differentiated (indolent) and poorly differentiated (aggressive) (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"mobipreview.htm?17/14/17644\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-differentiated NETs are subdivided in the WHO classification system into low grade (grade 1) and intermediate grade (grade 2), according to the proliferative rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The term &ldquo;atypical carcinoid&rdquo; is reserved for intermediate grade carcinoid tumor arising in the lung. Clinical behavior of grade 1 and 2 NETs are relatively indolent, and the management considerations are similar.",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas are high-grade tumors. Some of these have histology similar to small cell carcinoma of the lung; a large cell neuroendocrine variant also exists. Other poorly differentiated neuroendocrine carcinomas lack morphologic features of neuroendocrine differentiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/10\">",
"       10",
"      </a>",
"      ]. Diagnosis of these neuroendocrine tumors depends on immunohistochemical staining for chromogranin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      synaptophysin, or identification of neurosecretory granules by electron microscopy. Either of these histologic appearances can be present in patients with neuroendocrine tumors of unknown primary site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This classification is highly appropriate for identifying the best therapeutic approach. (See",
"    <a class=\"local\" href=\"#H7120407\">",
"     'Evaluation and management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    NETs of unknown primary, especially the well differentiated ones, often present initially with liver metastases, and most of these represent gastroenteropancreatic NETs. Histologic grade may be the only prognostic parameter available for this group of metastatic tumors. The uniform grading scheme for gastroenteropancreatic tumors, as established by the European Neuroendocrine Tumor Society (ENETS) and the World Health Organization (WHO), applies to this category unless a different primary site is found (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"mobipreview.htm?17/14/17644\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Just as immunohistochemistry can aid in identifying a tumor as having a neuroendocrine origin, it may also help to localize the site of origin. Thyroid transcription factor-1 (TTF-1) is expressed in most poorly differentiated neuroendocrine carcinomas and some well differentiated NETs of lung origin, while CDX2 may be expressed in well differentiated NETs of intestinal origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more detailed discussion of pathology and classification of NETs arising in the digestive tract is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7120407\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections will describe evaluation and management based upon the histologic pattern and clinical features of the neuroendocrine tumor of unknown primary site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Well-differentiated neuroendocrine tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with well differentiated neuroendocrine tumor of unknown primary site usually have liver metastases, and clinical syndromes from tumor production of bioactive substances may be apparent. In one series of 82 patients With NET of unknown primary site (70 well-differentiated), carcinoid syndrome was present in 14 (17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/7\">",
"     7",
"    </a>",
"    ]. The presence of the carcinoid syndrome usually suggests a small intestinal primary carcinoid, although pancreatic neuroendocrine tumors and bronchial carcinoids can occasionally secrete serotonin and other vasoactive substances associated with the carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146371\">",
"    <span class=\"h3\">",
"     Initial workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation should include cross sectional imaging, somatostatin receptor scintigraphy (OctreoScan&trade;), and assay for urine tumor markers in patients who have clinical symptoms or signs of a functioning tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT may identify a primary site in the luminal gastrointestinal (GI) tract or pancreas. In one series, among patients with liver metastases, CT was much more effective in localizing a primary tumor of the pancreas than of the GI tract, presumably because the average size of the pancreatic primaries was larger than both small and large bowel tumors (7.5 versus 1.7 and 3.8 cm, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Mesenteric masses are usually indicative of a primary tumor located in the small intestine. Most metastatic carcinoid patients whose scans feature a typical-appearing mesenteric mass (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72556 \" href=\"mobipreview.htm?6/28/6599\">",
"       image 1",
"      </a>",
"      ) can be presumptively considered to have a small intestinal primary and should be treated according to guidelines for metastatic small intestinal carcinoid tumors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link&amp;anchor=H3#H3\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 80 percent of NETs of unknown primary site including non-functioning islet cell tumors and carcinoids, have high concentrations of somatostatin receptors, and can be imaged using a radiolabeled form of the somatostatin analog",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      (indium-111 [111-In] pentetreotide) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/7\">",
"       7",
"      </a>",
"      ]. Somatostatin receptor scintigraphy (SRS; Octreoscan) may provide information regarding primary tumor location (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62072 \" href=\"mobipreview.htm?41/44/42703\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      MRI is an alternative imaging technique to CT and SRS that may be preferred by some clinicians; it is more sensitive than either CT or SRS for the presence of liver metastases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link&amp;anchor=H262522974#H262522974\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Cross-sectional imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If a primary site cannot be identified through these imaging modalities, upper and lower endoscopy (with attention to the terminal ileum) should be performed. While video capsule endoscopy allows for evaluation of the entire small intestine, routine use of capsule endoscopy cannot be recommended due to the risk of bowel obstruction from retention of the capsule at the site of an intestinal carcinoid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/13\">",
"       13",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      The advent of new systemic treatment options for pancreatic neuroendocrine tumors provides an additional impetus to identify an occult pancreatic primary site. Endoscopic ultrasonography (EUS) represents the most sensitive method for identification of a primary pancreatic tumor in patients with liver metastases who are lacking evidence of a small-intestinal primary (such as a mesenteric mass or symptoms of carcinoid syndrome) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=see_link&amp;anchor=H190949033#H190949033\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Pancreatic NET'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have symptoms suggestive of carcinoid syndrome, elevated urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) are highly specific for serotonin-producing carcinoid tumors (eg, those arising in the small bowel). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Biochemical testing for the carcinoid syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7121028\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-differentiated NETs of unknown primary site are usually approached similarly to well-differentiated NETs (carcinoids) of the gastrointestinal tract. Depending upon the clinical situation, appropriate management may include local therapy (eg, resection of isolated metastasis, hepatic arterial embolization), or systemic therapy (eg, with the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    ). Patients with clinical features suggestive of a functioning pancreatic NET should be considered for a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=see_link\">",
"     \"Treatment of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Poorly differentiated neuroendocrine carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with poorly differentiated neuroendocrine carcinomas of unknown primary typically present with widespread metastases. In addition to the liver, common metastatic sites include bone, lung and brain. Histological variants include small cell and large cell neuroendocrine carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146364\">",
"    <span class=\"h3\">",
"     Initial workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation should include cross sectional imaging of the chest, abdomen, and pelvis (CT or MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/19\">",
"     19",
"    </a>",
"    ]. Fluorodeoxyglucose (FDG)-PET scanning is a sensitive imaging modality due to the high metabolic rate of poorly differentiated neuroendocrine carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/20\">",
"     20",
"    </a>",
"    ]. On the other hand, somatostatin receptor scintigraphy is relatively insensitive and is not recommended in this setting. Brain MRI should be considered due to the high risk of CNS metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If cross sectional imaging is negative, bronchoscopy may be helpful since small cell tumors frequently originate in the lungs. However, small cell tumors can arise in other parts of the body, and the patient&rsquo;s symptoms should be used to guide further studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146401\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of metastatic poorly differentiated neuroendocrine carcinomas does not vary significantly based on primary site and therefore an intensive workup to identify a primary site is not warranted. Treatment generally parallels that of extensive stage small cell lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    High response rates (approximately 66 percent) have been well documented using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    in patients with poorly differentiated neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Similar high response rates have been seen in patients with poorly differentiated neuroendocrine carcinomas of unknown primary site, and this represents a standard approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/19\">",
"     19",
"    </a>",
"    ]. In the largest published series containing 99 patients, a response rate of 70 percent was observed with",
"    <span class=\"nowrap\">",
"     platinum/etoposide-based",
"    </span>",
"    chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of a three drug combination (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and etoposide) resulted in a similar response rate but greater toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41174/abstract/24\">",
"     24",
"    </a>",
"    ]. Systemic treatment for poorly differentiated neuroendocrine carcinoma is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=see_link&amp;anchor=H190949019#H190949019\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Poorly differentiated tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroendocrine tumors of unknown primary site should be classified as well-differentiated or poorly differentiated (",
"      <a class=\"graphic graphic_table graphicRef60365 \" href=\"mobipreview.htm?17/14/17644\">",
"       table 2",
"      </a>",
"      ). The biologic behavior of these two entities differs remarkably, and the distinction is important for planning therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathologic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most well-differentiated neuroendocrine tumors of unknown primary site present with liver metastases. In some patients, the primary site is subsequently identified in the intestinal tract or the pancreas. Patients with mesenteric masses on imaging scans and no evidence of disease on upper or lower endoscopy can be considered to have small-intestinal primary tumors, and should be treated according to guidelines for small intestinal carcinoid tumors. (See",
"      <a class=\"local\" href=\"#H7120407\">",
"       'Evaluation and management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The initial evaluation of these patients should include cross-sectional imaging, usually with CT, and somatostatin receptor scintigraphy (OctreoScan&trade;) to assist with primary localization. If a primary site cannot be identified through these imaging modalities, upper and lower endoscopy (with attention to the terminal ileum) should be performed. Endoscopic ultrasonography can be used to rule out an occult pancreatic primary tumor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Well-differentiated neuroendocrine tumor'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients who have symptoms suggestive of carcinoid syndrome, elevated urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) are highly specific for serotonin-producing carcinoid tumors (eg, those arising in the small bowel). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Biochemical testing for the carcinoid syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If a primary site cannot be identified, we recommend that these patients be managed like those with metastatic non-pancreatic well-differentiated neuroendocrine tumors (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Well-differentiated neuroendocrine tumor'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with high-grade neuroendocrine carcinomas generally have biologically aggressive tumors. Most either present with or rapidly develop disseminated disease. We recommend first-line treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , following treatment guidelines for small and large cell neuroendocrine tumors of the lung (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Poorly differentiated neuroendocrine carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Greco FA, Hainsworth JD. Cancer of unknown primary site. In: Cancer: Principles and Practice of Oncology, DeVita VT Jr, Hellman S, Rosenberg SA (Eds), JB Lippincott, Philadelphia 2011. p.2033.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/2\">",
"      Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol 2009; 36:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/3\">",
"      Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/4\">",
"      Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/5\">",
"      Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2008; 2:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/6\">",
"      Yao JC, Hassan M, Phan A, et al. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/7\">",
"      Catena L, Bichisao E, Milione M, et al. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms? Tumori 2011; 97:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/8\">",
"      Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.",
"     </a>",
"    </li>",
"    <li>",
"     Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/10\">",
"      Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988; 109:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/11\">",
"      Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009; 36:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/12\">",
"      Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/13\">",
"      Strosberg JR, Shibata D, Kvols LK. Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. Can J Gastroenterol 2007; 21:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/14\">",
"      Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/15\">",
"      R&ouml;sch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/16\">",
"      Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000; 95:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/17\">",
"      Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/18\">",
"      Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/19\">",
"      Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/20\">",
"      Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging 2010; 10 Spec no A:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/21\">",
"      Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010; 39:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/22\">",
"      Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/23\">",
"      Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41174/abstract/24\">",
"      Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24:3548.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4876 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-F6CCE2A0D3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41174=[""].join("\n");
var outline_f40_13_41174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7120407\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Well-differentiated neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1146371\">",
"      - Initial workup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7121028\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Poorly differentiated neuroendocrine carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1146364\">",
"      - Initial workup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1146401\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4876\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4876|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/28/6599\" title=\"diagnostic image 1\">",
"      Coronal CT met well-differentiated NET with mesenteric mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/44/42703\" title=\"diagnostic image 2\">",
"      Primary ileal NET somatostatin receptor scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4876|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/46/12011\" title=\"table 1\">",
"      Neuroendocr tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/14/17644\" title=\"table 2\">",
"      Nomenclature and classification for neuroendocrine tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14758?source=related_link\">",
"      Overview of the classification and management of cancers of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=related_link\">",
"      Treatment of the carcinoid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_13_41175="Calcium gluconate: Pediatric drug information";
var content_f40_13_41175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium gluconate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"    see \"Calcium gluconate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/2/5157?source=see_link\">",
"    see \"Calcium gluconate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6026083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cal-G [OTC] [DSC];",
"     </li>",
"     <li>",
"      Cal-GLU&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1003045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Hydrofluoric Acid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     of",
"     <b>",
"      elemental calcium",
"     </b>",
"     ; requirements may vary on prematurity, postnatal age, and other clinical factors; serum calcium concentrations should be monitored closely to determine patient-specific needs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Daily maintenance calcium:",
"     </b>",
"     I.V.: 3-4",
"     <b>",
"      mEq",
"     </b>",
"     /kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cardiac arrest in the presence of hyperkalemia or hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity:",
"     </b>",
"     Dosage expressed in mg of calcium gluconate: I.V., I.O.: 60-100 mg/kg/dose; may repeat in 10 minutes if necessary; if effective, consider I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Dose expressed in mg of",
"     <b>",
"      calcium gluconate",
"     </b>",
"     : 200-800 mg/kg/day as a continuous infusion or in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dose expressed in mg of",
"     <b>",
"      elemental calcium",
"     </b>",
"     : 50-150 mg/kg/day in 4-6 divided doses; not to exceed 1000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dose expressed in mg of",
"     <b>",
"      calcium gluconate",
"     </b>",
"     : 500-1500 mg/kg/day in 4-6 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia secondary to citrated blood infusion:",
"     </b>",
"     I.V.: 0.45",
"     <b>",
"      mEq elemental calcium",
"     </b>",
"     for each 100 mL citrated blood infused",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tetany:",
"     </b>",
"     Dose expressed in mg of",
"     <b>",
"      calcium gluconate",
"     </b>",
"     : I.V.: 100-200 mg/kg/",
"     <b>",
"      dose",
"     </b>",
"     ; over 5-10 minutes; may repeat after 6 hours or follow with an infusion with a maximum dose of 500 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1003071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"      see \"Calcium gluconate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral: Dosage expressed in terms of",
"     <b>",
"      elemental calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-6 months: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7-12 months: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral: Dosage expressed in terms of",
"     <b>",
"      elemental calcium;",
"     </b>",
"     during pregnancy and lactation, requirements may change:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-18 years: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Daily maintenance calcium:",
"     </b>",
"     I.V.: Dosage expressed in terms of",
"     <b>",
"      elemental calcium",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &lt;25 kg: 1-2 mEq/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 25-45 kg: 0.5-1.5 mEq/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;45 kg and Adolescents: 0.2-0.3 mEq/kg/",
"     <b>",
"      day",
"     </b>",
"     or 10-20 mEq/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Parenteral nutrition, maintenance requirement",
"     </b>",
"     (Mirtallo, 2004): I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &le;50 kg:  0.5-4 mEq/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt; 50 kg and Adolescents: 10-20 mEq/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Dose expressed as",
"     <b>",
"      elemental calcium",
"     </b>",
"     : 45-65 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 4 divided doses; maximum daily dose range: 1000-2000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Dose expressed as",
"     <b>",
"      calcium gluconate",
"     </b>",
"     : 500-725 mg/kg/day in 3-4 divided doses; maximum daily dose range: 500-2000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: Dose expressed as",
"     <b>",
"      calcium gluconate",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants and Children: 200-500 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     as a continuous infusion or in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: 200-500 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     as a continuous infusion or in divided doses; maximum daily dose range: 2000 mg to 15",
"     <b>",
"      g/day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cardiac arrest in the presence of hyperkalemia or hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity:",
"     </b>",
"     I.V., I.O.: Dosage expressed in mg of",
"     <b>",
"      calcium gluconate",
"     </b>",
"     : 60-100 mg/kg/dose (maximum dose: 3000 mg); may repeat in 10 minutes if necessary; if effective, consider I.V. infusion (Hegenbarth, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Routine use in cardiac arrest is not recommended due to the lack of improved survival (PALS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Calcium channel blocker toxicity; hypotension/conduction disturbances:",
"     </b>",
"     I.V., I.O. Dosage expressed in mg of",
"     <b>",
"      calcium gluconate",
"     </b>",
"     : 60 mg/kg/dose administered over 30-60 minutes (Hegenbarth, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Calcium chloride may provide a more rapid increase of ionized calcium in critically ill children. Calcium gluconate may be substituted if calcium chloride is not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypocalcemia secondary to citrated blood infusion:",
"     </b>",
"     I.V.: 0.45",
"     <b>",
"      mEq elemental calcium",
"     </b>",
"     for each 100 mL citrated blood infused",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Tetany:",
"     </b>",
"     I.V.: Dose expressed as",
"     <b>",
"      calcium gluconate",
"     </b>",
"     : 100-200 mg/kg/",
"     <b>",
"      dose",
"     </b>",
"     ; over 5-10 minutes; may repeat after 6 hours or follow with an infusion with a maximum dose of 500 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Dosages are expressed in terms of the",
"     <b>",
"      calcium gluconate salt",
"     </b>",
"     (unless otherwise specified as elemental calcium). Dosages expressed in terms of the c",
"     <b>",
"      alcium gluconate salt",
"     </b>",
"     are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg)/mL elemental calcium, except where noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Expressed in terms of elemental calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females/Males: RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     19-50 years: 1000 mg elemental calcium daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;51 years, females: 1200 mg elemental calcium daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     51-70 years, males: 1000 mg elemental calcium daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermittent I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Mild [ionized calcium: 4-5 mg/dL (1-1.2 mmol/L)]: 1000-2000 mg over 2 hours; asymptomatic patients may be given oral calcium (Ariyan, 2004; French, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Moderate to severe [without seizure or tetany; ionized calcium: &lt;4 mg/dL (&lt;1 mmol/L)]: 4000 mg over 4 hours (French, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Severe symptomatic (eg, seizure, tetany): 1000-2000 mg over 10 minutes; repeat every 60 minutes until symptoms resolve (French, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Repeat ionized calcium measurement 6-10 hours after completion of administration. Check for hypomagnesemia  and correct if present. Consider continuous infusion if hypocalcemia is likely to recur due to ongoing losses (French, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous I.V. infusion: 5-20 mg/kg/hour (Pai, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Cardiac arrest or cardiotoxicity in the presence of hyperkalemia, hypocalcemia, or hypermagnesemia:",
"     </b>",
"     I.V.: 1500-3000 mg over 2-5 minutes (Vanden Hoek, 2010);",
"     <b>",
"      Note:",
"     </b>",
"     Routine use in cardiac arrest is not recommended due to the lack of improved survival (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Maintenance electrolyte requirements for parenteral nutrition:",
"     </b>",
"     I.V. (Mirtallo, 2004):",
"     <b>",
"      Note:",
"     </b>",
"     Expressed in terms of elemental calcium: 10-20 mEq daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute may require dosage adjustment depending upon serum calcium level",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-G: 700 mg [DSC] [gluten free; equivalent to elemental calcium 65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-GLU&trade;: 515 mg [dye free, sugar free; equivalent to elemental calcium 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10% (10 mL, 50 mL, 100 mL) [equivalent to elemental calcium 9.3 mg (0.465 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral: (480 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg [equivalent to elemental calcium 45 mg], 648 mg [equivalent to elemental calcium 60 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1003076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with plenty of fluids with or following meals; for phosphate-binding, administer on an empty stomach before meals to optimize effectiveness; powder may be added to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.:  For direct I.V. injection, infuse slow IVP over 3-5 minutes or at a maximum rate of 50-100 mg calcium gluconate/minute; in situations of cardiac arrest, calcium gluconate may be administered over 10-20 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. infusion: May further dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; a maximum concentration of 50 mg/mL has been used by some centers; infuse at a rate not to exceed 200 mg/minute.  Do not inject calcium salts I.M. or administer SubQ since severe necrosis and sloughing may occur; extravasation of calcium can result in severe necrosis and tissue sloughing. Do not use scalp vein or small hand or foot veins for I.V. administration. Not for endotracheal administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F144688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR, NS, R, SL;",
"     <b>",
"      incompatible",
"     </b>",
"     in fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aldesleukin, allopurinol, amifostine, amiodarone, aztreonam, bivalirudin, caffeine citrate, cefazolin, cefepime, ciprofloxacin, cisatracurium, cladribine, dexmedetomidine, dobutamine, docetaxel, doripenem, doxorubicin liposome, enalaprilat, epinephrine, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, furosemide, gemcitabine, granisetron, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactated electrolyte injection (Hextend&reg;), labetalol, linezolid, melphalan, micafungin, midazolam, milrinone, nicardipine, nitroprusside, oxaliplatin, pancuronium, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, terbutaline, thiotepa, vecuronium, vinorelbine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, fluconazole, indomethacin, lansoprazole, pemetrexed.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin, doxapram, meropenem, pantoprazole, prochlorperazine edisylate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1003063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). If crystallization has occurred, place vial in a warm water bath for 15-30 minutes and occasionally shake to dissolve; cool to body temperature before use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Calcium-phosphate stability in parenteral nutrition solutions is dependent upon the pH of the solution, temperature, and relative concentration of each ion. The pH of the solution is primarily dependent upon the amino acid concentration. The higher the percentage amino acids the lower the pH, the more soluble the calcium and phosphate. Individual commercially available amino acid solutions vary significantly with respect to pH lowering potential and consequent calcium phosphate compatibility.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1003046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of hypocalcemia and conditions secondary to hypocalcemia (eg, tetany, seizures, arrhythmias); treatment of cardiac disturbances secondary to hyperkalemia; adjunctive treatment of rickets, osteomalacia, and magnesium sulfate overdose; decrease capillary permeability in allergic conditions, nonthrombocytopenic purpura, and exudative dermatoses (eg, dermatitis herpetiformis, pruritus secondary to certain drugs) (All indications: FDA approved in all ages); has also been used for calcium channel blocker toxicity  and as a supplement in total parenteral nutrition admixtures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Dietary supplementation of calcium (OTC: FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Calcium gluconate may be confused with calcium glubionate, cupric sulfate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calcium gluconate may be confused with calcium chloride.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Confusion with the different intravenous salt forms of calcium has occurred. There is a threefold difference in the primary cation concentration between calcium gluconate (in which 1 g = 4.65 mEq [90 mg] of elemental Ca++) and calcium chloride (in which 1 g = 14 mEq [270 mg] of elemental Ca++).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prescribers should specify which salt form is desired. Dosages should be expressed either as mEq, mg, or grams of the salt form.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular (with rapid I.V. injection): Arrhythmia, bradycardia, cardiac arrest, hypotension, syncope, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Sense of oppression (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Chalky taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tingling sensation (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Heat waves (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Postmarketing and/or case reports: Calcinosis cutis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Oral: Gastrointestinal: Constipation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1003048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcium formulation; hypercalcemia, ventricular fibrillation; in neonates: Concurrent intravenous use with ceftriaxone",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3429091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with chronic renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary. Use with caution in patients with severe hyperphosphatemia as elevated levels of phosphorus and calcium may result in soft tissue and pulmonary arterial calcium-phosphate precipitation. Use with caution in patients with severe hypokalemia as acute rises in serum calcium levels may result in life-threatening cardiac arrhythmias. Hypomagnesemia is a common cause of hypocalcemia; therefore, correction of hypocalcemia may be difficult in patients with concomitant hypomagnesemia. Evaluate serum magnesium and correct hypomagnesemia (if necessary), particularly if initial treatment of hypocalcemia is refractory. Use with caution in digitalized patients; hypercalcemia may precipitate cardiac arrhythmias. Use caution when administering calcium supplements to patients with a history of kidney stones.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral calcium administration interferes with absorption of some minerals and drugs; use caution with concomitant administration times; concomitant administration of oral vitamin D and food will optimize calcium absorption.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1003049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ceftriaxone may complex with calcium causing precipitation. Fatal lung and kidney damage associated with calcium-ceftriaxone precipitates has been observed in premature and term neonates. Due to reports of precipitation reaction in neonates, do not coadminister ceftriaxone with calcium-containing solutions, even via separate infusion lines/sites or at different times in any neonate. Ceftriaxone should not be administered simultaneously with any calcium-containing solution via a Y-site in any patient. However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another for use in patients",
"     <b>",
"      other than neonates",
"     </b>",
"     if infusion lines are thoroughly flushed (with a compatible fluid) between infusions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid too rapid I.V. administration; do not exceed 200 mg/minute except in emergency situations; rapid I.V. administration may result in vasodilation, hypotension, bradycardia, arrhythmias, and cardiac arrest. Avoid extravasation; adverse events from extravasation can be devastating (eg, profound tissue necrosis); monitor the I.V. site closely.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing. Some products may contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The parenteral product contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3429092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not give orally with bran, foods high in oxalates (spinach, sweet potatoes, rhubarb, beans), or phytic acid (unleavened bread, raw beans, seeds, nuts, grains, soy isolates) which may decrease calcium absorption; minimize administration with dairy products (when treating deficiency state) as this will reduce absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1891176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011). Information related to use as an antidote in pregnancy is limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3429093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium (ionized calcium preferred if available), phosphate, magnesium, heart rate, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F15670427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Normal Values",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Serum Concetration",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\" rowspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium, total",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cord blood",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         9-11.5 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Newborn 3-24 hours",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         9-10.6 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Newborn 24-48 hours",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         7-12 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4-7 days",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         9-10.9 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Child",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         8.8-10.8 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Adolescent to Adult",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         8.4-10.2 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium, ionized, whole blood",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cord blood",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5-6 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Newborn 3-24 hours",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4.3-5.1 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Newborn 24-48 hours",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4-4.7 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;2 days",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4.8-4.92 mg/dL (2.24-2.46 mEq/L)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1003066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium moderates nerve and muscle performance via action potential excitation threshold regulation; it is necessary for maintaining the functional integrity of nervous, muscular, and skeletal systems and cell-membrane and capillary permeability.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1003068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Requires vitamin D; varies with age: Infants 60%, prepubertal children 28%, pubertal children 34%, young adults 25%; calcium is absorbed in soluble, ionized form; absorption increased in an acidic environment; decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~40%, primarily to albumin (Wills, 1971)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily feces (as unabsorbed calcium salts); urine (20%)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3425503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 g  calcium gluconate = 90 mg elemental calcium  = 4.5 mEq calcium. Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended. If ionized calcium is unavailable, in low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL); [(4 &ndash; patient's albumin) x 0.8] + patient's measured total calcium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Calcium Content of Calcium Salts",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/1 g of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/g)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of calcium salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium acetate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         354",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium carbonate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         330",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium citrate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         211",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         425",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium glubionate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium lactate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium phosphate (tribasic)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         390",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         233",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Department Health &amp; Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011. Available at",
"      <a href=\"file://www.nap.edu/catalog.php?record_id=13050%20\" target=\"_blank\">",
"       file://www.nap.edu/catalog.php?record_id=13050",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French S, Subauste J, and Geraci S, \"Calcium Abnormalities in Hospitalized Patients,\"",
"      <i>",
"       South Med J",
"      </i>",
"      , 2012, 105(4):231-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41175/abstract-text/22475676/pubmed\" id=\"22475676\" target=\"_blank\">",
"        22475676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      ,  2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41175/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, \"Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41175/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, \"Safe Practices for Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41175/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, \"Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41175/abstract-text/20956224/pubmed\" id=\"20956224\" target=\"_blank\">",
"        20956224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, \"Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41175/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wills MR and Lewin MR, \"Plasma Calcium Fractions and the Protein-Binding of Calcium in Normal Subjects and in Patients With Hypercalcaemia and Hypocalcaemia,\"",
"      <i>",
"       J Clin Pathol",
"      </i>",
"      , 1971, 24(9):856-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41175/abstract-text/5139991/pubmed\" id=\"5139991\" target=\"_blank\">",
"        5139991",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Worthley LI and Phillips PJ, \"Intravenous Calcium Salts,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1980, 2(8186):149.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/13/41175/abstract-text/6105319/pubmed\" id=\"6105319\" target=\"_blank\">",
"        6105319",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12956 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41175=[""].join("\n");
var outline_f40_13_41175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6026083\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003045\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442188\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003071\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144645\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144630\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003076\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144688\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003063\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003046\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144690\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144687\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003048\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429091\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003049\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298941\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144639\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429092\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144642\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891176\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429093\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15670427\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003066\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003068\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425503\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12956|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=related_link\">",
"      Calcium gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/2/5157?source=related_link\">",
"      Calcium gluconate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_13_41176="Coronaviruses";
var content_f40_13_41176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronaviruses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41176/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41176/contributors\">",
"     Kenneth McIntosh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41176/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41176/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41176/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41176/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/13/41176/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronaviruses are important human and animal pathogens. They are the cause of up to one-third of community-acquired upper respiratory tract infections in adults and probably also play a role in severe respiratory infections in both children and adults. In addition, it is possible that certain coronaviruses cause diarrhea in infants and children, and their possible role in central nervous diseases has been suggested but not proven.",
"   </p>",
"   <p>",
"    The microbiology, epidemiology, clinical manifestations, diagnosis, treatment, and prevention of coronaviruses will be discussed here. Severe acute respiratory syndrome, which is caused by a coronavirus, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=see_link\">",
"     \"Severe acute respiratory syndrome (SARS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronaviruses are members of the Nidovirus family, viruses that replicate using a nested set of mRNAs (&ldquo;nido-&rdquo; for &ldquo;nest&rdquo;). The human coronaviruses are classified in two genera: alpha coronaviruses (HCoV-229E and HCoV-NL63) and beta coronaviruses (HCoV-HKU1, HCoV-OC43, HCoV-EMC, and the SARS coronavirus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Toroviruses are the only other nidoviruses known to cause disease in humans. They have similar genome organization compared with coronaviruses; however, they have different genome lengths and virion morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/3\">",
"     3",
"    </a>",
"    ]. Toroviruses have been associated only with diarrhea in humans and animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Viral composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronaviruses are medium-sized, enveloped, positive-stranded RNA viruses whose name derives from their characteristic crown-like appearance in electron micrographs (",
"    <a class=\"graphic graphic_picture graphicRef62033 \" href=\"mobipreview.htm?38/31/39410\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/3\">",
"     3",
"    </a>",
"    ]. These viruses have the largest known viral RNA genomes, with a length of 27 to 32 kb. The host-derived membrane is studded with glycoprotein spikes and surrounds the genome, which is encased in a nucleocapsid that is helical in its relaxed form but assumes a roughly spherical shape in the virus particle (",
"    <a class=\"graphic graphic_figure graphicRef53049 \" href=\"mobipreview.htm?29/36/30276\">",
"     figure 1",
"    </a>",
"    ). Replication of viral RNA occurs in the host cytoplasm by a unique mechanism in which RNA polymerase binds to a leader sequence and then detaches and reattaches at multiple locations, allowing for the production of a nested set of mRNA molecules with common 3&rsquo; ends (",
"    <a class=\"graphic graphic_figure graphicRef74041 \" href=\"mobipreview.htm?18/15/18678\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The genome encodes four or five structural proteins, S, M, N, HE, and E. Human coronavirus-229E (HCoV-229E), HCoV-NL63, and the SARS coronavirus possess four genes that encode the S, M, N, and E proteins, respectively, whereas HCoV-OC43 and HCoV-HKU1 also contain a fifth gene that encodes the HE protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spike (S) protein projects through the viral envelope and forms the characteristic spikes in the coronavirus &ldquo;crown.&rdquo; It is heavily glycosylated, probably forms a homotrimer, and mediates receptor binding and fusion with the host cell membrane. The major antigens that stimulate neutralizing antibody, as well as important targets of cytotoxic lymphocytes, are on the S protein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The membrane (M) protein has a short N-terminal domain that projects on the external surface of the envelope and spans the envelope three times, leaving a long C terminus inside the envelope. The M protein plays an important role in viral assembly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The nucleocapsid protein (N) associates with the RNA genome to form the nucleocapsid. It may be involved in the regulation of viral RNA synthesis and may interact with M protein during virus budding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Cytotoxic T lymphocytes recognizing portions of the N protein have been identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The hemagglutinin-esterase glycoprotein (HE) is found only in the betacoronaviruses, HCoV-OC43 and HKU1 (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Viral serotypes'",
"      </a>",
"      below). The hemagglutinin moiety binds to neuraminic acid on the host cell surface, possibly permitting initial adsorption of the virus to the membrane. The esterase cleaves acetyl groups from neuraminic acid. The HE genes of coronaviruses have sequence homology with influenza C HE glycoprotein and may reflect an early recombination between the two [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The small envelope (E) protein leaves its C terminus inside the envelope and then either spans the envelope or bends around and projects its N terminus internally. Its function is not known, although in the SARS-CoV the E protein, along with M and N, are required for proper assembly and release of the virus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Viral serotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal and human coronaviruses fall into three distinct genera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/1\">",
"     1",
"    </a>",
"    ]. There are four non-SARS coronavirus serotypes that are associated with disease in humans.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The alphacoronavirus genus includes two human viruses, human coronavirus-229E (HCoV-229E) and HCoV-NL63. HCoV-229E, like several animal alphacoronaviruses, utilizes aminopeptidase N (APN) as its major receptor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/11\">",
"       11",
"      </a>",
"      ]. In contrast, HCoV-NL63, like the SARS-CoV (a betacoronavirus), uses angiotensin converting enzyme-2 (ACE-2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/12\">",
"       12",
"      </a>",
"      ]. Important animal alphacoronaviruses are transmissible gastroenteritis virus of pigs and feline infectious peritonitis virus. As with all groups of coronaviruses there are several related bat coronaviruses among the alphacoronaviruses.",
"     </li>",
"     <li>",
"      The two non-SARS human members of the betacoronavirus genus, HCoV-OC43 and HCoV-HKU1, have hemagglutinin-esterase (HE) activity and probably utilize sialic acid residues as receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/13\">",
"       13",
"      </a>",
"      ]. This genus also contains several bat viruses, a novel coronavirus that caused disease in two humans in 2012 (HCoV-EMC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/2,14\">",
"       2,14",
"      </a>",
"      ], and the SARS-CoV, although the last two are genetically somewhat distant from HCoV-OC43 and HCoV-HKU1. Important animal betacoronaviruses are mouse hepatitis virus, a laboratory model for both viral hepatitis and demyelinating central nervous system disease, and bovine coronavirus, a diarrhea-causing virus of cattle. Bovine coronavirus is so similar to HCoV-OC43 that the two viruses have been merged into a single species termed betacoronavirus 1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/1\">",
"       1",
"      </a>",
"      ]. The species is thought to have jumped from one animal host to the other as recently as 1900 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The gammacoronavirus genus contains primarily avian coronaviruses, the most prominent of which is infectious bronchitis virus of chickens. This is an important veterinary pathogen causing respiratory and reproductive tract disease in chickens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the human coronaviruses grows easily in tissue culture, and until recently this impeded progress in their study. Both HCoV-229E and HCoV-OC43 were discovered in the 1960s and shown in volunteer experiments to produce common colds in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Studies in the 1970s and 1980s linked them to about one-third of upper respiratory tract infections in adults and some proportion of lower respiratory illness in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little further information developed after this until the emergence of SARS in 2002, and the development of molecular diagnostic methods. Then HCoV-NL63 and HCoV-HKU1 were quickly discovered and found to have worldwide distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. The polymerase chain reaction (PCR) may be used for the diagnosis of each of the four human coronaviruses, and this technique has allowed substantial investigation into their epidemiology and pathogenicity. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronaviruses are ubiquitous; wherever investigators have looked, they have been detected. In temperate climates coronavirus respiratory infections occur primarily in the winter, although smaller peaks are sometimes seen in the fall or spring, and infections can occur at any time of the year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/21,27,28\">",
"     21,27,28",
"    </a>",
"    ]. The human coronavirus strains HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1 appear to predominate unpredictably in certain years and in certain parts of the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/22,28\">",
"     22,28",
"    </a>",
"    ]. Because of the varying sensitivity of different diagnostic assays, as well as the unpredictable prevalence of the various strains from year to year, it is difficult to say which, if any, of the strains is the most common.",
"   </p>",
"   <p>",
"    Respiratory coronaviruses probably spread in a fashion similar to rhinoviruses, via direct contact with infected secretions or large aerosol droplets. Immunity develops soon after infection but wanes gradually over time. Reinfection is common, presumably because of waning immunity, but possibly because of antigenic variation within strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/29\">",
"     29",
"    </a>",
"    ]. In hospital settings, spread among pediatric patients probably occurs through shedding by their infected caretakers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/30\">",
"     30",
"    </a>",
"    ]. Outbreaks are common in long-term care facilities for elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558010536\">",
"    <span class=\"h2\">",
"     Novel human coronavirus (HCoV-EMC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012 and 2013, 14 human infections with a novel coronavirus, HCoV-EMC, were reported to the World Health Organization (WHO), occurring in Saudi Arabia, Qatar, Jordan, the United Kingdom, and possibly Pakistan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/32-39\">",
"     32-39",
"    </a>",
"    ]. Most of the reported patients were severely ill and eight have died. Seven of the 14 cases and five of the eight deaths have been reported from Saudi Arabia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/38\">",
"     38",
"    </a>",
"    ]. The virus has been classified through sequencing as a betacoronavirus, different from SARS-CoV, OC43, and HKU1, but closely related to two bat coronaviruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/14,40\">",
"     14,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cases are summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The index case was a patient in Saudi Arabia who was hospitalized with pneumonia in June 2012 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/14\">",
"       14",
"      </a>",
"      ]. The patient developed acute respiratory distress syndrome and acute kidney injury and died. HCoV-EMC was isolated from his sputum.",
"     </li>",
"     <li>",
"      In September 2012, a nearly identical coronavirus was detected in a patient who also had an acute respiratory distress syndrome and acute kidney injury requiring admission to the intensive care unit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/2,41,42\">",
"       2,41,42",
"      </a>",
"      ]. The patient initially developed symptoms in Qatar, but had recently traveled to Saudi Arabia and sought care in the United Kingdom.",
"     </li>",
"     <li>",
"      An additional case was reported from Qatar in a patient with severe pneumonia and acute kidney injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/32\">",
"       32",
"      </a>",
"      ]. There was no apparent epidemiologic link between this patient and the other patient from Qatar.",
"     </li>",
"     <li>",
"      Four additional confirmed cases have been reported from Saudi Arabia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/32\">",
"       32",
"      </a>",
"      ]. Three of these cases occurred in one family living within the same household; two of these individuals died. One additional family member in the household became ill with symptoms that were similar to those in patients with confirmed infection. This individual recovered and tested negative (by the polymerase chain reaction) for HCoV-EMC. (See",
"      <a class=\"local\" href=\"#H558010604\">",
"       'Novel human coronavirus (HCoV-EMC)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Two confirmed cases were subsequently reported in Jordan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/32\">",
"       32",
"      </a>",
"      ]. One patient had pneumonia and pericarditis and the other had pneumonia and disseminated intravascular coagulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/43\">",
"       43",
"      </a>",
"      ]. Both of these patients died during a cluster of 11 pneumonia cases that occurred in April 2012 and included 8 healthcare workers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/44\">",
"       44",
"      </a>",
"      ]. Disease was milder in the unconfirmed probable cases than in the confirmed cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/43\">",
"       43",
"      </a>",
"      ]. Testing of stored samples confirmed the diagnosis.",
"     </li>",
"     <li>",
"      In January 2013, a resident of the United Kingdom who had traveled to Saudi Arabia and Pakistan developed a severe respiratory illness, and diagnostic tests of respiratory specimens were positive for both HCoV-EMC and H1N1 influenza A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/33\">",
"       33",
"      </a>",
"      ]. In February 2013, the son of this patient (who was known to have underlying medical conditions) died from HCoV-EMC infection after being in close contact with his father [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Another family member developed a mild illness and was also found to have HCoV-EMC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/35\">",
"       35",
"      </a>",
"      ]. Neither of these individuals traveled to the Middle East, strongly suggesting that they acquired the virus via person-to-person spread.",
"     </li>",
"     <li>",
"      Two further fatal cases occurred in Saudi Arabia in January and February 2013 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two clusters in Saudi Arabia and Jordan also raise the possibility of limited human-to-human transmission, but could also be explained by exposure to a common source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, it is possible that some infections occur via intermittent zoonotic transmission or an environmental source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For epidemiologic purposes, a",
"    <a class=\"external\" href=\"file://www.who.int/csr/disease/coronavirus_infections/case_definition/en/index.html\">",
"     case definition",
"    </a>",
"    has been proposed by the WHO. Updated information about HCoV-EMC can be found on the",
"    <a class=\"external\" href=\"file://www.who.int/csr/disease/coronavirus_infections/en/\">",
"     WHO&rsquo;s web site",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of infections caused by the usual HCoVs that circulate in the community are described here. HCoV-EMC, the novel coronavirus detected in 2012, is discussed above, and SARS-CoV is discussed separately. (See",
"    <a class=\"local\" href=\"#H558010536\">",
"     'Novel human coronavirus (HCoV-EMC)'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=see_link&amp;anchor=H12#H12\">",
"     \"Severe acute respiratory syndrome (SARS)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Respiratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human coronavirus-229E (HCoV-229E) and HCoV-OC43 have been proven to have pathogenicity in humans in volunteer studies where they, along with other less well characterized coronavirus strains, reproducibly induced colds very similar to those induced by rhinoviruses, characterized by upper respiratory tract symptoms such as nasal congestion and rhinorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/19,45\">",
"     19,45",
"    </a>",
"    ]. It is assumed that HCoV-NL63 and HCoV-HKU1 have similar pathogenicity, but proof of this is lacking. Moreover, asymptomatic individuals of all ages periodically carry coronaviruses when tested by sensitive methods. Human coronaviruses probably account for about one-third of all acute upper respiratory tract infections in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/22\">",
"     22",
"    </a>",
"    ]. Like rhinoviruses, coronaviruses can be detected in middle ear effusions and have been implicated as important viral causes of acute otitis media in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/46\">",
"     46",
"    </a>",
"    ]. However, surveys that include asymptomatic children indicate that coronaviruses are often found in the absence of symptoms, suggesting that although common, their pathogenicity in healthy infants and children may be low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19383?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Viruses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coronavirus infections have also been linked to more severe respiratory diseases. They have been temporally linked to acute asthmatic attacks in both children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. They have been found in variable proportions, ranging from 2 to 8 percent, of neonates, infants, and young children hospitalized with community-acquired pneumonia, and have been identified even more frequently in lower respiratory tract disease in outpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/20,50,51\">",
"     20,50,51",
"    </a>",
"    ]. They are also an important cause of nosocomial infections in neonatal intensive care units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/52\">",
"     52",
"    </a>",
"    ]. As noted above, a novel coronavirus, HCoV-EMC, caused acute respiratory distress syndrome in two patients in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. One of the more recently discovered human coronaviruses, HCoV-NL63, has been associated with croup in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among elderly patients, there is increasing evidence that coronaviruses are important causes of influenza-like illness, acute exacerbations of chronic bronchitis, and pneumonia, where their frequency is usually below those of influenza and respiratory syncytial virus, but equal to or greater than that of rhinoviruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/55-58\">",
"     55-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coronaviruses also probably cause pneumonia in immunocompromised hosts, including adults with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. There is some evidence of an association between coronavirus infection and acute rejection and bronchiolitis obliterans syndrome in lung transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Enteric",
"    </span>",
"    &nbsp;&mdash;&nbsp;The idea that coronaviruses produce diarrhea in humans is intriguing because of their clear intestinal pathogenicity in animals. Early human studies depended on finding &ldquo;coronavirus-like particles&rdquo; (CVLPs) by electron microscopy in stool samples. The most convincing studies showed a strong association between the presence of CVLPs and diarrhea in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/63\">",
"     63",
"    </a>",
"    ] or necrotizing enterocolitis in newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/64\">",
"     64",
"    </a>",
"    ]. In several studies, CVLPs have been purified that appear to be antigenically related to HCoV-OC43 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/63\">",
"     63",
"    </a>",
"    ]. However, many studies may have confused coronaviruses and toroviruses, since these viruses are very similar when examined by electron microscopy of negatively stained preparations of stool.",
"   </p>",
"   <p>",
"    More recently, both HCoV-HKU1 and HCoV-OC43 have been found in infants hospitalized with diarrhea (often with respiratory symptoms as well) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/27\">",
"     27",
"    </a>",
"    ]. Two surveys of diarrhea used molecular methods to screen for all four HCoV species. In one study, all four species were found in stools from 2.5 percent of 878 children with diarrhea and 1.8 percent of 112 asymptomatic children by reverse-transcriptase polymerase chain reaction (RT-PCR); however, most diarrhea-associated coronavirus-positive stools also contained other known pathogens, such as rotavirus or norovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/65\">",
"     65",
"    </a>",
"    ]. In a study that used RT-PCR to investigate the frequency of coronaviruses in stool samples from children and adults with gastrointestinal illness, CoV-HKU1 was found in 4 of 479 patients (0.8 percent), and no other HCoV species were found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further adequately controlled studies using molecular methods are needed. Although it appears possible that coronaviruses are etiologically related to diarrhea, their role relative to other causes of diarrhea appears to be minor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSSIBLE DISEASE ASSOCIATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the observation that rats and mice infected with certain strains of mouse hepatitis virus (MHV) developed a severe demyelinating encephalitis similar to multiple sclerosis (MS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/67\">",
"     67",
"    </a>",
"    ], investigators have sought to link coronaviruses with MS. Currently available evidence is inconclusive. It has been shown that human coronaviruses can infect neural tissue in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/68\">",
"     68",
"    </a>",
"    ]. T-cell clones from patients with MS have been shown to react both with HCoV-229E antigens and myelin basic protein, suggesting molecular mimicry as a basis of pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/69\">",
"     69",
"    </a>",
"    ]. Some, but not all, investigators have detected RNA of the human coronaviruses, HCoV-OC43 and HCoV-229E, more frequently in brain tissue from MS patients by reverse transcriptase polymerase chain reaction (RT-PCR) than in healthy individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these findings, however, an etiologic connection between coronaviruses and MS, or other demyelinating diseases, remains tentative and unproven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association of coronavirus infection with Kawasaki disease was reported by one group of investigators and stimulated a flurry of investigation worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/71\">",
"     71",
"    </a>",
"    ]. Others failed to confirm this finding, and at the present time it is assumed that known coronaviruses have no role in this disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=see_link&amp;anchor=H8#H8\">",
"     \"Kawasaki disease: Epidemiology and etiology\", section on 'Infectious etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronaviruses are difficult to grow in tissue culture. Until recently, no sensitive, rapid method existed to detect all of the known human coronavirus strains. Furthermore, since there is no effective treatment for coronavirus infections, establishing the diagnosis is of limited utility.",
"   </p>",
"   <p>",
"    Rapid techniques that can be used to detect coronaviruses from nasopharyngeal samples include reverse transcriptase polymerase chain reaction (RT-PCR) and immunofluorescence antigen detection assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of its utility for detecting all four of the known human coronavirus strains in clinical samples, RT-PCR has supplanted other diagnostic methods. Although broadly reacting, pan-coronavirus primers have been developed, they are less sensitive than primers designed for each of the four human strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/74\">",
"     74",
"    </a>",
"    ]. The sensitivity may be further improved by using real-time RT-PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=see_link&amp;anchor=H18#H18\">",
"     \"Severe acute respiratory syndrome (SARS)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558010604\">",
"    <span class=\"h2\">",
"     Novel human coronavirus (HCoV-EMC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a novel coronavirus, HCoV-EMC, causing severe respiratory illness was isolated in 2012 and 2013 from patients who became ill in Saudi Arabia, Qatar, Jordan, the United Kingdom, and possibly Pakistan. (See",
"    <a class=\"local\" href=\"#H558010536\">",
"     'Novel human coronavirus (HCoV-EMC)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recommendations issued by the World Health Organization (WHO) for laboratory testing for HCoV-EMC can be found",
"    <a class=\"external\" href=\"file://www.who.int/csr/disease/coronavirus_infections/LaboratoryTestingNovelCoronavirus_21Dec12.pdf\">",
"     here",
"    </a>",
"    . The WHO recommends that individuals who meet any of the following criteria be tested for HCoV-EMC; various respiratory specimens (eg, tracheal aspirates, bronchoalveolar lavage fluid, nasopharyngeal swabs or aspirates) should be sent for real-time RT-PCR; other appropriate specimens and tests are reviewed in the",
"    <a class=\"external\" href=\"file://www.who.int/csr/disease/coronavirus_infections/LaboratoryTestingNovelCoronavirus_21Dec12.pdf\">",
"     WHO document",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/42,77,78\">",
"     42,77,78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patients under investigation",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A person with an acute respiratory infection, which may include history of fever or measured fever (&ge;38&deg;C [100.4&deg;F]) and cough",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Suspicion of pulmonary parenchymal disease (eg, pneumonia or acute respiratory distress syndrome), based on clinical or radiographic evidence of consolidation",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Residence in or history of travel to the Arabian Peninsula or neighboring countries within 10 days before onset of illness",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      The illness is not explained by any other infection or etiology; although patients should be tested for other causes of community-acquired pneumonia as clinically indicated, it is not necessary to wait for test results for other pathogens before testing for HCoV-EMC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ill contacts",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Individuals with acute respiratory illness of any degree of severity who, within 10 days before onset of illness, were in close physical contact with a patient who has been classified as a confirmed or probable case of HCoV-EMC infection while he or she was ill",
"     </li>",
"     <li>",
"      Any person who has had close contact with a patient who has been classified as a probable or confirmed case while he or she was ill should be carefully monitored for the appearance of respiratory symptoms; if symptoms develop within the first 10 days after contact, the individual should be considered a &ldquo;patient under investigation,&rdquo; regardless of the severity of illness, and investigated accordingly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clusters",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Any cluster of severe acute respiratory infection, particularly clusters of patients requiring intensive care, without regard to place of residence or history of travel",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      The illness is not explained by any other infection or etiology; although patients should be tested for other causes of community-acquired pneumonia as clinically indicated, it is not necessary to wait for test results for other pathogens before testing for HCoV-EMC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Healthcare workers",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Healthcare workers with pneumonia who have been caring for patients with severe acute respiratory infections, particularly patients requiring intensive care, without regard to place of residence or history of travel",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      The illness is not explained by any other infection or etiology; although patients should be tested for other causes of community-acquired pneumonia as clinically indicated, it is not necessary to wait for test results for other pathogens before testing for HCoV-EMC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The WHO has also issued the following recommendations for enhanced surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthcare providers should report all individuals recommended for investigation immediately to national authorities through established reporting channels. Follow existing protocols for respiratory disease surveillance, which includes the investigation of clusters and other unusual respiratory events.",
"     </li>",
"     <li>",
"      Based upon current information about confirmed cases, the WHO does not advise special screening at points of entry for possible HCoV-EMC infection, nor does it recommend that any travel or trade restrictions be applied.",
"     </li>",
"     <li>",
"      WHO Member States that have the capacity may wish to also consider testing of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with pneumonia who have unusual or unusually severe clinical course with no other known etiology, without regard to place of residence or a history of travel",
"     </li>",
"     <li>",
"      Retrospective testing of stored respiratory specimens from patients with pneumonia of unexplained etiology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Probable and confirmed cases should be reported within 24 hours of classification through the Regional Contact Point for International Health Regulations at the appropriate WHO Regional Office.",
"   </p>",
"   <p>",
"    Updated information about HCoV-EMC can be found on the",
"    <a class=\"external\" href=\"file://www.who.int/csr/disease/coronavirus_infections/en/\">",
"     WHO&rsquo;s web site",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no treatment recommended for coronavirus infections except for supportive care as needed. Several antivirals and other agents were used during the SARS outbreak but the efficacy of these drugs has not been established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=see_link&amp;anchor=H21#H21\">",
"     \"Severe acute respiratory syndrome (SARS)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The World Health Organization has issued",
"    <a class=\"external\" href=\"file://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13.pdf\">",
"     recommendations",
"    </a>",
"    for the management of severe respiratory infections suspected to be caused by the novel coronavirus, HCoV-EMC, which emerged in 2012 in the Middle East.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    , which has potent antiviral activity against the SARS coronavirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/79\">",
"     79",
"    </a>",
"    ], has been shown to have similar activity against HCoV-229E in cultured cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/80\">",
"     80",
"    </a>",
"    ], and against HCoV-OC43 both in cultured cells and in a mouse model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/81\">",
"     81",
"    </a>",
"    ]. However, there have been no studies of efficacy in humans.",
"   </p>",
"   <p>",
"    Preventive measures are the same as for rhinovirus infections, which consist of careful handwashing and the careful disposal of materials infected with nasal secretions. Several",
"    <span class=\"nowrap\">",
"     antiseptic/disinfectant",
"    </span>",
"    solutions used commonly in hospitals and households, including chloroxylenol, benzalkonium chloride, and",
"    <span class=\"nowrap\">",
"     cetrimide/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"      chlorhexidine",
"     </a>",
"     ,",
"    </span>",
"    have been shown to be ineffective against coronaviruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been little interest in developing vaccines for the non-SARS respiratory coronaviruses for several reasons. First, four separate species have been described and there is evidence within at least one of these species of clinically significant antigenic variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/29\">",
"     29",
"    </a>",
"    ]. It is also likely that more coronavirus species will be discovered, making vaccine development complex. In addition, vaccine enhancement of disease has been shown for one animal coronavirus, feline coronavirus; hypersensitivity was induced in some animals by prior exposure to a vaccine containing the S protein, with the production of an immunologically mediated severe disease, feline infectious peritonitis, upon reinfection with a coronavirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41176/abstract/83\">",
"     83",
"    </a>",
"    ]. On the other hand, there has been some interest in the development of a SARS-CoV vaccine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=see_link\">",
"     \"Severe acute respiratory syndrome (SARS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronaviruses are the cause of up to one-third of community-acquired upper respiratory tract infections in adults and probably also play a role in severe respiratory infections in both children and adults, particularly elderly adults. In addition, it is possible that certain coronaviruses cause diarrhea in infants and children, and their possible role in central nervous diseases in humans has been suggested but not proven. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coronaviruses are medium-sized, enveloped, positive-stranded RNA viruses whose name derives from their characteristic crown-like appearance in electron micrographs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Viral composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coronaviruses are ubiquitous; wherever investigators have looked, they have been detected. In temperate climates coronavirus respiratory infections occur primarily in the winter, although smaller peaks are sometimes seen in the fall or spring, and infections can occur at any time of the year. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A novel coronavirus, HCoV-EMC, causing severe respiratory illness emerged in 2012 in the Middle East. (See",
"      <a class=\"local\" href=\"#H558010536\">",
"       'Novel human coronavirus (HCoV-EMC)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most coronavirus infections are diagnosed clinically, although reverse transcriptase polymerase chain reaction (RT-PCR) applied to respiratory secretions is the diagnostic test of choice. The World Health Organization (WHO) has issued",
"      <a class=\"external\" href=\"file://www.who.int/csr/disease/coronavirus_infections/LaboratoryTestingNovelCoronavirus_21Dec12.pdf\">",
"       recommendations",
"      </a>",
"      for testing certain individuals for HCoV-EMC. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H558010604\">",
"       'Novel human coronavirus (HCoV-EMC)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is currently no treatment recommended for coronavirus infections except for supportive care as needed. The WHO has issued",
"      <a class=\"external\" href=\"file://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13.pdf\">",
"       recommendations",
"      </a>",
"      for the management of severe respiratory infections suspected to be caused by HCoV-EMC. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/1\">",
"      Carstens EB. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2009). Arch Virol 2010; 155:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Severe respiratory illness associated with a novel coronavirus--Saudi Arabia and Qatar, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:820.",
"     </a>",
"    </li>",
"    <li>",
"     Lai MMC, Perlman S, Anderson LJ. Coronaviridae. In: Fields Virology, 5th ed, Knipe DM, Howley PM, Griffin DE, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. p.1305.",
"    </li>",
"    <li>",
"     McIntosh K, Peiris JSM. Coronaviruses. In: Clinical Virology, 3rd ed, Richman DD, Whitley RJ, Hayden FG (Eds), ASM Press, Washington, DC 2009. p.1155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/5\">",
"      Enjuanes L, Smerdou C, Castilla J, et al. Development of protection against coronavirus induced diseases. A review. Adv Exp Med Biol 1995; 380:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/6\">",
"      Masters PS, Kuo L, Ye R, et al. Genetic and molecular biological analysis of protein-protein interactions in coronavirus assembly. Adv Exp Med Biol 2006; 581:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/7\">",
"      Kuo L, Masters PS. Genetic evidence for a structural interaction between the carboxy termini of the membrane and nucleocapsid proteins of mouse hepatitis virus. J Virol 2002; 76:4987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/8\">",
"      Perlman S. Pathogenesis of coronavirus-induced infections. Review of pathological and immunological aspects. Adv Exp Med Biol 1998; 440:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/9\">",
"      Luytjes W, Bredenbeek PJ, Noten AF, et al. Sequence of mouse hepatitis virus A59 mRNA 2: indications for RNA recombination between coronaviruses and influenza C virus. Virology 1988; 166:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/10\">",
"      Siu YL, Teoh KT, Lo J, et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol 2008; 82:11318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/11\">",
"      Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 1992; 357:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/12\">",
"      Hofmann H, Pyrc K, van der Hoek L, et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 2005; 102:7988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/13\">",
"      Vlasak R, Luytjes W, Spaan W, Palese P. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci U S A 1988; 85:4526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/14\">",
"      Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/15\">",
"      Vijgen L, Keyaerts E, Mo&euml;s E, et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol 2005; 79:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/16\">",
"      Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 1966; 121:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/17\">",
"      McIntosh K, Dees JH, Becker WB, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A 1967; 57:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/18\">",
"      Bradburne AF. Antigenic relationships amongst coronaviruses. Arch Gesamte Virusforsch 1970; 31:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/19\">",
"      Bradburne AF, Bynoe ML, Tyrrell DA. Effects of a \"new\" human respiratory virus in volunteers. Br Med J 1967; 3:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/20\">",
"      McIntosh K, Chao RK, Krause HE, et al. Coronavirus infection in acute lower respiratory tract disease of infants. J Infect Dis 1974; 130:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/21\">",
"      McIntosh K, Kapikian AZ, Turner HC, et al. Seroepidemiologic studies of coronavirus infection in adults and children. Am J Epidemiol 1970; 91:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/22\">",
"      Monto AS. Medical reviews. Coronaviruses. Yale J Biol Med 1974; 47:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/23\">",
"      Esper F, Weibel C, Ferguson D, et al. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis 2005; 191:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/24\">",
"      Fouchier RA, Hartwig NG, Bestebroer TM, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci U S A 2004; 101:6212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/25\">",
"      van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004; 10:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/26\">",
"      Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/27\">",
"      Vabret A, Dina J, Gouarin S, et al. Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France. J Paediatr Child Health 2008; 44:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/28\">",
"      Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 2010; 48:2940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/29\">",
"      Reed SE. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains. J Med Virol 1984; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/30\">",
"      Gagneur A, Vallet S, Talbot PJ, et al. Outbreaks of human coronavirus in a pediatric and neonatal intensive care unit. Eur J Pediatr 2008; 167:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/31\">",
"      Falsey AR, Dallal GE, Formica MA, et al. Long-term care facilities: a cornucopia of viral pathogens. J Am Geriatr Soc 2008; 56:1281.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global Alert and Response. Background and summary of novel coronavirus infection &ndash; as of 30 November 2012. file://www.who.int/csr/disease/coronavirus_infections/update_20121130/en/index.html (Accessed on December 06, 2012).",
"    </li>",
"    <li>",
"     World Health Organization. Global Alert and Response. Novel coronavirus infection &ndash; update. file://www.who.int/csr/don/2013_02_11b/en/index.html (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     European Centre for Disease Prevention and Control. Epidemiological update: case of severe lower respiratory tract disease associated with a novel coronavirus. file://ecdc.europa.eu/en/press/news/Lists/News/ECDC_DispForm.aspx?List=32e43ee8%2De230%2D4424%2Da783%2D85742124029a&amp;ID=841&amp;RootFolder=%2Fen%2Fpress%2Fnews%2FLists%2FNews (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global Alert and Response. Novel coronavirus infection &ndash; update. file://www.who.int/csr/don/2013_02_16/en/index.html (Accessed on February 17, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global Alert and Response. Novel coronavirus infection &ndash; update. file://www.who.int/csr/don/2013_02_13/en/index.html (Accessed on February 17, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global Alert and Response. Novel coronavirus &ndash; update. file://www.who.int/csr/don/2013_02_21/en/index.html# (Accessed on March 06, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global Alert and Response. Novel coronavirus infection - update. file://www.who.int/csr/don/2013_03_06/en/index.html (Accessed on March 07, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/39\">",
"      Update: Severe respiratory illness associated with a novel coronavirus &mdash; worldwide, 2012&ndash;2013. MMWR Morb Mortal Wkly Rep 2013; 62 (Early Release):1.",
"     </a>",
"    </li>",
"    <li>",
"     United Kingdom Health Protection Agency. Partial genetic sequence information for scientists about the novel coronavirus 2012. file://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/RespiratoryViruses/NovelCoronavirus/respPartialgeneticsequenceofnovelcoronavirus/ (Accessed on September 27, 2012).",
"    </li>",
"    <li>",
"     World Health Organization. Novel coronavirus infection in the United Kingdom. file://www.who.int/csr/don/2012_09_23/en/index.html (Accessed on September 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/42\">",
"      Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012; 17.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global Alert and Response. Background and summary of novel coronavirus infection &ndash; as of 21 December 2012. file://www.who.int/csr/disease/coronavirus_infections/update_20121221/en/index.html (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research and Policy. Jordan calls novel coronavirus cases isolated. file://www.cidrap.umn.edu/cidrap/content/other/sars/news/dec0312corona.html (Accessed on December 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/45\">",
"      Bradburne AF, Somerset BA. Coronative antibody tires in sera of healthy adults and experimentally infected volunteers. J Hyg (Lond) 1972; 70:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/46\">",
"      Chonmaitree T, Revai K, Grady JJ, et al. Viral upper respiratory tract infection and otitis media complication in young children. Clin Infect Dis 2008; 46:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/47\">",
"      Prill MM, Iwane MK, Edwards KM, et al. Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls. Pediatr Infect Dis J 2012; 31:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/48\">",
"      McIntosh K, Ellis EF, Hoffman LS, et al. The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children. J Pediatr 1973; 82:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/49\">",
"      Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993; 307:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/50\">",
"      Kuypers J, Martin ET, Heugel J, et al. Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics 2007; 119:e70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/51\">",
"      Talbot HK, Shepherd BE, Crowe JE Jr, et al. The pediatric burden of human coronaviruses evaluated for twenty years. Pediatr Infect Dis J 2009; 28:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/52\">",
"      Sizun J, Soupre D, Legrand MC, et al. Neonatal nosocomial respiratory infection with coronavirus: a prospective study in a neonatal intensive care unit. Acta Paediatr 1995; 84:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/53\">",
"      van der Hoek L, Sure K, Ihorst G, et al. Croup is associated with the novel coronavirus NL63. PLoS Med 2005; 2:e240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/54\">",
"      Sung JY, Lee HJ, Eun BW, et al. Role of human coronavirus NL63 in hospitalized children with croup. Pediatr Infect Dis J 2010; 29:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/55\">",
"      Falsey AR, McCann RM, Hall WJ, et al. The \"common cold\" in frail older persons: impact of rhinovirus and coronavirus in a senior daycare center. J Am Geriatr Soc 1997; 45:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/56\">",
"      Graat JM, Schouten EG, Heijnen ML, et al. A prospective, community-based study on virologic assessment among elderly people with and without symptoms of acute respiratory infection. J Clin Epidemiol 2003; 56:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/57\">",
"      Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997; 315:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/58\">",
"      Kherad O, Kaiser L, Bridevaux PO, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest 2010; 138:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/59\">",
"      Garbino J, Inoubli S, Mossdorf E, et al. Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection. AIDS 2008; 22:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/60\">",
"      Pene F, Merlat A, Vabret A, et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis 2003; 37:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/61\">",
"      Simon A, V&ouml;lz S, Fleischhack G, et al. Human coronavirus OC43 pneumonia in a pediatric cancer patient with down syndrome and acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2007; 29:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/62\">",
"      Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/63\">",
"      Gerna G, Passarani N, Battaglia M, Rondanelli EG. Human enteric coronaviruses: antigenic relatedness to human coronavirus OC43 and possible etiologic role in viral gastroenteritis. J Infect Dis 1985; 151:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/64\">",
"      Chany C, Moscovici O, Lebon P, Rousset S. Association of coronavirus infection with neonatal necrotizing enterocolitis. Pediatrics 1982; 69:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/65\">",
"      Risku M, Lappalainen S, R&auml;s&auml;nen S, Vesikari T. Detection of human coronaviruses in children with acute gastroenteritis. J Clin Virol 2010; 48:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/66\">",
"      Esper F, Ou Z, Huang YT. Human coronaviruses are uncommon in patients with gastrointestinal illness. J Clin Virol 2010; 48:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/67\">",
"      Houtman JJ, Fleming JO. Pathogenesis of mouse hepatitis virus-induced demyelination. J Neurovirol 1996; 2:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/68\">",
"      Arbour N, Ekand&eacute; S, C&ocirc;t&eacute; G, et al. Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. J Virol 1999; 73:3326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/69\">",
"      Boucher A, Desforges M, Duquette P, Talbot PJ. Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. Clin Immunol 2007; 123:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/70\">",
"      Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol 2000; 74:8913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/71\">",
"      Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/72\">",
"      Chang LY, Chiang BL, Kao CL, et al. Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan. J Infect Dis 2006; 193:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/73\">",
"      Dominguez SR, Anderson MS, Glod&eacute; MP, et al. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki syndrome. J Infect Dis 2006; 194:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/74\">",
"      Gerna G, Campanini G, Rovida F, et al. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J Med Virol 2006; 78:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/75\">",
"      Gerna G, Percivalle E, Sarasini A, et al. Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. J Clin Virol 2007; 38:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/76\">",
"      Sizun J, Arbour N, Talbot PJ. Comparison of immunofluorescence with monoclonal antibodies and RT-PCR for the detection of human coronaviruses 229E and OC43 in cell culture. J Virol Methods 1998; 72:145.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Interim surveillance recommendations for human infection with novel coronavirus. file://www.who.int/csr/disease/coronavirus_infections/InterimRevisedSurveillanceRecommendations_nCoVinfection_03Dec12.pdf (Accessed on December 05, 2012).",
"    </li>",
"    <li>",
"     World Health Organization. Laboratory testing for novel coronavirus. Interim recommendations - 21 December 2012. file://www.who.int/csr/disease/coronavirus_infections/LaboratoryTestingNovelCoronavirus_21Dec12.pdf (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/79\">",
"      Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/80\">",
"      Kono M, Tatsumi K, Imai AM, et al. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res 2008; 77:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/81\">",
"      Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009; 53:3416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/82\">",
"      Wood A, Payne D. The action of three antiseptics/disinfectants against enveloped and non-enveloped viruses. J Hosp Infect 1998; 38:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41176/abstract/83\">",
"      Vennema H, de Groot RJ, Harbour DA, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 1990; 64:1407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8298 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41176=[""].join("\n");
var outline_f40_13_41176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Viral composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Viral serotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558010536\">",
"      Novel human coronavirus (HCoV-EMC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Respiratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Enteric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSSIBLE DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558010604\">",
"      Novel human coronavirus (HCoV-EMC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8298\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8298|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/36/30276\" title=\"figure 1\">",
"      Coronavirus structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/15/18678\" title=\"figure 2\">",
"      Coronavirus replication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8298|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/31/39410\" title=\"picture 1\">",
"      Coronavirus EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19383?source=related_link\">",
"      Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=related_link\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_13_41177="Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis";
var content_f40_13_41177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41177/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41177/contributors\">",
"     Sudie Back, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41177/contributors\">",
"     Megan M Moran-Santa Maria, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41177/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41177/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41177/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/13/41177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20550097\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety disorders and substance use disorders (SUDs) commonly co-occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The association between these disorders is multifaceted. Anxiety disorders may increase the risk for the development of SUDs, and may alter the presentation and treatment outcome of SUDs. SUDs may alter the presentation and outcome of treatment for anxiety disorders.",
"   </p>",
"   <p>",
"    The complexity of these comorbidities highlights the importance of a comprehensive understanding of symptoms of each disorder, proper diagnosis, and use of effective treatments as well as consideration of potentially toxic drug-drug interactions, medication abuse liability, and patient adherence.",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of co-occurring anxiety disorders and SUDs. The treatment of co-occurring anxiety disorders and SUDs are described separately. Individual anxiety disorders and SUDs are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10488?source=see_link\">",
"     \"Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1079?source=see_link\">",
"     \"Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3784?source=see_link\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20550104\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance use disorders (SUDs) have been found to co-occur at an increased rate in individuals with posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder (SAD) compared to rates in the general population. Obsessive-compulsive disorder (OCD) and SUDs have not been found to co-occur at a higher rate than each disorder individually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H554290\">",
"    <span class=\"h2\">",
"     Substance use disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 12-month prevalence of substance use disorders (SUD) in the adult general population of the United States (US) is [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcohol use disorders &mdash; 8.5 percent",
"     </li>",
"     <li>",
"      Other substances &mdash; 2 percent (most commonly cannabis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17734023\">",
"    <span class=\"h2\">",
"     Posttraumatic stress disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTSD, one of the most common anxiety disorders (lifetime prevalence of 7.8 percent in US general population), has been shown to commonly co-occur with SUDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The lifetime prevalence of SUDs in persons with non-military PTSD has been reported to range from 21.6 to 43 percent, compared to a range of 8.1 to 24.7 percent in individuals without PTSD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/1,5-7\">",
"       1,5-7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A study of 2633 individuals in the general US adult population found that cocaine and opiate users had the highest rates of trauma exposure and PTSD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared to the general population, military personnel are at increased risk of both PTSD and SUDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of over 88,000 US veterans returning from the Iraq war found that 16.7 percent had symptoms of PTSD at six months post-deployment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Millennium Cohort Study, which included over 48,000 military personnel, 53.6 percent reported binge drinking and 15.2 percent reported alcohol related problems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/11\">",
"       11",
"      </a>",
"      ]. Deployment and exposure to combat were related to increased risk of binge drinking (OR=1.46) and alcohol-related problems (OR=1.63).",
"     </li>",
"     <li>",
"      A study of 1120 US soldiers found that 25 percent screened positive for alcohol misuse three to four months post-deployment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17734030\">",
"    <span class=\"h2\">",
"     Generalized anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;GAD has a lifetime prevalence in the general population of 5.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The likelihood of having GAD has been strongly associated with the presence of alcohol or drug dependence in data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), which is based on a nationally representative sample in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Across several studies, the prevalence of GAD among patients with an alcohol use disorder ranged from 8.3 to 52.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/16\">",
"     16",
"    </a>",
"    ]. Data from the National Comorbidity Study (NCS), a nationally representative sample of US adults, found an association between lifetime GAD and lifetime use of stimulants (odds ratio 2.07), cocaine (odds ratio 2.39), hallucinogens (odds ratio 5.09), and heroin (odds ratio 4.27) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17734037\">",
"    <span class=\"h2\">",
"     Panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Epidemiological Catchment Area (ECA) study in five US cities found a lifetime prevalence of panic disorder among adults of 1.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/18\">",
"     18",
"    </a>",
"    ]. Thirty six percent of patients with panic disorder were additionally diagnosed with an SUD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from four large epidemiological surveys found that the estimated lifetime risk of panic disorder in individuals with alcohol abuse or dependence ranged from 0.97 to 3.82 percent, compared to individuals without an SUD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. A study of 1,071 subjects participating in the National Household Survey on Drug Abuse in the US estimated that cocaine use was associated with a 3.3-fold excess occurrence of panic attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/23\">",
"     23",
"    </a>",
"    ]. The lifetime prevalence of panic disorder with and without agoraphobia among patients with an opiate use disorder was 5 percent and 14 percent, respectively, in a study of data from the NESARC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17734046\">",
"    <span class=\"h2\">",
"     Social anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies of nationally representative samples in the US estimated the lifetime prevalence of SAD to range from 5.0 to 13.3 percent and the 12-month prevalence to range from 2.8 to 7.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. Alcohol use disorders in individuals with SAD were common, for example, the NESARC found a 48 percent lifetime prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/25\">",
"     25",
"    </a>",
"    ]. A study demonstrated modestly increased associations between lifetime SAD and lifetime stimulant, cocaine, hallucinogen, and heroin use (OR: 1.86, 1.45, 2.3, and 1.6 respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/17\">",
"     17",
"    </a>",
"    ]. A strong association has been observed between SAD and marijuana use. The NCS found that individuals with SAD are seven times more likely to experience marijuana dependence than individuals without SAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with SAD are highly vulnerable to substance use disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/17\">",
"     17",
"    </a>",
"    ]. Research shows that socially phobic individuals are two to three times more likely than individuals without SAD to develop an alcohol use disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/16\">",
"     16",
"    </a>",
"    ]. The onset of SAD typically precedes the development of the substance use disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/27\">",
"     27",
"    </a>",
"    ], and up to 16.4 percent of socially phobic individuals endorse self-medicating anxiety symptoms with alcohol and drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18656367\">",
"    <span class=\"h2\">",
"     Obsessive-compulsive disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike other anxiety disorders, individuals with OCD do not appear to have a higher rate of co-occurring SUDs than the general population. A large epidemiological study of six geographic areas in the US found no difference between rates of OCD among individuals with alcohol dependence compared to a control group without alcohol dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/29\">",
"     29",
"    </a>",
"    ]. Two studies of patients receiving psychiatric treatment in the US found that only 1.3 to 4.0 percent of patients with OCD met criteria for a lifetime substance use disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20550111\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent data suggest that substance use disorders (SUDs) and anxiety disorders share common neurobiological substrates that include the hypothalamic pituitary adrenal (HPA) axis and noradrenergic system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20550118\">",
"    <span class=\"h2\">",
"     Hypothalamic pituitary adrenal (HPA) axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the findings on HPA axis reactivity are mixed, a preponderance of evidence suggests that a disruption in normal HPA hormonal feedback is a common physical feature of both substance use and anxiety disorders. More specifically, these studies suggest that a hyperactive HPA axis occurs as a function of long-term drug use",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged stress exposure.",
"   </p>",
"   <p>",
"    The HPA axis has been implicated in behaviors associated with substance dependence. As an example, stress is a powerful predictor of relapse, and perturbations within the HPA axis as a result of long-term drug exposure are hypothesized to culminate in an addictive phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Even acute drug exposure in drug-na&iuml;ve humans and rodents increases circulating HPA hormone levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/34\">",
"     34",
"    </a>",
"    ]. Clinical studies of cocaine dependent men and women demonstrate that corticotropin releasing hormone (CRH) promotes drug craving and subjective stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/35\">",
"     35",
"    </a>",
"    ]. CRH receptor antagonists administered directly into limbic nuclei block stress-induced relapse in animal models of drug dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of posttraumatic stress disorder (PTSD) and HPA axis reactivity are complex and have yielded equivocal findings. Findings from studies of patients with PTSD have been mixed. For example, compared with healthy controls, patients with PTSD have higher, lower and normal 24-hour urinary cortisol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. However, the majority of studies support enhanced glucocorticoid negative feedback in patients with PTSD, suggesting a hyperactive physiological stress system. As an example, clinical studies have shown elevated lymphocyte glucocorticoid receptor levels in patients with PTSD and enhanced suppression of cortisol following a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    challenge, as well as elevated ACTH levels following a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Patients with PTSD exhibit higher levels of cerebral spinal fluid CRH than healthy controls. The hyperactive HPA hormonal response is thought to be involved in hyperarousal that is commonly observed in PTSD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of the HPA axis in individuals with panic disorder, generalized anxiety disorder (GAD), and social anxiety disorder have been inconclusive. As an example, one study found that individuals with panic disorder exhibited a similar HPA hormone response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    and metyrapone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    as controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/45\">",
"     45",
"    </a>",
"    ]. Another study found higher diurnal cortisol levels in individuals with panic disorder than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/46\">",
"     46",
"    </a>",
"    ]. Elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/47\">",
"     47",
"    </a>",
"    ] and normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/48\">",
"     48",
"    </a>",
"    ] basal cortisol levels have been reported among individuals with GAD. Dexamethasone challenge results in patients with GAD are difficult to interpret, as greater non-suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/49\">",
"     49",
"    </a>",
"    ] and normal suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/50\">",
"     50",
"    </a>",
"    ] have been reported.",
"   </p>",
"   <p>",
"    Findings regarding HPA axis functioning in patients with OCD are mixed. As an example, both cortisol suppression and non-suppression have been found in OCD patients in response to a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Both higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/53\">",
"     53",
"    </a>",
"    ] and normal CRH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/54\">",
"     54",
"    </a>",
"    ] levels have been reported in the cerebral spinal fluid of OCD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. However, other studies have been more conclusive demonstrating elevated cortisol and ACTH concentrations and higher 24-hour urinary cortisol levels in OCD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20550125\">",
"    <span class=\"h2\">",
"     Noradrenaline systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models of addiction demonstrate that norepinephrine plays a critical role in the transition from recreational drug use to dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/57\">",
"     57",
"    </a>",
"    ]. Dopamine &beta;-hydroxylase inhibitors attenuate alcohol intake in rodents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/58\">",
"     58",
"    </a>",
"    ]. Alpha1-noradrenergic receptor antagonists prevent escalation of drug seeking behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Noradrenergic activity has been linked to anxiety and negative affect during opiate withdrawal. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/61\">",
"     61",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Compared with healthy controls, PTSD patients have a lower number of platelet positive alpha2-adrenergic receptors, and higher 24-hour urinary norepinephrine levels. PTSD patients exhibit a sensitized cardiovascular response to the alpha2-receptor antagonist yohimbine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/62\">",
"     62",
"    </a>",
"    ]. The alpha2-receptor agonist clonidine has been the used to treat symptoms of PTSD and opiate withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1191?source=see_link&amp;anchor=H7#H7\">",
"     \"Opioid detoxification during treatment for addiction\", section on 'Clonidine and other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The strongest evidence for a role of noradrenergic systems in mediating symptoms of GAD may be from pharmacotherapy trials, which have found serotonin- norepinephrine reuptake inhibitors (SNRIs) to be effective in the treatment of GAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=see_link&amp;anchor=H450954836#H450954836\">",
"     \"Pharmacotherapy for generalized anxiety disorder\", section on 'Serotonin&ndash;norepinephrine reuptake inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Yohimbine produces panic-like symptoms in healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/65\">",
"     65",
"    </a>",
"    ]. Administration of yohimbine to individuals with panic disorder caused greater increases norepinephrine turnover than in healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/66\">",
"     66",
"    </a>",
"    ]. SNRIs are clinically effective at attenuating symptoms of panic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=see_link&amp;anchor=H11968407#H11968407\">",
"     \"Pharmacotherapy for panic disorder\", section on 'Serotonin-norepinephrine re-uptake inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few, limited studies have examined noradrenergic dysregulation in patients with OCD, with inconclusive results. Data from the existing studies are inconclusive. One study has shown elevated plasma norepinephrine levels in OCD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20550132\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with co-occurring substance use disorders (SUDs) and anxiety disorders on average present with a more severe clinical profile as compared to individuals with either disorder alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. As an example, research involving individuals seeking treatment has demonstrated that cocaine dependent individuals with PTSD, as compared to without PTSD, present with more severe depression, vocational impairment, interpersonal dysfunction, medical problems, and other Axis I and II disorders.",
"   </p>",
"   <p>",
"    Substance use, abuse, or dependence can mimic or exacerbate symptoms of anxiety",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stimulants, in particular, can cause heart palpitations, trembling or shaking, sweating, dizziness or feeling faint, depersonalization, paresthesias, nausea, and hot flushes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Withdrawal from substances of abuse, including opioids, alcohol, and benzodiazepines, can generate anxiety symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Opiate withdrawal is characterized by insomnia, nausea, and diarrhea, but may be distinguished from independent anxiety by the often severe muscle aches, vomiting and fever. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/5/28758?source=see_link\">",
"       \"Opioid withdrawal in the emergency setting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alcohol and benzodiazepine withdrawal may also generate anxiety symptoms, such as insomnia, psychomotor agitation, tachycardia, perspiration, nausea, and tremor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20550139\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median age of onset for alcohol and other drug dependence has been estimated at 23 and 21 years of age, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/14\">",
"     14",
"    </a>",
"    ]. The median age of onset for anxiety disorders ranges from 7 years old for specific phobia to 31 years old for generalized anxiety disorder.",
"   </p>",
"   <p>",
"    In the majority of cases, the anxiety disorder is temporally primary, meaning that the onset of the anxiety disorder precedes the onset of the substance use disorder (SUD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/2,16,71\">",
"     2,16,71",
"    </a>",
"    ]. An analysis of data from several epidemiologic studies found that among individuals with both alcohol dependence and an anxiety disorder, the anxiety disorder preceded alcohol dependence in 56.7 to 79.4 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/72\">",
"     72",
"    </a>",
"    ]. Among individuals with both drug dependence and an anxiety disorder, the anxiety disorder preceded drug dependence in 67.6 percent to 100 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/72\">",
"     72",
"    </a>",
"    ]. This temporal ordering of onset suggests that anxiety disorders predispose individuals to developing SUDs later in life; however, available evidence does not allow for definitive conclusions on causality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/16,71\">",
"     16,71",
"    </a>",
"    ]. This link between anxiety disorders and SUDs may be related to self-medication of anxiety symptoms, shared neurobiological connections, or genetic predispositions.",
"   </p>",
"   <p>",
"    Both SUDs and anxiety disorders are chronic, relapsing conditions. Comorbid SUDs and anxiety disorders are more chronic than non-comorbid substance use or anxiety disorders, and are associated with increased likelihood of poverty, homelessness, being the victim or perpetrator of abuse, and risk of death by homicide, suicide or accidental means [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20550146\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating diagnostically between a substance-induced state and a true anxiety disorder needs to be addressed in the psychiatric examination. Most of the time, however, the co-occurring anxiety disorder will be independent and will not be a substance-induced anxiety disorder. Grant and colleagues (2004) investigated co-occurring substance use disorders (SUDs) and independent anxiety disorders and the findings demonstrated that only a few individuals experienced current anxiety disorders that were only substance induced. These findings strongly suggest that co-occurring anxiety disorders among patient with SUDs be targeted in treatment. Otherwise, the anxiety symptoms will continue to serve as a trigger for relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presentations can be challenging to diagnose due to several areas of overlapping manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The active use of some substances, such as stimulants, may produce anxiety states that mimic true anxiety disorders.",
"     </li>",
"     <li>",
"      Withdrawal from some substances, such as opiates and benzodiazepines, lead to anxiety states.",
"     </li>",
"     <li>",
"      The chronic use of drugs and alcohol exerts a powerful influence on neurotransmitter systems related to the development of anxiety disorders, and may unmask a biological susceptibility or lead to neurobiologic changes over time that manifest as anxiety disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical assessment needs to consider illicit drugs, caffeine, and over-the-counter medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    and diet pills, all of which may produce substantial anxiety, irritability and panic attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/73\">",
"     73",
"    </a>",
"    ], and mimic the symptoms of panic disorder and drug withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Decreasing consumption of these substances may help to significantly decrease anxiety. As example, patients with panic disorder may find that reducing their consumption of caffeinated sodas, coffees and teas leads to a decrease in the frequency and severity of their panic attacks.",
"   </p>",
"   <p>",
"    Clinical observation during a period of abstinence from substances can distinguish a substance-induced, transient state from a true anxiety disorder. The duration of abstinence necessary for accurate diagnosis varies depending on the substance.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For substances with a long half-life (eg, benzodiazepines such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      ), withdrawal symptoms may be protracted. Several weeks of abstinence may be needed to distinguish anxiety stemming from withdrawal from an independent anxiety disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For substances with a shorter half-life (eg, alcohol and cocaine), accurate diagnosis may be possible after a shorter period of abstinence (eg, 30 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several questions may help differentiate between a substance-induced state and a true anxiety disorder. Endorsement of the following questions supports a primary anxiety diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Were the anxiety symptoms present before substance use commenced?",
"     </li>",
"     <li>",
"      Is there a positive family history of anxiety disorders?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16814853\">",
"    <span class=\"h2\">",
"     Generalized anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized anxiety disorder (GAD) in particular can be difficult to diagnose in the presence of active substance use. Symptoms of GAD, which include anxiety, worry, restlessness, fatigue, irritability, poor concentration, muscle tension, and sleep impairment, can be mimicked by substance use. To accurately diagnose GAD, the assessment should be delayed until intoxication or withdrawal has terminated. Reassessment of the patient after a period of prolonged abstinence can confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early identification of drug or alcohol use among patients with GAD is critical, because GAD is associated with significantly faster progression from initial substance use to the development of a substance use disorder. In a study of 1,269 adolescents and young adults, GAD was associated with a 3.5-fold increase in rate of progression from first drink to the onset of alcohol dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16814860\">",
"    <span class=\"h2\">",
"     Obsessive-compulsive disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obsessive-compulsive disorder (OCD) has symptoms that overlap with substance use disorders. However, while SUDs are characterized by elements of obsessive thinking and compulsive behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/78\">",
"     78",
"    </a>",
"    ], a diagnosis of OCD is differentiated by the focus of the obsessions and compulsions. Patients with OCD endorse thoughts centered on contamination or doubt. Patients with SUDs endorse intrusive thoughts centered on alcohol or drugs, feel compelled to use alcohol or drugs, and may feel that if they use substances, the distressing thoughts or compulsions to use will be quelled. The use of substances is connected in a realistic way with the cravings that patients with SUDs experience (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16814871\">",
"    <span class=\"h2\">",
"     Panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis of panic disorder and SUDs can be complicated by the fact that acute intoxication or withdrawal from alcohol, stimulants, and opioids can precipitate panic-like symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=see_link&amp;anchor=H191515190#H191515190\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Assessment and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heavy alcohol use increases sensitivity to carbon dioxide, thereby increasing the possibility of a panic attack [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Because of noradrenergic stimulation, the use of stimulants may induce panic attacks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41177/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Irritability and anxiety are observed during withdrawal from sedatives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2348985\">",
"    <span class=\"h2\">",
"     Other anxiety disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance-induced anxiety can be distinguished from social anxiety disorder (SAD) by the latter&rsquo;s requirement for the presence of a fear of public scrutiny, which is not mimicked by substance use, intoxication, or withdrawal. In addition, symptoms of SAD usually present early in life, before the onset of substance use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link&amp;anchor=H147157737#H147157737\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of PTSD result from exposure to a traumatic life event (eg, physical or sexual assault, natural disaster, serious accident, combat experiences). Intrusive thoughts or images related to the trauma are unlikely to be mimicked by substance use, intoxication or withdrawal. Hyperarousal symptoms of PTSD (eg, irritability, sleep impairment, difficulty concentrating, exaggerated startle response) can be mimicked or exacerbated by the use of or withdrawal from alcohol and drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link&amp;anchor=H13#H13\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16815232\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Substance use disorders (SUDs) have been found to co-occur at an increased rate in posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder (SAD). In most instances, the anxiety disorder onset precedes that of the SUD(s). Obsessive-compulsive disorder (OCD) and SUDs have not been found to be strongly associated. (See",
"      <a class=\"local\" href=\"#H20550104\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preclinical studies demonstrate that SUDs and anxiety disorders share common neurobiological substrates that include disruptions within the hypothalamic-pituitary-adrenal (HPA) axis and noradrenergic systems. (See",
"      <a class=\"local\" href=\"#H20550111\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with co-occurring SUDs and anxiety disorders present with a more severe clinical profile and greater chronicity as compared to individuals with either disorder alone. (See",
"      <a class=\"local\" href=\"#H20550132\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20550139\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical observation during a period of prolonged abstinence from substances can distinguish a transient, substance-induced state from a true anxiety disorder. The duration of abstinence necessary for accurate diagnosis varies depending on the substance. (See",
"      <a class=\"local\" href=\"#H20550146\">",
"       'Assessment and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Substances with a long half-life (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      ) may require several weeks of abstinence to make an accurate diagnosis.",
"     </li>",
"     <li>",
"      Substances with a shorter half-life (eg, alcohol and cocaine), can generally be accurately diagnosed after approximately 30 days of abstinence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tips for distinguishing anxiety disorders from the effects of substance intoxication or withdrawal differ by disorder:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most all the symptoms of generalized anxiety disorder can be mimicked by substance use. Assessment should be delayed until symptoms of intoxication or withdrawal have resolved. (See",
"      <a class=\"local\" href=\"#H16814853\">",
"       'Generalized anxiety disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to obsessive-compulsive disorder, obsessive thinking and compulsive behaviors that occur secondary to a SUD center around the substances used. (See",
"      <a class=\"local\" href=\"#H16814860\">",
"       'Obsessive-compulsive disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Substances, stimulants in particular, can induce panic attacks. In contrast to panic experienced in the context of SUDs, attacks characteristic of panic disorder occur unexpectedly, and patients experience persistent worry about having another attack. (See",
"      <a class=\"local\" href=\"#H16814871\">",
"       'Panic disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperarousal symptoms of posttraumatic stress disorder (eg, irritability, sleep impairment, difficulty concentrating, exaggerated startle response) can be exacerbated by the use of, or withdrawal from, alcohol and drugs. (See",
"      <a class=\"local\" href=\"#H2348985\">",
"       'Other anxiety disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary feature of social anxiety disorder (SAD), fear of public scrutiny, is not typically mimicked by substance use, intoxication, or withdrawal. Symptoms of SAD that present only in the context of intoxication or withdrawal are not sufficient to meet criteria for a diagnosis of SAD. (See",
"      <a class=\"local\" href=\"#H2348985\">",
"       'Other anxiety disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/1\">",
"      Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/2\">",
"      Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/3\">",
"      Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007; 64:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/4\">",
"      Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/5\">",
"      Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/6\">",
"      Breslau N, Davis GC, Andreski P, Peterson E. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 1991; 48:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/7\">",
"      Breslau N, Davis GC, Peterson EL, Schultz L. Psychiatric sequelae of posttraumatic stress disorder in women. Arch Gen Psychiatry 1997; 54:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/8\">",
"      Cottler LB, Compton WM 3rd, Mager D, et al. Posttraumatic stress disorder among substance users from the general population. Am J Psychiatry 1992; 149:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/9\">",
"      Hoge CW, Auchterlonie JL, Milliken CS. Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan. JAMA 2006; 295:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/10\">",
"      Milliken CS, Auchterlonie JL, Hoge CW. Longitudinal assessment of mental health problems among active and reserve component soldiers returning from the Iraq war. JAMA 2007; 298:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/11\">",
"      Jacobson IG, Ryan MA, Hooper TI, et al. Alcohol use and alcohol-related problems before and after military combat deployment. JAMA 2008; 300:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/12\">",
"      Wilk JE, Bliese PD, Kim PY, et al. Relationship of combat experiences to alcohol misuse among U.S. soldiers returning from the Iraq war. Drug Alcohol Depend 2010; 108:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/13\">",
"      Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 Suppl 8:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/14\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/15\">",
"      Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2005; 35:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/16\">",
"      Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 1990; 147:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/17\">",
"      Sareen J, Chartier M, Paulus MP, Stein MB. Illicit drug use and anxiety disorders: findings from two community surveys. Psychiatry Res 2006; 142:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/18\">",
"      Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/19\">",
"      Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/20\">",
"      Canino GJ, Bird HR, Shrout PE, et al. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry 1987; 44:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/21\">",
"      Angst J, Dobler-Mikola A, Binder J. The Zurich study--a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. I. Problem, methodology. Eur Arch Psychiatry Neurol Sci 1984; 234:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/22\">",
"      Swendsen JD, Merikangas KR, Canino GJ, et al. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry 1998; 39:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/23\">",
"      O'Brien MS, Wu LT, Anthony JC. Cocaine use and the occurrence of panic attacks in the community: a case-crossover approach. Subst Use Misuse 2005; 40:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/24\">",
"      Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/25\">",
"      Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/26\">",
"      Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 2002; 28:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/27\">",
"      Carrigan MH, Randall CL. Self-medication in social phobia: a review of the alcohol literature. Addict Behav 2003; 28:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/28\">",
"      Bolton J, Cox B, Clara I, Sareen J. Use of alcohol and drugs to self-medicate anxiety disorders in a nationally representative sample. J Nerv Ment Dis 2006; 194:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/29\">",
"      Schuckit MA, Tipp JE, Bucholz KK, et al. The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction 1997; 92:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/30\">",
"      Sbrana A, Bizzarri JV, Rucci P, et al. The spectrum of substance use in mood and anxiety disorders. Compr Psychiatry 2005; 46:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/31\">",
"      Schuckit MA, Tipp JE, Bergman M, et al. Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am J Psychiatry 1997; 154:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/32\">",
"      Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berl) 2001; 158:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/33\">",
"      Erb S, Shaham Y, Stewart J. Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology (Berl) 1996; 128:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/34\">",
"      Moldow RL, Fischman AJ. Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone. Peptides 1987; 8:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/35\">",
"      Brady KT, McRae AL, Moran-Santa Maria MM, et al. Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. Arch Gen Psychiatry 2009; 66:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/36\">",
"      Shaham Y, Erb S, Leung S, et al. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 1998; 137:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/37\">",
"      Erb S, Salmaso N, Rodaros D, Stewart J. A role for the CRF-containing pathway from central nucleus of the amygdala to bed nucleus of the stria terminalis in the stress-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) 2001; 158:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/38\">",
"      Maes M, Lin A, Bonaccorso S, et al. Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998; 98:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/39\">",
"      Mason JW, Giller EL, Kosten TR, et al. Urinary free-cortisol levels in posttraumatic stress disorder patients. J Nerv Ment Dis 1986; 174:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/40\">",
"      Baker DG, West SA, Nicholson WE, et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999; 156:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/41\">",
"      Yehuda R, Lowy MT, Southwick SM, et al. Lymphocyte glucocorticoid receptor number in posttraumatic stress disorder. Am J Psychiatry 1991; 148:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/42\">",
"      Yehuda R, Boisoneau D, Lowy MT, Giller EL Jr. Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder. Arch Gen Psychiatry 1995; 52:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/43\">",
"      Yehuda R, Levengood RA, Schmeidler J, et al. Increased pituitary activation following metyrapone administration in post-traumatic stress disorder. Psychoneuroendocrinology 1996; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/44\">",
"      Bremner JD, Licinio J, Darnell A, et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997; 154:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/45\">",
"      Kellner M, Schick M, Yassouridis A, et al. Metyrapone tests in patients with panic disorder. Biol Psychiatry 2004; 56:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/46\">",
"      Abelson JL, Curtis GC. Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry 1996; 53:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/47\">",
"      Mantella RC, Butters MA, Amico JA, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 2008; 33:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/48\">",
"      Rosenbaum AH, Schatzberg AF, Jost FA 3rd, et al. Urinary free cortisol levels in anxiety. Psychosomatics 1983; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/49\">",
"      Okasha A, Bishry Z, Khalil AH, et al. Panic disorder. An overlapping or independent entity? Br J Psychiatry 1994; 164:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/50\">",
"      Tiller JW, Biddle N, Maguire KP, Davies BM. The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biol Psychiatry 1988; 23:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/51\">",
"      Catapano F, Monteleone P, Maj M, Kemali D. Dexamethasone suppression test in patients with primary obsessive-compulsive disorder and in healthy controls. Neuropsychobiology 1990; 23:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/52\">",
"      Coryell WH, Black DW, Kelly MW, Noyes R Jr. HPA axis disturbance in obsessive-compulsive disorder. Psychiatry Res 1989; 30:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/53\">",
"      Altemus M, Pigott T, Kalogeras KT, et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/54\">",
"      Chappell P, Leckman J, Goodman W, et al. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry 1996; 39:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/55\">",
"      Gehris TL, Kathol RG, Black DW, Noyes R Jr. Urinary free cortisol levels in obsessive-compulsive disorder. Psychiatry Res 1990; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/56\">",
"      Kluge M, Sch&uuml;ssler P, K&uuml;nzel HE, et al. Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder. J Psychiatr Res 2007; 41:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/57\">",
"      Koob GF. Brain stress systems in the amygdala and addiction. Brain Res 2009; 1293:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/58\">",
"      Amit Z, Brown ZW, Levitan DE, Ogren SO. Noradrenergic mediation of the positive reinforcing properties of ethanol: I. Suppression of ethanol consumption in laboratory rats following dopamine-beta-hydroxylase inhibition. Arch Int Pharmacodyn Ther 1977; 230:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/59\">",
"      Walker BM, Rasmussen DD, Raskind MA, Koob GF. alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol 2008; 42:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/60\">",
"      Wee S, Mandyam CD, Lekic DM, Koob GF. Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. Eur Neuropsychopharmacol 2008; 18:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/61\">",
"      Delfs JM, Zhu Y, Druhan JP, Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 2000; 403:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/62\">",
"      Southwick SM, Bremner JD, Rasmusson A, et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 46:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/63\">",
"      Agren H. Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory. Acta Psychiatr Scand Suppl 1986; 327:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/64\">",
"      Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/65\">",
"      Vasa RA, Pine DS, Masten CL, et al. Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology (Berl) 2009; 204:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/66\">",
"      Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986; 43:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/67\">",
"      Freire RC, Hallak JE, Crippa JA, Nardi AE. New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother 2011; 12:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/68\">",
"      Fluitman SB, Denys DA, Heijnen CJ, Westenberg HG. Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive-compulsive disorder. Psychoneuroendocrinology 2010; 35:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/69\">",
"      Najavits LM, Weiss RD, Shaw SR, Muenz LR. \"Seeking safety\": outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence. J Trauma Stress 1998; 11:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/70\">",
"      Back SE, Dansky BS, Carroll KM, et al. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: description of procedures. J Subst Abuse Treat 2001; 21:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/71\">",
"      Compton WM 3rd, Cottler LB, Phelps DL, et al. Psychiatric disorders among drug dependent subjects: are they primary or secondary? Am J Addict 2000; 9:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/72\">",
"      Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav 1998; 23:893.",
"     </a>",
"    </li>",
"    <li>",
"     Uhde TW. Effects of caffeine pn anxiety and depression. In: Neurobiology of Panic Disorder, Ballenger JC.  (Ed), Wiley-Liss, New York 1990. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/74\">",
"      Kendler KS, Myers J, O Gardner C. Caffeine intake, toxicity and dependence and lifetime risk for psychiatric and substance use disorders: an epidemiologic and co-twin control analysis. Psychol Med 2006; 36:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/75\">",
"      Veleber DM, Templer DI. Effects of caffeine on anxiety and depression. J Abnorm Psychol 1984; 93:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/76\">",
"      Quello SB, Brady KT, Sonne SC. Mood disorders and substance use disorder: a complex comorbidity. Sci Pract Perspect 2005; 3:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/77\">",
"      Sartor CE, Lynskey MT, Heath AC, et al. The role of childhood risk factors in initiation of alcohol use and progression to alcohol dependence. Addiction 2007; 102:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/78\">",
"      Modell JG, Glaser FB, Cyr L, Mountz JM. Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin Exp Res 1992; 16:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/79\">",
"      Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 1992; 32:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/80\">",
"      Cosci F, Schruers KR, Abrams K, Griez EJ. Alcohol use disorders and panic disorder: a review of the evidence of a direct relationship. J Clin Psychiatry 2007; 68:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41177/abstract/81\">",
"      Louie AK, Lannon RA, Rutzick EA, et al. Clinical features of cocaine-induced panic. Biol Psychiatry 1996; 40:938.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14850 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-FDE34C00CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41177=[""].join("\n");
var outline_f40_13_41177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16815232\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20550097\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20550104\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H554290\">",
"      Substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17734023\">",
"      Posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17734030\">",
"      Generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17734037\">",
"      Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17734046\">",
"      Social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18656367\">",
"      Obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20550111\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20550118\">",
"      Hypothalamic pituitary adrenal (HPA) axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20550125\">",
"      Noradrenaline systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20550132\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20550139\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20550146\">",
"      ASSESSMENT AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16814853\">",
"      Generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16814860\">",
"      Obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16814871\">",
"      Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2348985\">",
"      Other anxiety disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16815232\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10488?source=related_link\">",
"      Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1079?source=related_link\">",
"      Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3784?source=related_link\">",
"      Opioid abuse and dependence: Overview and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_13_41178="Approach to symptom assessment in palliative care";
var content_f40_13_41178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to symptom assessment in palliative care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41178/contributors\">",
"     Victor T Chang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41178/contributors\">",
"     Robert M Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/13/41178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/13/41178/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/13/41178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving suffering, and on supporting the best possible quality of life for patients who are facing a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;Palliative care aims to relieve suffering in all stages of disease, and is not limited to end of life care. Within an integrated model of medical care, palliative care is provided at the same time as curative or life-prolonging treatments (",
"    <a class=\"graphic graphic_algorithm graphicRef64252 \" href=\"mobipreview.htm?42/14/43246\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients in the advanced stage of a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life threatening illness typically experience multiple symptoms, the most common of which are pain, depression, anxiety, confusion, fatigue, breathlessness, insomnia, nausea, constipation, diarrhea, and anorexia (",
"    <a class=\"graphic graphic_table graphicRef87163 \" href=\"mobipreview.htm?11/27/11710\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. These symptoms may result from a number of factors. Among patients with advanced cancer, for example, symptoms may result from the disease (eg, bone pain from metastases, dyspnea from pleural effusions), from treatment (eg, esophagitis with thoracic radiation therapy), or from other concurrent conditions (eg, osteoarthritis).",
"   </p>",
"   <p>",
"    This topic review provides a suggested approach to assessment for the most common physical and psychological symptoms that arise in patients receiving palliative care for an advanced serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness. The principles underlying the comprehensive palliative care assessment (which include domains other than physical and psychologic symptoms), and an overview of treatment for symptoms commonly encountered in a palliative care population are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient descriptions of physical symptoms and their severity are the primary data for symptom assessment in palliative care. Exploring patients&rsquo; reports of symptoms requires thoroughness, persistence, and patience; this is a fundamental aspect of patient-centered care.",
"   </p>",
"   <p>",
"    It is important to assess mental status and stamina before starting to elicit information as to the nature and severity of symptoms. Seriously fatigued patients may only be able to answer a few questions briefly, and more than one visit may be necessary. Patients who are confused or delirious will not be able to cooperate fully, making symptom identification and assessment difficult; failure to recognize delirium may lead to inaccurate assessments and inappropriate therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with advanced illnesses typically have multiple symptoms, and systematic assessment is preferable to relying on spontaneously described symptoms. A study of patients referred to a palliative medicine program found that there were 10 symptoms for every one symptom that was volunteered by a patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/6\">",
"     6",
"    </a>",
"    ]. A careful review of symptoms with a focus on common problems in palliative care practice is required. Comprehensive symptom assessment can contribute to significant symptom improvement and better quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Each identified symptom should be investigated in regard to its Onset, Palliating and Provoking factors, Quality, Response to previous treatments, Related",
"    <span class=\"nowrap\">",
"     factors/symptoms,",
"    </span>",
"    Severity, and Temporality (the OPQRST historical structure for evaluating medical complaints). Of comparable importance, but less emphasized, is understanding the personal meaning of a symptom to the patient and how the symptom affects their psychosocial well-being (the MOPQRST mnemonic, (",
"    <a class=\"graphic graphic_table graphicRef87818 \" href=\"mobipreview.htm?12/59/13243\">",
"     table 2",
"    </a>",
"    )). Sample questions to explore the meaning of specific symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the symptoms that have been bothering you, which symptom bothers you the most [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/9\">",
"       9",
"      </a>",
"      ]?",
"     </li>",
"     <li>",
"      How do the symptoms affect you? How much do they interfere with your life (eg, sleep? daily activities? your sense of well-being?)",
"     </li>",
"     <li>",
"      What ideas do you have about the meaning of these symptoms?",
"     </li>",
"     <li>",
"      Do they make you worry about your",
"      <span class=\"nowrap\">",
"       health/illness?",
"      </span>",
"      What are your concerns?",
"     </li>",
"     <li>",
"      How are these symptoms affecting your family and friends?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discussing symptoms with the patient&rsquo;s caregivers may also be informative and provide opportunities to be supportive and educate family and friends [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following initial assessment, periodic symptom reassessment is valuable for identifying or modifying treatment goals, monitoring the response to specific symptomatic interventions, and for communicating between members of the health care team and with caregivers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4277426\">",
"    <span class=\"h2\">",
"     Dimensions of symptom assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dimensions are different aspects of symptoms, such as severity, frequency, level of interference with activities, and level of distress associated with the symptom.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Symptom severity is a useful guide to treatment (eg, pain) and it may also provide some prognostic information (eg, dyspnea). (See",
"    <a class=\"local\" href=\"#H192146909\">",
"     'Performance status, symptoms, and prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of rating instruments that are completed by patients themselves represents a major change in symptom assessment over the last 30 years. In evaluating symptoms, it is helpful to obtain the patient's rating of severity within a given time frame, such as the last 24 hours. The approach to rating pain relies exclusively on how the patient reports pain, using a verbal or numerical scale. The patient can be asked to make a mark on a 10 cm straight line (Visual Analog Scale or VAS, (",
"    <a class=\"graphic graphic_figure graphicRef62346 \" href=\"mobipreview.htm?41/46/42723\">",
"     figure 1",
"    </a>",
"    )) or rate severity on a scale of 0 to 10, where 10 is worst. These approaches are based upon psychophysical studies in the field of subjective sensory physiology, where it has been shown that perception of a stimulus is closely related to the strength of the stimulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients are unable to rate their symptom severity on a numerical scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/12\">",
"     12",
"    </a>",
"    ]. An alternative approach is to ask patients for their rating of symptom distress rather than severity, and to give them categories of response (eg, bothered not at all, a little bit, somewhat, quite a bit, very much). Some symptoms, such as fatigue, may be rated by patients as mild in severity, but severe in distress. The amount and type of interference with daily activities caused by a symptom also can illustrate symptom severity and provide another means of determining therapeutic success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4277550\">",
"    <span class=\"h2\">",
"     Symptom change",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's assessment of symptom relief is also important since it drives the therapeutic plan. The definition of the minimum clinically significant differences in symptom instruments for pain, fatigue, and dyspnea has been an important advance in the interpretation of symptom ratings, and can be considered to be a 2 point change on an 11 point scale (eg, 0 to 10, (",
"    <a class=\"graphic graphic_figure graphicRef62346 \" href=\"mobipreview.htm?41/46/42723\">",
"     figure 1",
"    </a>",
"    )) or any change in categories of a Likert scale, such as the faces pain scale (",
"    <a class=\"graphic graphic_form graphicRef67351 \" href=\"mobipreview.htm?12/21/12624\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1507215\">",
"    <span class=\"h2\">",
"     Challenges in symptom assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of situations raise particular challenges for symptom assessment in palliative care patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient&rsquo;s assessment of symptoms may differ from that of the health professional. In general, clinicians (and caregivers) have greater discordance with patients in assessing the severity of subjective symptoms than for objective states, such as the presence of vomiting. Clinicians tend to rate the severity of symptoms lower than do patients and family members, and to tolerate levels of symptom-related distress and suffering that patients find unacceptable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/18-22\">",
"       18-22",
"      </a>",
"      ]. In contrast, family members tend to over-rate symptoms as well [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. However, where pain is concerned, older family members tend to over-rate while younger family members tend to under-rate pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/23\">",
"       23",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Patients may downplay or not report symptoms (particularly pain) because of fears that worsening symptoms reflect disease progression. Underreporting may also occur if a patient feels that a symptom such as pain is an inevitable consequence of the disease, its treatment, or of dying. In addition, if patients do not receive attention to oft-voiced complaints, they may stop communicating about distress related to that specific complaint.",
"     </li>",
"     <li>",
"      Many symptoms are multifactorial in origin. A comprehensive assessment process will help define all the possible factors that may be causing a specific symptom. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to specific symptoms'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      their families may have suffered harm in the health care system and lost trust in the system",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      care providers. This may make them particularly reluctant to discuss psychological symptoms. Particularly in these cases, the assessment interview with the patient and family may itself have therapeutic value in enhancing the care provider relationships with patient and family, eliciting care preferences and developing trust. &nbsp;",
"     </li>",
"     <li>",
"      Cultural factors may affect symptom assessment. Cultural factors may determine which symptoms are acceptable for discussion between patients and physicians, and how patients perceive their symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/26\">",
"       26",
"      </a>",
"      ]. As an example, in some cultures, women may not be comfortable sharing gynecologic complaints with a male physician. &nbsp;",
"     </li>",
"     <li>",
"      Patients may have difficulty communicating. Examples include intubated patients in the intensive care unit, patients who are withdrawn or who have cognitive impairment, and those who are just too ill to voice complaints. As patients near death, symptom assessment becomes more difficult because the majority of patients become noncommunicative and other symptoms, such as restlessness and confusion, may interfere with effective communication. The study of behavioral changes as clues to the presence of pain (eg, grimacing) is an area of ongoing research, and forms the basis for observer-based rating instruments such as the",
"      <a class=\"external\" href=\"file://web.missouri.edu/~proste/tool/cog/painad.pdf\">",
"       Pain Assessment in Advanced Dementia [PAINAD] tool",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patients unable to self-report'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Involved family members and caregivers may be asked by health professionals to assess and rate symptoms (proxy ratings). However, there may be disparities between patient and caregiver symptom assessments or ratings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/23,27,28\">",
"       23,27,28",
"      </a>",
"      ]. For patients with impaired communication, the palliative care consultant may have to balance multiple assessments by family, caregivers, and health care personnel. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patients unable to self-report'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Care providers (physicians and nurses alike) may not be aware of the high prevalence of symptoms in these patients, may not have symptom assessment incorporated into their conversations with patients, and may lack knowledge about symptom identification and management. The average number of symptoms ranges from 11 to 18 in a wide variety of illnesses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/29-31\">",
"       29-31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND RATING INSTRUMENTS FOR SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal multiple symptom assessment tools, especially those that are symptom inventories like the revised Edmonton Symptom Assessment Scale, provide a good overview of symptoms in individual patients (",
"    <a class=\"graphic graphic_figure graphicRef65702 \" href=\"mobipreview.htm?3/30/3567\">",
"     figure 2",
"    </a>",
"    ). In particular, multiple symptom assessment tools are highly effective in the recognition of unreported symptoms, when combined with further patient interviewing to delineate the details of positive responses. When a specific tool has been chosen, it should be used consistently to ensure reliability in the clinical setting.",
"   </p>",
"   <p>",
"    Many of these symptom assessment tools have been tested for reliability and validity. However, like any other measurement of health outcomes, there are potential errors in assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/32\">",
"     32",
"    </a>",
"    ]. The possibilities for assessment errors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motor, hearing, and visual impairments may impede the usefulness of symptom assessment tools in the elderly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/23/20855?source=see_link&amp;anchor=H2#H2\">",
"       \"Palliative care: Issues specific to geriatric patients\", section on 'Symptom assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cognitive dysfunction may lead to misleading responses and inaccurate assessment, even when paired with behavioral indicators [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/5\">",
"       5",
"      </a>",
"      ]. The cognitive dysfunction may be quite subtle. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patients unable to self-report'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Shorter tools may miss symptoms that are important to the patient, and longer tools may be too tiring for patients to complete. (See",
"      <a class=\"local\" href=\"#H1507215\">",
"       'Challenges in symptom assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As the patient&rsquo;s condition changes, symptom ratings may change as he or she accommodates to the new condition, even if the symptom has not changed. This is referred to as the phenomenon of response shift. Ratings may also be influenced by other symptoms, especially anxiety and other emotional reactions, which may change over time. (See",
"      <a class=\"local\" href=\"#H4277550\">",
"       'Symptom change'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Interpretation of the &ldquo;anchors&rdquo; (0 and 10 on the numerical 0 to 10 scale) may vary between patients, depending upon their previous experience. Caregivers and health care personnel may also interpret the anchors differently. It may be necessary to repeat the definitions of the anchors when asking patients to give a rating.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these limitations, a number of validated multiple symptom assessment tools are in wide usage in palliative and end of life care settings, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Edmonton Symptom Assessment Scale, which is available as a nine-item (",
"      <a class=\"graphic graphic_figure graphicRef65702 \" href=\"mobipreview.htm?3/30/3567\">",
"       figure 2",
"      </a>",
"      ) and a 15-item scale (",
"      <a class=\"graphic graphic_table graphicRef56065 \" href=\"mobipreview.htm?25/43/26299\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. A revised version is available online that reorders the symptoms into physical first, psychosocial second, and overall well-being last (",
"      <a class=\"external\" href=\"file://www.palliative.org/NewPC/_pdfs/tools/ESAS-r.pdf\">",
"       ESAS-r",
"      </a>",
"      ). A Spanish language version has also been developed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Memorial Symptom Assessment Scale-Short (MSAS) Form (",
"      <a class=\"graphic graphic_figure graphicRef60205 \" href=\"mobipreview.htm?23/13/23762\">",
"       figure 3",
"      </a>",
"      ) and Condensed MSAS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      MD Anderson Brief Symptom Inventory [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rotterdam Symptom Checklist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Symptom Distress Scale [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patient-Reported Outcomes Measurement Information System (PROMIS,",
"      <a class=\"external\" href=\"file://www.nihpromis.org/\">",
"       www.nihpromis.org",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/44\">",
"       44",
"      </a>",
"      ]), as developed by the US National Institutes of Health (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4120?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation of health-related quality of life\", section on 'Combined instruments for patient-reported outcomes'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&amp;pageId=86426\">",
"       Interactive Symptom Assessment and Collection",
"      </a>",
"      (ISAAC) tool, developed and hosted by Cancer Care Ontario",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/pdf/distress.pdf\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      Distress thermometer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Instruments are available that focus on one symptom, such as dyspnea or pain. One example is the Brief Pain Inventory, a patient self-rating scale that assesses pain intensity and pain interference in various areas of function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]; a short-form version is available online",
"    <a class=\"external\" href=\"file://www.npcrc.org/usr_doc/adhoc/painsymptom/briefpain_short.pdf\">",
"     (BPI-SF)",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H9\">",
"     'History'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    However, detailed instruments such as these are not available for all symptoms, and patients may not be able to answer the multiple questions from many instruments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192146909\">",
"    <span class=\"h1\">",
"     PERFORMANCE STATUS, SYMPTOMS, AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performance status is a critical aspect of patient assessment in palliative care. As a general rule, performance status, as assessed by the Karnofsky or ECOG performance status scales (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 5",
"    </a>",
"    ) is a key indicator of prognosis in individuals with advanced terminal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/47\">",
"     47",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://pallipedia.org/term.php?id=504\">",
"     Palliative Performance Scale",
"    </a>",
"    (PPS) is gaining wide acceptance as a tool for assessing functional levels and as a method of estimating prognosis in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The PPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/49,50\">",
"     49,50",
"    </a>",
"    ] may be a better indicator of functional status than other types of performance status scales, including Karnofsky and ECOG, in this population. Comparisons suggest there is considerable overlap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link&amp;anchor=H93043526#H93043526\">",
"     \"Survival estimates in advanced terminal cancer\", section on 'Patients receiving supportive care only'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link&amp;anchor=H5#H5\">",
"     \"Survival estimates in advanced terminal cancer\", section on 'Performance status'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less well recognized is the relationship between symptoms, performance status, and prognosis. As an example, symptom number and intensity correlate significantly with performance status and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/52\">",
"     52",
"    </a>",
"    ]. As a terminal disease progresses, there is often a continual decline in function that is accompanied by increasing fatigue and cachexia.",
"   </p>",
"   <p>",
"    Other specific clinical signs and symptoms may represent independent prognostic factors in patients with advanced serious or life-threatening disease. As an example, in a systematic review of survival prediction in terminal cancer, the strongest evidence after performance status for an independent association with death was for dyspnea, dysphagia, weight loss, xerostomia, anorexia, and cognitive impairment (delirium) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/50\">",
"     50",
"    </a>",
"    ]. The following table shows the range of median survivals in patients with various signs and symptoms in univariate analyses from this and other studies (",
"    <a class=\"graphic graphic_table graphicRef56650 \" href=\"mobipreview.htm?3/36/3660\">",
"     table 6",
"    </a>",
"    ). These findings suggest that for patients with advanced life threatening diseases, such as those referred to palliative care programs, the presence of these symptoms may help physicians estimate patient survival.",
"   </p>",
"   <p>",
"    Dyspnea is a particularly important indicator of shortened survival in a variety of diseases, but especially in terminally ill cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/3,6,34,37-39,53\">",
"     3,6,34,37-39,53",
"    </a>",
"    ]. In one study, the presence of dyspnea was associated with a median survival of less than 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/53\">",
"     53",
"    </a>",
"    ]. The impact of dyspnea and other symptoms on prognostic estimates in advanced cancer, and assessment of dyspnea in palliative care patients are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link&amp;anchor=H6#H6\">",
"     \"Survival estimates in advanced terminal cancer\", section on 'Clinical signs and symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89104000#H89104000\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Assessment of dyspnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among dyspneic patients, other findings may help to predict the likelihood of imminent death. As an example, in a retrospective sample of 122 patients with cancer who presented to an emergency room with acute dyspnea, a respiratory rate greater than",
"    <span class=\"nowrap\">",
"     28/min,",
"    </span>",
"    heart rate greater than 110 beats per minute, uncontrolled disease, and the presence of metastases were all predictive of death within two weeks; the relative risk for imminent death among patients with a respiratory rate above",
"    <span class=\"nowrap\">",
"     28/min,",
"    </span>",
"    compared to the overall group, was 12.7 (95% CI 3.1-52.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noisy breathing, also known as the \"death rattle\", refers to gurgling breath sounds and is usually a preterminal finding, with death likely in hours to days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of managing common non-pain symptoms in palliative care\", section on 'Last hours of life'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     APPROACH TO SPECIFIC SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a brief discussion about assessing highly prevalent symptoms in the palliative care patient. More detailed discussions of some of these symptoms are available in related topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10693177\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of pain assessment is to obtain a rating of severity and to make a diagnosis of the likely cause. The identification of a specific pain syndrome in cancer patients may lead to a specific management plan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first step is to ask the patient about the presence of pain and its severity and to believe the answers. As noted above, there is a great divergence between how patients and professionals evaluate pain severity. In a study of 103 cancer patients, a comparison of Visual Analogue Scale (VAS) pain ratings by health professionals with those of patients showed lower ratings of severe pain by health care professionals more than 70 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain does not occur just in patients with cancer, however. It is also experienced by a large percentage of patients with end stage heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], chronic obstructive pulmonary disease (COPD), and cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], and is particularly associated with arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following sections will briefly summarize the components of the pain evaluation. A more detailed discussion is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;In eliciting a pain history, initial questions should include site, nature and severity, interference, and relief. In addition, patients may have had (untreated) chronic pains, such as that related to arthritis, that predate the advanced illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Site",
"      </strong>",
"      &mdash; It is always wise to have the patient point to the site of pain to avoid a misunderstanding of anatomical terms.",
"     </li>",
"     <li>",
"      <strong>",
"       Type of pain",
"      </strong>",
"      &mdash; Among patients with cancer, the specific type of pain may help to elucidate the specific pathophysiology. As examples (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H8#H8\">",
"       \"Assessment of cancer pain\", section on 'Inferred pathophysiology (types of cancer pain)'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nociceptive pain is sustained predominantly by ongoing tissue injury. Somatic nociceptive pain involves injury to somatic structures like skin, bone, joints, or muscles. It is usually well localized, and often described by patients as \"aching\", \"stabbing\" or \"throbbing\", in quality. Visceral nociceptive pain results from distension, injury to, or inflammation of visceral organs. It is usually poorly localized, and characterized as \"gnawing\" or \"crampy\" when arising from the obstruction of a hollow viscus (eg, the bowel lumen), or as \"aching\" or \"stabbing\" when arising from other somatically innervated visceral structures, such as organ capsules or parietal pleura. Visceral pain can be referred to somatic structures.&nbsp;Further evaluation often yields an abnormal finding that can be identified on physical examination (such as localized tenderness to palpation) or radiographic scans to explain the symptoms.",
"     </li>",
"     <li>",
"      Neuropathic pain is sustained by abnormal somatosensory processing in the peripheral or central nervous system, or direct damage to nerves. Examples include postherpetic neuralgia, postchemotherapy neuropathy, and phantom pain. Patients may describe unpredictable shooting, burning, numbness, or pruritus. The sensory examination is often helpful if abnormalities such as lack of sensation, increased sensitivity (hyperesthesia), or pain with nonpainful stimuli (allodynia) can be demonstrated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending on the location of the mass, neuropathic pain may be present with nociceptive pain, and may not have its signature features of sensory disturbance or shooting pain, but may be gnawing or constant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severity and QOL impact",
"      </strong>",
"      &mdash; Pain severity guides medication choice and dosage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link\">",
"       \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12890?source=see_link\">",
"       \"Pain assessment and management in the last weeks of life\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There are a number of simple ways to assess pain severity, including a Faces scale (",
"      <a class=\"graphic graphic_form graphicRef67351 \" href=\"mobipreview.htm?12/21/12624\">",
"       form 1",
"      </a>",
"      ), a VAS (",
"      <a class=\"graphic graphic_figure graphicRef62346 \" href=\"mobipreview.htm?41/46/42723\">",
"       figure 1",
"      </a>",
"      ), or a categorical Likert scale (none, a little, somewhat, quite a bit, very much).",
"      <br/>",
"      <br/>",
"      Formal instruments have also been developed to rate pain severity in multiple dimensions. These include the Brief Pain Inventory (BPI; a short-form version of which is available online",
"      <a class=\"external\" href=\"file://www.npcrc.org/usr_doc/adhoc/painsymptom/briefpain_short.pdf\">",
"       (BPI-SF)",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/45,46\">",
"       45,46",
"      </a>",
"      ], the McGill Pain Questionnaire [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/61\">",
"       61",
"      </a>",
"      ] (a",
"      <a class=\"external\" href=\"file://hypnosishelpcenter.net/McGillPainQuestionnaire-Short.pdf\">",
"       shortened version",
"      </a>",
"      is available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/62\">",
"       62",
"      </a>",
"      ]), and the Memorial Pain Assessment Card [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/63\">",
"       63",
"      </a>",
"      ]. Both the McGill Pain Questionnaire and the BPI have been translated into several languages. Although many of these tools were developed for patients with cancer, they are equally applicable to patients with other serious",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      life threatening conditions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H4#H4\">",
"       \"Assessment of cancer pain\", section on 'Intensity'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Another way to evaluate severity is through assessment of the impact of pain on physical and psychological function and quality of life (QOL). Family members may be able to provide important information in this regard. Pain can interfere with QOL by interfering with daily activities, walking, and sleep, and by affecting mood. Severe pain may engender a sense of hopelessness and anxiety. Anxiety, in turn, may increase reactions to pain, while fear can decrease pain reactivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Aggravating and alleviating factors",
"      </strong>",
"      &ndash; This includes response to prior treatment(s)",
"     </li>",
"     <li>",
"      <strong>",
"       Associated symptoms",
"      </strong>",
"      &ndash; This includes paresthesias, weakness, nausea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Temporal patterns",
"      </strong>",
"      &mdash; Temporal assessment of the pain may include information about onset, duration, and fluctuation. Both the extent and duration of relief provided by interventions should be determined.",
"      <br/>",
"      <br/>",
"      Pseudoaddiction describes a situation in which a patient&rsquo;s legitimate chronic pain condition is undertreated with pain medication, leading the patient to act in a way that resembles addictive behavior (requesting extra medications and demanding attention); such patients are often labeled as demonstrating \"drug seeking behaviors\". A careful pain history that emphasizes perceived pain relief will help clarify the issue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=see_link&amp;anchor=H415115661#H415115661\">",
"       \"Prescription drug abuse and addiction: Prevention, identification, and management\", section on 'Pseudoaddiction'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most patients with chronic cancer pain experience periodic flares, often referred to as \"breakthrough pain\". Breakthrough pain can be caused by inadequate dosing, an unprovoked flare of the underlying pain syndrome, or be provoked by a procedure or activity (incident pain). Especially for inpatients, procedural pain is an experience that is often overlooked. Breakthrough pain may result from such routine procedures as dressing changes for pressure ulcers or wounds, positioning for change of bed sheets, or movement in bed for a radiographic study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H3#H3\">",
"       \"Assessment of cancer pain\", section on 'Pain characteristics'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link&amp;anchor=H20#H20\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Management of breakthrough pain'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patient and family perspective",
"      </strong>",
"      &ndash; Patients and their family members should be asked about the meaning of the pain, their understanding of its cause, worries about relief, personal and cultural attitudes, concerns about opioid tolerance and addiction, diversion, and expense. Inquiring about personal experiences with pain earlier in the course of the disease, or in friends and family members can dispel hidden anxieties and misunderstandings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533711386\">",
"    <span class=\"h3\">",
"     Special circumstances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Patients with a history of substance abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids are widely used for treatment of pain in patients with cancer because of their safety, multiple routes of administration, ease of titration, reliability, and effectiveness for all types of pain (ie, somatic, visceral, neuropathic). However, opioids are also potentially abusable drugs. The public health consequences of opioid abuse drive the imperative that all physicians assume responsibility for risk management when these drugs are prescribed for legitimate medical purposes. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'Risk assessment and management for patients receiving opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessing and managing pain is difficult in patients who have a history of substance abuse. Patients with a history of substance abuse who complain of pain can cause considerable apprehension for their care providers because of fears about the potential for deception, drug abuse, addiction, and diversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a remote history of substance use and who have a stable support system are less likely to abuse opioids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/67\">",
"     67",
"    </a>",
"    ]. In our own experience, these patients appreciate a careful and objective pain evaluation and are generally responsible and appropriate in their use of opioids as a component of their medical treatment. Further inquiry into the circumstances of past substance use is helpful. Sometimes they and their family members are even more concerned about addiction to pain medications than are professional staff.",
"   </p>",
"   <p>",
"    Patients who are actively using \"street drugs\" at the time of initial evaluation should have a careful and objective pain evaluation. The possibility that they are using street drugs to obtain pain relief should be considered. Even if they have an addiction, their pain is real and assessment needs to focus on ways to both treat their pain and help with their addiction. The initial encounter with the patient is most important, as failure to establish a relationship will make it nearly impossible to obtain an accurate pain history and render trials of medications impossible to interpret.",
"   </p>",
"   <p>",
"    Principles of risk management in these patients are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef50477 \" href=\"mobipreview.htm?23/31/24061\">",
"     table 7",
"    </a>",
"    ). Psychologic evaluation may be helpful in evaluating underlying psychiatric or personality disorders. Assessment and recognition of substance abuse disorders and risk assessment in patients receiving opioids for management of cancer pain are all discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'Risk assessment and management for patients receiving opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Patients unable to self-report",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of pain in patients who are unable to self-report is a challenging problem in symptom assessment. The spectrum of patients who have impaired communication includes patients with permanent deficits such as dementia, and those with more temporary cognitive impairments such as delirium, sedation, or trauma. Patients with impaired ability to self-report pain present across the continuum of care, from intensive care units to clinics, home, and long term care settings. Individuals who are unable to communicate their pain are at greater risk for underrecognition and undertreatment of pain.",
"   </p>",
"   <p>",
"    Patients with mild dementia are often able to give a description and rating of their pain. Patients with advanced dementia may express pain by distress behaviors such as restlessness, grimacing, moaning, guarding, and changes in daily activity, but these behaviors are not specific for pain. When such behaviors occur, a physical examination should be performed with attention to the association of the pain behavior with movement, pressure, toileting, hunger, fear, loneliness, or visual impairment.",
"   </p>",
"   <p>",
"    A hierarchical approach has been proposed for this set of patients, whereby multiple sources of information are integrated by the examiner, starting with patient report, and including reports from observers (proxy reporting of pain), observation of patient behavior, use of behavioral pain assessment tools, and search for potential causes of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/68\">",
"     68",
"    </a>",
"    ]. A number of instruments have been developed to systematically assess pain-related behaviors in non-verbal adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. A review of tools to assess pain in non-verbal adults is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/73\">",
"     73",
"    </a>",
"    ]. Sufficient evidence has accumulated to support the use of the",
"    <a class=\"external\" href=\"file://web.missouri.edu/~proste/tool/cog/painad.pdf\">",
"     Pain Assessment in Advanced Dementia (PAINAD) tool",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An empiric trial of analgesics may be warranted if, after the initial assessment, questions remain as to whether a distress behavior is indicative of pain in a patient with cognitive dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea is a particularly common symptom in patients who have advanced COPD, heart failure, primary lung cancer, or intrathoracic metastatic disease. However, for unclear reasons, it is also a common symptom in patients with no direct lung pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/74\">",
"     74",
"    </a>",
"    ]. As an example, a National Hospice Study found that 24 percent of terminally-ill cancer patients had dyspnea in the absence of known cardiopulmonary pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89103972#H89103972\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with pain, dyspnea is defined solely by patient self-report. Attention to the words that patients use in describing their breathing discomfort may provide insight into the underlying clinical condition as well as the basic physiologic mechanisms producing dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89104000#H89104000\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Assessment of dyspnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Objective measures, such as respiratory rate, oxygen saturation, and arterial blood gas determination may not correlate with, nor provide a quantitative measure of the degree of dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Physical examination, pulse oximetry, and chest x-ray do not clarify whether the patient has dyspnea, but may help the clinician to identify likely causes for the symptom (",
"    <a class=\"graphic graphic_table graphicRef83934 \" href=\"mobipreview.htm?6/45/6878\">",
"     table 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89104035#H89104035\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Role of investigations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many methods for assessing the severity of dyspnea are based upon functional assessment (ie, studies of tasks and effort) and quantify the amount of exertion required to cause dyspnea. Breathless patients inevitably reduce their activity level to accommodate dyspnea, so questions about limitations in performing specific activities can be used to assess the impact of dyspnea. As an example, the Oxygen Cost Diagram (",
"    <a class=\"graphic graphic_figure graphicRef64769 \" href=\"mobipreview.htm?43/31/44542\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/78\">",
"     78",
"    </a>",
"    ]&nbsp;asks patients to identify the level of activity they are unable to perform due to dyspnea, giving clinicians valuable information regarding the functional impact of the symptom. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89104021#H89104021\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Functional impact'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient rated scales of dyspnea intensity have been based upon psychophysical descriptions of the relationship between work and perceived exertion. As an example, the Borg scale (",
"    <a class=\"graphic graphic_table graphicRef63981 \" href=\"mobipreview.htm?15/10/15532\">",
"     table 9",
"    </a>",
"    ) measures the severity of dyspnea using a scale from 0 to 10, anchored by descriptive words; it may be used in conjunction with an exertional test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/79\">",
"     79",
"    </a>",
"    ]. The most common exertional tests involve having the patient walk for 6 or 12 minutes and then rate their dyspnea afterwards. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89104014#H89104014\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Intensity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with COPD, the frequency and severity of dyspnea can be assessed using validated questionnaires such as the Clinical COPD Questionnaire (",
"    <a class=\"graphic graphic_table graphicRef86308 \" href=\"mobipreview.htm?11/35/11838\">",
"     table 10",
"    </a>",
"    ) or the Chronic Respiratory Questionnaire (CRQ), a shortened version of which is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/80\">",
"     80",
"    </a>",
"    ]. Although these approaches are useful for evaluating symptom severity in patients with COPD, neither is appropriate for patients with advanced serious life-threatening illness and severe dyspnea at rest. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    None of these tools adequately measure the multidimensionality of dyspnea. A Cancer Dyspnea Scale has been developed in Japan for use in patients with lung cancer and translated into English [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/81\">",
"     81",
"    </a>",
"    ]. Although it appears to reliably measure the sensation and psychologic components of dyspnea, further validation in other palliative care populations is needed.",
"   </p>",
"   <p>",
"    The prognostic implications of dyspnea, particularly in patients with cancer, are discussed above. (See",
"    <a class=\"local\" href=\"#H192146909\">",
"     'Performance status, symptoms, and prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88107081\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the terms &ldquo;asthenia&rdquo; and &ldquo;weakness&rdquo; were used to describe a subjective sensation of tiredness, while the specific term &ldquo;fatigue&rdquo; was used to describe a symptom of tiredness precipitated by effort. However, the terms are currently often used in the same context, and this broad sense of the term &ldquo;fatigue&rdquo; has gained widespread acceptance in the medical literature. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=see_link&amp;anchor=H29611044#H29611044\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fatigue is a highly prevalent and poorly understood symptom in patients with advanced serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness. It is reported by 80 percent of cancer patients overall, and by up to 99 percent of patients following radiotherapy or chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/82\">",
"     82",
"    </a>",
"    ]. Fatigue is also prevalent in palliative care patients with advanced life threatening illness other than cancer, including those with HIV, multiple sclerosis, COPD, and heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link\">",
"     \"End of life considerations for heart failure patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=see_link&amp;anchor=H29611051#H29611051\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assessment of fatigue in palliative care patients can be complex given its subjective and multidimensional nature. As such, there is a trend towards multidimensional assessment (ie, asking about different aspects of fatigue, such as muscular weakness of tiredness associated with a sleep disturbance) rather than asking a single question \"are you tired?\". (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=see_link&amp;anchor=H29611093#H29611093\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\", section on 'Clinical assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Instruments have been developed for assessment of fatigue in cancer patients which assess both severity and functional impact (eg, the Brief Fatigue Inventory (",
"    <a class=\"graphic graphic_table graphicRef54810 \" href=\"mobipreview.htm?9/29/9692\">",
"     table 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/83\">",
"     83",
"    </a>",
"    ]), and this subject is addressed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link&amp;anchor=H12#H12\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Clinical assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A listing of assessment tools for fatigue in patients with cancer as well as other serious life-threatening illnesses is available in the table (",
"    <a class=\"graphic graphic_table graphicRef86228 \" href=\"mobipreview.htm?17/13/17627\">",
"     table 12",
"    </a>",
"    ). Questions about fatigue are also present in some symptom assessment instruments for patients with COPD and heart failure. However, in such patients, it can be difficult to separate out fatigue from dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/84\">",
"     84",
"    </a>",
"    ]. A combined",
"    <span class=\"nowrap\">",
"     dyspnea/fatigue",
"    </span>",
"    instrument has been developed for patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link\">",
"     \"End of life considerations for heart failure patients\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Fatigue severity can also be quantified using a 0 to 10 visual analog scale such as provided in the Edmonton Symptom Assessment Scale (",
"    <a class=\"graphic graphic_figure graphicRef65702 \" href=\"mobipreview.htm?3/30/3567\">",
"     figure 2",
"    </a>",
"    ). Ratings of fatigue severity have been shown to be clinically meaningful in patients with cancer in terms of interference with function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link&amp;anchor=H12#H12\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Clinical assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=see_link&amp;anchor=H29611093#H29611093\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\", section on 'Clinical assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cause of fatigue in palliative care patients is typically multifactorial; acute fatigue, which may be caused by acute illness such as infection or cardiac decompensation, must be distinguished from more chronic fatigue, which is more typically (particularly for cancer patients) related to the underlying illness or its treatment. A comprehensive history and physical examination should be undertaken to ascertain the various organ systems affected by the underlying disease and the impact of fatigue on activities of daily living and quality of life, to search for potentially reversible or treatable contributory factors, and to direct the diagnostic work-up. Review of all medications (both prescribed and over the counter, including",
"    <span class=\"nowrap\">",
"     complementary/alternative",
"    </span>",
"    therapies) is important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=see_link&amp;anchor=H4310459#H4310459\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\", section on 'Causes and pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that are often causally related to fatigue should be specifically assessed, including anemia, uncontrolled pain, emotional distress, sleep disturbance, weight loss and malnutrition, electrolyte disturbances (",
"    <a class=\"graphic graphic_table graphicRef64018 \" href=\"mobipreview.htm?4/38/4715\">",
"     table 13",
"    </a>",
"    ), and the presence of other comorbidities (eg, infection, cardiopulmonary, renal, hepatic, neurologic, or endocrine dysfunction). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link&amp;anchor=H15#H15\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Moderate to severe fatigue'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dry mouth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xerostomia, the feeling of a dry mouth, is a highly prevalent symptom in palliative care. Risk factors include medications, mouth breathing, advanced age, and in cancer patients, a previous history of radiation to the head and neck. A number of medical conditions such as Sj&ouml;gren's syndrome, diabetes mellitus, and anxiety states can contribute to this symptom. Dehydration from reduced oral intake may be associated with a dry mouth. Medications are a significant cause of xerostomia in palliative care; in one survey, hospice patients were on a median number of four drugs that were associated with xerostomia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\", section on 'Xerostomia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822348#H3822348\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Salivary gland damage and xerostomia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/24/38282?source=see_link&amp;anchor=H23810875#H23810875\">",
"     \"Normal aging\", section on 'Oropharynx'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link\">",
"     \"End of life care: Stopping nutrition and hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A dry mouth can alter taste and make it difficult for patients to eat and swallow. Patients with xerostomia may also complain of mouth pain and difficulty with speaking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On examination, the presence of dry lips, dry mucosa, dental caries, a coated tongue, and ropy saliva helps confirm the impression of xerostomia. Associated findings of relevance include the presence of thrush, periodontal disease, and herpetic infection. Patients with erythematous candidiasis may have patchy erythema of the dorsal tongue and other mucosal surfaces and angular cheilitis.",
"   </p>",
"   <p>",
"    While there are objective tests to confirm the presence of xerostomia (eg, measures of saliva production, such as the unstimulated and stimulated [after eating] whole salivary flow rates), these tests are used primarily for research purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia, which is sometimes associated with odynophagia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspiration, occurs regularly in patients with advanced illness, especially in the setting of neurologic disorders (including amyotrophic lateral sclerosis [ALS] and other motor neuron diseases, brain metastases, and leptomeningeal carcinomatosis), as well as cancers of the head and neck and esophagus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2037?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link&amp;anchor=H30#H30\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Upper motor neuron symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=see_link&amp;anchor=H178953881#H178953881\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\", section on 'Aspiration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In dysphagia, patients will complain of a bolus getting &ldquo;stuck&rdquo; after swallowing and often can point to a site. Aspiration should be suspected when patients start coughing after drinking liquids, with accompanying hoarseness. &nbsp;",
"   </p>",
"   <p>",
"    Dysphagia may be classified as oropharyngeal or esophageal and patients may have difficulty with ONE OR BOTH phases of the swallowing mechanism (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2037?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\", section on 'Physiology of swallowing'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oropharyngeal dysphagia, also called transfer dysphagia, arises from disorders that affect the function of the oropharynx, larynx, and upper esophageal sphincter. Neurogenic and myogenic disorders as well as oropharyngeal tumors are the most common underlying mechanisms for oropharyngeal dysphagia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Esophageal dysphagia arises within the body of the esophagus, the lower esophageal sphincter, or cardia, and is most commonly due to mechanical causes or a motility disturbance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of the many causes of oropharyngeal dysphagia is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef52707 \" href=\"mobipreview.htm?16/45/17117\">",
"     table 14",
"    </a>",
"    ). The differential diagnosis of esophageal dysphagia is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2037?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\", section on 'Pathogenesis of oropharyngeal dysphagia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12569?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of dysphagia in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate but related problem, pain upon swallowing (odynophagia), can result from inflammation, infection, or neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37078?source=see_link\">",
"     \"Medication-induced esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29972?source=see_link\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6647?source=see_link\">",
"     \"Herpes simplex virus infection of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link&amp;anchor=H30#H30\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4707?source=see_link&amp;anchor=H19605015#H19605015\">",
"     \"Evaluation of the HIV-infected patient with odynophagia and dysphagia\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Algorithmic approaches to the differential diagnosis of dysphagia and suggested workup for patients with esophageal dysphagia and oropharyngeal dysphagia are presented in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef70866 \" href=\"mobipreview.htm?31/33/32287\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef81108 \" href=\"mobipreview.htm?16/8/16527\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef54485 \" href=\"mobipreview.htm?22/24/22912\">",
"     algorithm 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12569?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of dysphagia in adults\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12569?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of dysphagia in adults\", section on 'Specific testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\", section on 'Diagnostic testing'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315170\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A disordered swallowing mechanism predisposes to aspiration. In addition to dysphagia, other factors that predispose to aspiration include reduced consciousness which compromises the cough reflex, mechanical disruption of the upper airway or gastrointestinal tract, and recumbent patients who receive large volume tube feedings and feeding gastrostomy. All patients with these conditions should be asked about and observed for cough after swallowing. A history of coughing while eating or drinking is likely to indicate aspiration, but aspiration may also be clinically silent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When aspiration is suspected, bedside assessment includes observation of the patient after swallowing a sample of thin liquids, thick liquids, and solids. In addition to cough, helpful signs include drooling after swallowing, wet or hoarse vocal quality after swallowing, head or neck repositioning while swallowing, and multiple attempts to swallow a bolus. When evaluated with formal swallowing studies, some of these patients will be found to have laryngeal penetration. In such cases, a balance has to be struck between quality of life issues (ie, continue eating despite the high risk for aspiration) and safety considerations (mechanical soft or pureed diets, nasogastric tube, gastrostomy tube, or nothing by mouth). Interestingly, many patients who aspirate when swallowing still are able to swallow small pills without difficulty. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link&amp;anchor=H3#H3\">",
"     \"Aspiration pneumonia in adults\", section on 'Evaluation of dysphagia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link&amp;anchor=H4#H4\">",
"     \"Aspiration pneumonia in adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lack of appetite",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of appetite is frequently seen in patients with many kinds of advanced illnesses (eg, heart failure, cancer, COPD, frail elderly), and is often a foremost concern of patients and their families.",
"   </p>",
"   <p>",
"    Although the reliability of subjective assessments of appetite is debated, they are probably the simplest and most practical measures available. Patient-rated assessment measures have been developed in the setting of trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    for cancer or HIV-related anorexia (eg, Functional Assessment of",
"    <span class=\"nowrap\">",
"     Anorexia/Cachexia",
"    </span>",
"    Therapy, FAACT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/89\">",
"     89",
"    </a>",
"    ]). Another instrument, the Subjective Global Assessment of Nutrition instrument, has been correlated with nutritional status and caloric intake, but requires further validation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/90\">",
"     90",
"    </a>",
"    ]. A simple vertical VAS measurement has been shown to correlate with nutritional intake in cancer patients in the last few weeks of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/91\">",
"     91",
"    </a>",
"    ]. Simply asking about what the patient eats and drinks in a typical day can allow the clinician to estimate caloric intake. &nbsp;",
"   </p>",
"   <p>",
"    Lack of appetite can be a consequence of chronic fatigue or associated with barely noticeable nausea; depression, pain, xerostomia, and constipation can also contribute. An important and treatable etiology is early satiety due to disorders of gastric motility. Lack of appetite does not always lead to weight loss, but recognition of weight loss should lead to questions about lack of appetite. It is helpful to determine whether the patient is distressed by lack of appetite (ie, whether or not they feel hunger) in prioritizing symptoms for treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7226?source=see_link\">",
"     \"Malignancy-associated gastroparesis: Pathophysiology and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24985?source=see_link\">",
"     \"Diabetic autonomic neuropathy of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other common considerations include medications (amphetamines, antibiotics, antihistamines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    ), depression, taste disturbances, and food aversions. &nbsp;Decreased appetite is a component of the &ldquo;failure to thrive&rdquo; (FTT) syndrome, which is described by The National Institute of Aging as \"syndrome of weight loss, decreased appetite and poor nutrition, and inactivity, often accompanied by dehydration, depressive symptoms, impaired immune function, and low cholesterol\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/92\">",
"     92",
"    </a>",
"    ]. In geriatric practice, FTT describes a point further along a geriatric functional continuum that is closer to full dependence and death, with &ldquo;frailty as a mid-point between independence and pre-death&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=see_link\">",
"     \"Failure to thrive in elderly adults: Evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15069336\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with advanced illness, weight loss may occur even in the setting of a good appetite and adequate caloric intake, as typified by cachexia associated with advanced heart and lung disease, cancer, and HIV and other chronic infections. Weight loss of greater than 5 percent of baseline is generally accepted as significant. Determining whether patients feel they &ldquo;look like themselves&rdquo; may lead to a discussion of weight loss. Cachexia is a hypercatabolic state that is characterized by an accelerated loss of skeletal muscle in the context of a chronic inflammatory response, and should be distinguished from sarcopenia, loss of muscle. In advanced illness, weight loss is not remedied by nutritional supplementation. Important physical findings that support the suspicion of cachexia are temporal wasting, thenar wasting, and dorsal interosseous wasting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link&amp;anchor=H13#H13\">",
"     \"End of life considerations for heart failure patients\", section on 'Anorexia and cachexia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While cachexia in advanced illness typically reflects a metabolic disorder of uncertain cause and for which treatment is largely ineffective, the usual causes of weight loss, such as loss of appetite, inadequate nutritional intake, and malabsorption, should not be overlooked. In some cases, cancer treatment (eg, androgen deprivation therapy for advanced prostate cancer, tyrosine kinase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ) may contribute to loss of lean body mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and pathogenesis of cancer cachexia\", section on 'Cancer treatment and sarcopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1557944583#H1557944583\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Sorafenib and muscle wasting/sarcopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nausea with or without vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and vomiting are symptoms that are common near the end of life, and they can cause substantial physical and psychological distress for patients and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/94\">",
"     94",
"    </a>",
"    ]. Although vomiting is more easily quantified, nausea has been routinely measured using a visual analog scale in clinical trials of antiemetics in patients with chemotherapy-induced nausea and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thorough history and physical examination are essential first steps in the management of these patients to define the severity of the symptoms and identify clues to the underlying etiology. Among patients receiving chemotherapy, nausea and vomiting should not be automatically assumed to represent breakthrough chemotherapy-induced nausea and vomiting (CINV), particularly if symptoms develop at a time point that is not consistent with CINV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From a pathophysiologic standpoint, nausea and vomiting can be vagally mediated through the emesis center in the medulla, systemically mediated through the chemoreceptor trigger zone (CTZ), vestibular, or centrally mediated (",
"    <a class=\"graphic graphic_figure graphicRef87723 \" href=\"mobipreview.htm?16/60/17352\">",
"     figure 5",
"    </a>",
"    ). The differential diagnosis of nausea and vomiting in the adult is broad, and includes medications and toxic etiologies (including chemotherapy and opioids), disorders of the gut and peritoneum (including gastroparesis), central nervous system disorders (brain metastases, cranial irradiation), vestibular disorders, and",
"    <span class=\"nowrap\">",
"     endocrinologic/metabolic",
"    </span>",
"    causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=see_link&amp;anchor=H558191174#H558191174\">",
"     \"Approach to the adult with nausea and vomiting\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common causes of nausea and vomiting in palliative care patients are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef87625 \" href=\"mobipreview.htm?22/14/22765\">",
"     table 15",
"    </a>",
"    ). Most palliative care patients who are nauseated have more than one contributory factor.",
"   </p>",
"   <p>",
"    Among patients receiving chemotherapy, nausea and vomiting should not be automatically assumed to represent breakthrough chemotherapy-induced nausea and vomiting (CINV), particularly if symptoms develop at a time point that is not consistent with CINV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the presence of constipation can be difficult as the term has varied meanings for different people. For some, it may mean that stools are too hard or too small, or that defecation is too difficult or infrequent. The first three complaints are difficult to quantify in clinical practice; the last can be measured and compared to the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and evaluation of chronic constipation in adults\", section on 'Definition of constipation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient with constipation should be asked when he or she last had a bowel movement, and for any associated symptoms. In the palliative care setting, patients with constipation may present with abdominal pain, nausea, vomiting, diarrhea, or difficulty with a bowel movement. Consistency of stool (soft or hard) is a helpful detail.",
"   </p>",
"   <p>",
"    Formal criteria are available to define functional constipation (the Rome III criteria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/95\">",
"     95",
"    </a>",
"    ], but they are not useful in palliative care as the criteria must be fulfilled for at least three months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35048?source=see_link&amp;anchor=H29212415#H29212415\">",
"     \"Constipation in the older adult\", section on 'Definition of constipation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for constipation in patients with a serious or life-threatening illness include advanced disease, older age, decreased physical activity, low fiber diet, depression, and cognitive impairment. Medications which can cause or exacerbate constipation include opioids, calcium channel blockers, diuretics, anticholinergic drugs, iron, serotonin antagonists, and chemotherapy (vinca alkaloids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    ). There are also neural (eg, epidural spinal cord compression) and metabolic causes of constipation (eg, hypercalcemia and hypothyroidism).",
"   </p>",
"   <p>",
"    A comprehensive physical examination should be performed that includes a rectal exam to palpate for hard stool, assess for masses, anal fissures, hemorrhoids, sphincter tone, push effort during attempted defecation, prostatic hypertrophy in males, and posterior vaginal masses in females. Rectal examination may demonstrate impaction, or the rectal vault may be empty. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology and evaluation of chronic constipation in adults\", section on 'Physical examination'",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    If the rectal vault is empty and a diagnosis of malignant bowel obstruction is suspected, radiographic imaging with abdominal x-ray or CT scan is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients without clinical suspicion of bowel obstruction, abdominal plain films can be used to estimate the degree of retention of stool which may be difficult to determine from history and physical exam. Some have proposed scoring systems for assessing the severity of constipation in terminal cancer patients based upon the amount and distribution of stool in different quadrants of the large bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Each abdominal quadrant on plain films can be assessed for stool content and ranked for 0 to 3, resulting in a severity score from 0 to 12. A clinical constipation assessment scale also has been developed and validated (",
"    <a class=\"graphic graphic_table graphicRef62148 \" href=\"mobipreview.htm?11/62/12268\">",
"     table 16",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Swelling in the arms and legs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral edema, palpable swelling that is produced by expansion of the interstitial fluid volume, is a common complication in patients with advanced organ dysfunction. When massive and generalized, the excess fluid accumulation is called anasarca. Anasarca or just lower extremity edema can interfere with ambulation and is often a source of pain from stretching of the skin. It may also directly affect the patient's sense of body image. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=see_link\">",
"     \"Clinical manifestations and diagnosis of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of edema starts with the history which should include questions about area(s) of involvement, associated symptoms (eg, pain), use of medications that may be associated with edematous states (eg, nonsteroidal antiinflammatory agents) or that are being used to treat edema (eg, diuretics), progression of symptoms, and history of medical conditions associated with lymphedema, including surgery and prior radiation therapy, travel, or infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathophysiology and etiology of edema in adults\", section on 'Drug-induced edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination should be aimed at establishing the pattern of edema (pulmonary, peripheral, ascites, localized) and an assessment of the central venous pressure. The results can indicate the likely cause of edema (",
"    <a class=\"graphic graphic_table graphicRef72002 \" href=\"mobipreview.htm?32/42/33451\">",
"     table 17",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H802880404#H802880404\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology and etiology of edema in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with lymphedema, clinical measurements of girth or estimates of lymphedema volume are necessary to establish baseline and to track changes during treatment. Methods to obtain clinical measurements are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H857615700#H857615700\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Clinical measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of clinical conditions are associated with the development of edema, including heart failure, cirrhosis, hypothyroidism, and the nephrotic syndrome, as well as local conditions such as venous and lymphatic disease or malignant ascites (",
"    <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"     table 18",
"    </a>",
"    ). Among patients who are terminally ill with a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness, the most common causes of chronic lower extremity edema are venous obstruction, hypoalbuminemia, decreased mobility, fluid retention and medications including corticosteroids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphedema, a specific type of peripheral edema that is usually (but not always) nonpitting, may represent a complication of a cancer or its treatment. Lymphedema occurs when the lymphatic load exceeds the transport capacity of the lymphatic system, which causes filtered protein-rich fluid to accumulate in the interstitium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/100\">",
"     100",
"    </a>",
"    ]. Lymphedema is generally due to disruption of lymphatic flow which may be secondary to injury, surgery, radiotherapy, infection, or malignancy. As compared to generalized edematous states, the rate of capillary filtration is normal in patients with lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H1652245637#H1652245637\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Physiologic basis of lymphedema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic lymphedema affects both physical and psychological wellbeing as a result of interruption of normal daily activities. Cancer patients with lymphedema are more likely to experience greater disability, poorer quality of life, and greater psychological distress as compared to cancer patients without lymphedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/101\">",
"     101",
"    </a>",
"    ]. It may cause patients to feel mental suffering, discomfort, and reduce mobility as well as function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Psychological and cognitive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key psychological symptoms requiring assessment in palliative care patients are depression (as distinct from adjustment reaction and grief), anxiety, and delirium. Clinicians should screen for the multiple factors that increase the prevalence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of psychological distress (rapidly advancing disease, medications such as interferon or glucocorticoids, metabolic abnormalities, uncontrolled pain, impaired cognition, financial distress) and address them, if possible. Psychological distress frequently lessens with adequate pain relief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2853694\">",
"    <span class=\"h3\">",
"     Sadness, grief, and depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of mood disorders and conditions seen in palliative care patients includes sadness, normal grief reaction (including anticipatory grief), pathologic grief, adjustment disorder with depressed features, and minor as well as major depression. Grief, a natural and expected reaction to having a life-limiting illness and loss, can and should be distinguished from major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A summary of some of the contrasting characteristics of normal grief versus depression in terminally-ill patients is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef53062 \" href=\"mobipreview.htm?35/46/36587\">",
"     table 19",
"    </a>",
"    ), and this subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H15#H15\">",
"     \"Assessment and management of depression in palliative care\", section on 'Assessment and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link&amp;anchor=H2#H2\">",
"     \"Grief and bereavement\", section on 'Normal bereavement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link&amp;anchor=H6#H6\">",
"     \"Grief and bereavement\", section on 'Abnormal bereavement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a high frequency of mood disorders in patients with a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness. As an example, in a meta-analysis, there was a 25 percent combined prevalence of all types of depression, and 38 percent prevalence of mood disorders among palliative care patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, depression is frequently unrecognized and undiagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/19,107\">",
"     19,107",
"    </a>",
"    ]. The prevalence, burden, and challenges in recognizing and treating depression in palliative care patients are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H5#H5\">",
"     \"Assessment and management of depression in palliative care\", section on 'Prevalence of depression in palliative care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H3#H3\">",
"     \"Assessment and management of depression in palliative care\", section on 'Burden of depression'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Patients with advanced illness may display many of the vegetative signs of depression (sleep disorder, poor concentration, fatigue, lack of appetite) without being depressed, since such symptoms can be caused by the medical condition or its treatment. Patients facing the end of life may also demonstrate significant guilt and preoccupation with death without being depressed. Nevertheless, the presence of these markers in the absence of other causes should lead to the suspicion of depression. Indicators of poor emotional well being, such as a sense of pervasive hopelessness, helplessness, worthlessness, or guilt, may be more useful in making the diagnosis and in assessing suicide risk. Unrelieved symptoms, particularly pain, may contribute to a sense of hopelessness and lead to depression. Among patients with severe pain or other symptoms, a diagnosis of depression should not be made until symptoms are controlled.",
"   </p>",
"   <p>",
"    The impact of mood disorders in palliative care is underscored by one study which found that mortality rates in cancer patients are up to 25 percent higher in those who experience depressive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/108\">",
"     108",
"    </a>",
"    ]. In addition, individuals who suffer from depression are at increased risk of suicide. Passive suicidal ideation (I'd be better off dead) should be distinguished from active suicidal ideation (I'd be better off dead and this is how I'm going to do it). An expressed desire for a hastened death should not be considered a request for euthanasia, but as a marker for intense distress which requires further exploration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H3#H3\">",
"     \"Assessment and management of depression in palliative care\", section on 'Burden of depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24778?source=see_link\">",
"     \"Euthanasia and physician assisted suicide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of screening tools for symptoms of depression are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abbreviated screening instruments (",
"      <a class=\"graphic graphic_table graphicRef61549 \" href=\"mobipreview.htm?28/53/29531\">",
"       table 20",
"      </a>",
"      ) appear to be as effective as longer instruments to screen for depression. As an example, screening using a simple one question assessment (\"Are you depressed?\" or \"Have you been depressed most of the time for the past two weeks?\") has a negative predictive value (NPV) of 94 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/110,111\">",
"       110,111",
"      </a>",
"      ]&nbsp;in identifying patients in whom a diagnosis of depression would be excluded on the basis of a full psychiatric interview. Adding a second question that addresses anhedonia (&ldquo;Have you experienced loss of interest in things or activities that you would normally enjoy?&rdquo;) increases the NPV to 98 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another simple screening strategy for mood disorder and psychosocial distress utilizes the Distress and Impact Thermometer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/112\">",
"       112",
"      </a>",
"      ]&nbsp;or other ultra-short methods [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, these brief tools are designed for screening patients who may subsequently need a full diagnostic evaluation for depression. The subject of screening for depression in palliative care patients is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H19#H19\">",
"     \"Assessment and management of depression in palliative care\", section on 'Simple screening instruments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2853905\">",
"    <span class=\"h3\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety is common in patients with an advanced serious or life-threatening illness. As an example, the reported prevalence of anxiety among advanced cancer patients is 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\", section on 'Anxiety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anxiety may also be related to a preexisting anxiety disorder, substance abuse, delirium, or under-treated symptoms, most commonly pain. A single aggregate question (&ldquo;Have you felt anxious, nervous, uneasy, tense, or frightened in the recent days&rdquo;) can be utilized to screen for symptoms of anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2861007\">",
"    <span class=\"h3\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium and confusional states are among the most common neuropsychiatric disorders encountered in patients with medical illness, particularly the elderly. The American Psychiatric Association's Diagnostic and Statistical Manual, 4th edition (DSM-IV) lists four key features that characterize delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/115\">",
"     115",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disturbance of consciousness with reduced ability to focus, sustain, or shift attention.",
"     </li>",
"     <li>",
"      A change in cognition or the development of a perceptual disturbance that is not better accounted for by a preexisting, established, or evolving dementia.",
"     </li>",
"     <li>",
"      The disturbance develops over a short period of time (usually hours to days) and tends to fluctuate during the course of the day.",
"     </li>",
"     <li>",
"      There is evidence from the history, physical examination, or laboratory findings that the disturbance is caused by a medical condition, substance intoxication, or medication side effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional features that may accompany delirium and confusion include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychomotor behavioral disturbances such as hypoactivity, hyperactivity with increased sympathetic activity, and impairment in sleep duration and architecture.",
"     </li>",
"     <li>",
"      Variable emotional disturbances, including fear, depression, euphoria, or perplexity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mnemonic FACT provides a summary of the diagnostic criteria of delirium:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluctuating cognitive deficit(s) with acute onset",
"     </li>",
"     <li>",
"      Attention deficits, and either",
"     </li>",
"     <li>",
"      Consciousness level disturbance, or",
"     </li>",
"     <li>",
"      Thought disorganization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Delirium is the most common neuropsychiatric complication seen in patients with advanced cancer nearing the end of life and can result in distress for patients, family members, and healthcare providers. It is also a marker for shortened survival in hospitalized and institutionalized patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/63,116\">",
"     63,116",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H192146909\">",
"     'Performance status, symptoms, and prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For many terminally ill patients with COPD, end-stage renal disease, heart failure, and other serious life-threatening diseases, global cerebral dysfunction without a definable reversible cause, manifested as delirium, is the final common complication that precedes death. However, for many palliative care patients, a number of factors may contribute to the development of delirium, many of which are potentially reversible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/117\">",
"     117",
"    </a>",
"    ]. Some of the most frequent contributors are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/118\">",
"     118",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Opioid-induced toxicity (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H6#H6\">",
"       \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Somnolence and mental clouding'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brain",
"      <span class=\"nowrap\">",
"       tumor/metastases/cerebral",
"      </span>",
"      edema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cancer treatment (chemotherapy, radiation therapy) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H20#H20\">",
"       \"Complications of cranial irradiation\", section on 'Neurocognitive effects in adults'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link\">",
"       \"Neurologic complications of non-platinum cancer chemotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\", section on 'Delirium and dementia'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychotropic drugs (tricyclic antidepressants, benzodiazepines)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Metabolic (increased calcium, decreased sodium, renal failure) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"       \"Hypercalcemia of malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=see_link\">",
"       \"Clinical manifestations of hypercalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link\">",
"       \"Overview of the treatment of hyponatremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=see_link\">",
"       \"Evaluation of the patient with hyponatremia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disturbed sleep (in the ICU setting), and other causes of sleep deprivation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sepsis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Paraneoplastic neurologic syndromes (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"       \"Overview of paraneoplastic syndromes of the nervous system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=see_link\">",
"       \"Paraneoplastic and autoimmune encephalitis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of the risk factors for delirium are already present in patients with advanced terminal illnesses, although many patients improve with treatment of specific causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of managing common non-pain symptoms in palliative care\", section on 'Delirium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fact that delirium may be reversible in up to 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/117\">",
"     117",
"    </a>",
"    ] underscores the importance of early recognition and aggressive evaluation and management.",
"   </p>",
"   <p>",
"    Multiple instruments have been developed for assessing delirium, which are based upon the criteria for delirium in the DSM-IV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/119\">",
"     119",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Confusion Assessment Method (CAM, (",
"      <a class=\"graphic graphic_table graphicRef69489 \" href=\"mobipreview.htm?1/48/1804\">",
"       table 21",
"      </a>",
"      )) has become a standard screening device in clinical studies of delirium, conducted across multiple settings including emergency rooms and long-term care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/120\">",
"       120",
"      </a>",
"      ]; a version is available (CAM-ICU) that is validated in patients in the intensive care unit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/121,122\">",
"       121,122",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MDAS (",
"      <a class=\"graphic graphic_form graphicRef56787 graphicRef69509 \" href=\"mobipreview.htm?37/57/38810\">",
"       form 2A-B",
"      </a>",
"      ) is a 10-item, four-point (0 to 3) observer-rated scale that was designed to quantify the severity of delirium in medically ill patients with serial observations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/123,124\">",
"       123,124",
"      </a>",
"      ]. It includes assessment of disturbances in awareness, orientation, short-term memory, digit span, attention capacity, organized thinking, perception, delusions, psychomotor activity, and arousal in a way that reflects all the main diagnostic criteria according to the Diagnostic and Statistical Manual for Mental Illness.",
"      <br/>",
"      <br/>",
"      The MDAS has been used and validated for screening and diagnosis of delirium in cancer patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/124\">",
"       124",
"      </a>",
"      ] and is able to distinguish patients with delirium from those with other cognitive or noncognitive psychiatric disorders. In one study, a cutoff score of",
"      <span class=\"nowrap\">",
"       7/30",
"      </span>",
"      on the MDAS yielded the highest sensitivity (98 percent) and specificity (96 percent) for the diagnosis of delirium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/124\">",
"       124",
"      </a>",
"      ]. In many institutions, this tool has replaced the mini-mental status examination for assessment and monitoring of delirium.",
"     </li>",
"     <li>",
"      The bedside confusion scale (ability to recite the 12 months in reverse order and assessment of consciousness state) is another excellent tool to screen and longitudinally follow delirium in palliative care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/13/41178/abstract/125\">",
"       125",
"      </a>",
"      ]. Serial-sevens and spelling a word such as &ldquo;farm&rdquo; or &ldquo;world&rdquo; backward are other simple tests of attention. Another bedside test of attention is outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef59119 \" href=\"mobipreview.htm?17/52/18251\">",
"       table 22",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link\">",
"       \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1508773\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION AND INVESTIGATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both physical examination and investigations may be important in characterizing a symptom and for definitive diagnosis. &nbsp;",
"   </p>",
"   <p>",
"    When considering new investigations on palliative care patients who may be quite ill (particularly if they are at the end of life), an important consideration is that if the result is not expected to change management of a symptom complex, the investigation should NOT be done. Sometimes, even necessary investigations may have to be eliminated or postponed because of patient frailty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequently encountered symptoms in patients with an advanced serious",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      life-threatening illness include pain, dyspnea, fatigue, dry mouth, dysphagia and aspiration, loss of appetite and weight,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      constipation, edema, depression, anxiety, and delirium. An approach to assessment of these symptoms is outlined in the sections above (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to specific symptoms'",
"      </a>",
"      above). In palliative care populations, symptom etiology is commonly multifactorial. As an example, among patients with advanced cancer, symptoms may result from the disease, from treatment for the disease, or from other concurrent unrelated conditions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient descriptions and symptom ratings are the primary data for overall assessment. The use of different dimensions (severity, frequency, distress, interference) may help when patients and families get stuck on trying to describe the impact of a symptom.",
"     </li>",
"     <li>",
"      Once a symptom is identified, timely reevaluation is necessary to determine whether it has improved after a specific therapeutic intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinician, caregiver, and patient assessments of symptoms may differ; clinicians tend to rate the severity of symptoms lower than patients. &nbsp;",
"     </li>",
"     <li>",
"      The patient's assessment of symptom relief is important, and may differ from that of the health professional. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Performance status (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 5",
"      </a>",
"      ) is a key indicator of prognosis in individuals with advanced terminal disease, and is associated with symptom severity. &nbsp;For patients with advanced serious life threatening diseases, such as those referred to palliative care programs, the presence or absence of certain symptoms, particularly dyspnea, may help physicians provide a more refined estimate of patient survival. (See",
"      <a class=\"local\" href=\"#H192146909\">",
"       'Performance status, symptoms, and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of validated symptom assessment tools may be useful in palliative care settings, including those that evaluate multiple symptoms such as the Edmonton Symptom Assessment Scale, and symptom-specific tools such as the Brief Pain Inventory. Multisymptom assessment tools definitely yield a higher number of symptoms, and can be used as checklists.",
"      <br/>",
"      <br/>",
"      All of these tools (which often address both severity and how much a specific symptom is bothering or impairing the patient) are most effective combined with careful patient interviews to delineate the details of each symptom. Furthermore, when a specific tool has been chosen, it should be used consistently. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Assessment and rating instruments for symptoms'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New investigations on palliative care patients who may be quite ill (particularly if they are at the end of life), should not be pursued unless the result is expected to change management of a symptom complex. (See",
"      <a class=\"local\" href=\"#H1508773\">",
"       'Physical examination and investigations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/1\">",
"      Sep&uacute;lveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization's global perspective. J Pain Symptom Manage 2002; 24:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/2\">",
"      Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988; 148:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/3\">",
"      Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000; 8:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/4\">",
"      Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/5\">",
"      Coyle N, Breitbart W, Weaver S, Portenoy R. Delirium as a contributing factor to \"crescendo\" pain: three case reports. J Pain Symptom Manage 1994; 9:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/6\">",
"      Homsi J, Walsh D, Rivera N, et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer 2006; 14:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/7\">",
"      Yennurajalingam S, Urbauer DL, Casper KL, et al. Impact of a Palliative Care Consultation Team on Cancer-Related Symptoms in Advanced Cancer Patients Referred to an Outpatient Supportive Care Clinic. J Pain Symptom Manage 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/8\">",
"      Williams PD, Graham KM, Storlie DL, et al. Therapy-Related Symptom Checklist Use During Treatments at a Cancer Center. Cancer Nurs 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/9\">",
"      Hoekstra J, Vernooij-Dassen MJ, de Vos R, Bindels PJ. The added value of assessing the 'most troublesome' symptom among patients with cancer in the palliative phase. Patient Educ Couns 2007; 65:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/10\">",
"      Mehta A, Ezer H. My love is hurting: the meaning spouses attribute to their loved ones' pain during palliative care. J Palliat Care 2003; 19:87.",
"     </a>",
"    </li>",
"    <li>",
"     Dudel, J. General sensory physiology, psychophysics. In: Fundamentals of sensory physiology, General sensory physiology, psychophysics (Eds), Springer Verlag, New York 1977. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/12\">",
"      Sze FK, Chung TK, Wong E, et al. Pain in Chinese cancer patients under palliative care. Palliat Med 1998; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/13\">",
"      Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/14\">",
"      Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/15\">",
"      Schwartz AL, Meek PM, Nail LM, et al. Measurement of fatigue. determining minimally important clinical differences. J Clin Epidemiol 2002; 55:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/16\">",
"      de Torres JP, Pinto-Plata V, Ingenito E, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002; 121:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/17\">",
"      Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/18\">",
"      Grossman SA, Sheidler VR, Swedeen K, et al. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 1991; 6:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/19\">",
"      Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/20\">",
"      Marqui&eacute; L, Raufaste E, Lauque D, et al. Pain rating by patients and physicians: evidence of systematic pain miscalibration. Pain 2003; 102:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/21\">",
"      Sutherland JE, Wesley RM, Cole PM, et al. Differences and similarities between patient and physician perceptions of patient pain. Fam Med 1988; 20:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/22\">",
"      Lesho E, Foster L, Wang Z, et al. The accuracy of physicians' perceptions of patients' suffering: findings from two teaching hospitals. Acad Med 2009; 84:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/23\">",
"      Kurtz ME, Kurtz JC, Given CC, Given B. Concordance of cancer patient and caregiver symptom reports. Cancer Pract 1996; 4:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/24\">",
"      Silveira MJ, Given CW, Given B, et al. Patient-caregiver concordance in symptom assessment and improvement in outcomes for patients undergoing cancer chemotherapy. Chronic Illn 2010; 6:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/25\">",
"      McMillan SC, Moody LE. Hospice patient and caregiver congruence in reporting patients' symptom intensity. Cancer Nurs 2003; 26:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/26\">",
"      Koffman J, Morgan M, Edmonds P, et al. Cultural meanings of pain: a qualitative study of Black Caribbean and White British patients with advanced cancer. Palliat Med 2008; 22:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/27\">",
"      Nekolaichuk CL, Maguire TO, Suarez-Almazor M, et al. Assessing the reliability of patient, nurse, and family caregiver symptom ratings in hospitalized advanced cancer patients. J Clin Oncol 1999; 17:3621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/28\">",
"      Redinbaugh EM, Baum A, DeMoss C, et al. Factors associated with the accuracy of family caregiver estimates of patient pain. J Pain Symptom Manage 2002; 23:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/29\">",
"      Saleem TZ, Higginson IJ, Chaudhuri KR, et al. Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: A cross-sectional study of patients with Parkinson's disease and related neurological conditions. Palliat Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/30\">",
"      Harding R, Selman L, Agupio G, et al. Prevalence, burden, and correlates of physical and psychological symptoms among HIV palliative care patients in sub-Saharan Africa: an international multicenter study. J Pain Symptom Manage 2012; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/31\">",
"      Lokker ME, Offerman MP, van der Velden LA, et al. Symptoms of patients with incurable head and neck cancer: Prevalence and impact on daily functioning. Head Neck 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/32\">",
"      Hahn EA, Cella D, Chassany O, et al. Precision of health-related quality-of-life data compared with other clinical measures. Mayo Clin Proc 2007; 82:1244.",
"     </a>",
"    </li>",
"    <li>",
"     Jacox, A, Carr, DB, Payne, R, et al. Management of cancer pain. Clinical practice guideline, #9, Agency for Health Care Policy and Research, Rockville, MD 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/34\">",
"      Bruera E, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     Edmonton symptom assessment scale file://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=13846 (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/36\">",
"      Carvajal A, Hribernik N, Duarte E, et al. The Spanish version of the Edmonton Symptom Assessment System-revised (ESAS-r): first psychometric analysis involving patients with advanced cancer. J Pain Symptom Manage 2013; 45:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/37\">",
"      Chang VT, Hwang SS, Feuerman M, et al. The memorial symptom assessment scale short form (MSAS-SF). Cancer 2000; 89:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/38\">",
"      Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Invest 2004; 22:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/39\">",
"      Tranmer JE, Heyland D, Dudgeon D, et al. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 2003; 25:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/40\">",
"      Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000; 89:1634.",
"     </a>",
"    </li>",
"    <li>",
"     M D Anderson Sysmptom Assessment Scale www.mdanderson.org/departments/prg/display.cfm?id=0EE78C60-6646-11D5-812400508B603A14&amp;pn=0EE78204-6646-11D5-812400508B603A14&amp;method=displayfull (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/42\">",
"      de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/43\">",
"      McCorkle R. The measurement of symptom distress. Semin Oncol Nurs 1987; 3:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/44\">",
"      Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; 45:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/45\">",
"      Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     A sample version of the Brief Pain Inventory file://www.painknowledge.org/physiciantools/opioid_toolkit/components/BPI.pdf (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/47\">",
"      Lunney JR, Lynn J, Foley DJ, et al. Patterns of functional decline at the end of life. JAMA 2003; 289:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/48\">",
"      Ho F, Lau F, Downing MG, Lesperance M. A reliability and validity study of the Palliative Performance Scale. BMC Palliat Care 2008; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/49\">",
"      Anderson F, Downing GM, Hill J, et al. Palliative performance scale (PPS): a new tool. J Palliat Care 1996; 12:5.",
"     </a>",
"    </li>",
"    <li>",
"     Components of the palliative performance scale (PPS) available online at file://pallipedia.org/term.php?id=504 (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/51\">",
"      Ma C, Bandukwala S, Burman D, et al. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer 2010; 46:3175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/52\">",
"      Chang VT, Hwang SS, Feuerman M, Kasimis BS. Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. Cancer 2000; 88:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/53\">",
"      Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995; 75:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/54\">",
"      Escalante CP, Martin CG, Elting LS, et al. Identifying risk factors for imminent death in cancer patients with acute dyspnea. J Pain Symptom Manage 2000; 20:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/55\">",
"      K&aring;ss RM, Ellershaw J. Respiratory tract secretions in the dying patient: a retrospective study. J Pain Symptom Manage 2003; 26:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/56\">",
"      Blinderman CD, Homel P, Billings JA, et al. Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manage 2008; 35:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/57\">",
"      Rust&oslash;en T, Stubhaug A, Eidsmo I, et al. Pain and quality of life in hospitalized patients with heart failure. J Pain Symptom Manage 2008; 36:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/58\">",
"      Lynn J, Ely EW, Zhong Z, et al. Living and dying with chronic obstructive pulmonary disease. J Am Geriatr Soc 2000; 48:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/59\">",
"      Roth K, Lynn J, Zhong Z, et al. Dying with end stage liver disease with cirrhosis: insights from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc 2000; 48:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/60\">",
"      Smith AK, Cenzer IS, Knight SJ, et al. The epidemiology of pain during the last 2 years of life. Ann Intern Med 2010; 153:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/61\">",
"      Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/62\">",
"      Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/63\">",
"      Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer 1987; 60:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/64\">",
"      Rhudy JL, Meagher MW. Fear and anxiety: divergent effects on human pain thresholds. Pain 2000; 84:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/65\">",
"      Puntillo KA, White C, Morris AB, et al. Patients' perceptions and responses to procedural pain: results from Thunder Project II. Am J Crit Care 2001; 10:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/66\">",
"      Whitcomb LA, Kirsh KL, Passik SD. Substance abuse issues in cancer pain. Curr Pain Headache Rep 2002; 6:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/67\">",
"      Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage 1996; 11:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/68\">",
"      Herr K, Coyne PJ, McCaffery M, et al. Pain assessment in the patient unable to self-report: position statement with clinical practice recommendations. Pain Manag Nurs 2011; 12:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/69\">",
"      Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc 2003; 4:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/70\">",
"      Kovach CR, Noonan PE, Griffie J, et al. The assessment of discomfort in dementia protocol. Pain Manag Nurs 2002; 3:16.",
"     </a>",
"    </li>",
"    <li>",
"     file://prc.coh.org/PAIN-NOA.htm (Accessed on May 18, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/72\">",
"      Herr K, Bursch H, Ersek M, et al. Use of pain-behavioral assessment tools in the nursing home: expert consensus recommendations for practice. J Gerontol Nurs 2010; 36:18.",
"     </a>",
"    </li>",
"    <li>",
"     file://prc.coh.org/PAIN-NOA.htm (Accessed on February 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/74\">",
"      Thomas JR, von Gunten CF. Management of dyspnea. J Support Oncol 2003; 1:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/75\">",
"      Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986; 89:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/76\">",
"      Dudgeon DJ, Lertzman M, Askew GR. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage 2001; 21:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/77\">",
"      Bruera E, Schmitz B, Pither J, et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 2000; 19:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/78\">",
"      McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J 1978; 2:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/79\">",
"      Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970; 2:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/80\">",
"      Williams JE, Singh SJ, Sewell L, et al. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 2001; 56:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/81\">",
"      Uronis HE, Shelby RA, Currow DC, et al. Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer. J Pain Symptom Manage 2012; 44:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/82\">",
"      Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients -- an EAPC approach. Palliat Med 2008; 22:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/83\">",
"      Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/84\">",
"      Kinsman RA, Yaroush RA, Fernandez E, et al. Symptoms and experiences in chronic bronchitis and emphysema. Chest 1983; 83:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/85\">",
"      Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989; 64:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/86\">",
"      Hwang SS, Chang VT, Kasimis BS. A comparison of three fatigue measures in veterans with cancer. Cancer Invest 2003; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/87\">",
"      Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage 2001; 22:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/88\">",
"      Sweeney MP, Bagg J. The mouth and palliative care. Am J Hosp Palliat Care 2000; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/89\">",
"      Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 2000; 9:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/90\">",
"      Thoresen L, Fjeldstad I, Krogstad K, et al. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med 2002; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/91\">",
"      Corli O, Cozzolino A, Battaiotto L, et al. A new method of food intake quantification: application to the care of cancer patients. J Pain Symptom Manage 1992; 7:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/92\">",
"      Sarkisian CA, Lachs MS. \"Failure to thrive\" in older adults. Ann Intern Med 1996; 124:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/93\">",
"      Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999; 130:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/94\">",
"      Wood GJ, Shega JW, Lynch B, Von Roenn JH. Management of intractable nausea and vomiting in patients at the end of life: \"I was feeling nauseous all of the time . . . nothing was working\". JAMA 2007; 298:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/95\">",
"      Drossman DA. The Rome criteria process: diagnosis and legitimization of irritable bowel syndrome. Am J Gastroenterol 1999; 94:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/96\">",
"      Bruera E, Suarez-Almazor M, Velasco A, et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage 1994; 9:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/97\">",
"      Starreveld JS, Pols MA, Van Wijk HJ, et al. The plain abdominal radiograph in the assessment of constipation. Z Gastroenterol 1990; 28:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/98\">",
"      McMillan SC. Presence and severity of constipation in hospice patients with advanced cancer. Am J Hosp Palliat Care 2002; 19:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/99\">",
"      McMillan SC, Williams FA. Validity and reliability of the Constipation Assessment Scale. Cancer Nurs 1989; 12:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/100\">",
"      Bruera E. Patient assessment in palliative cancer care. Cancer Treat Rev 1996; 22 Suppl A:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/101\">",
"      Pyszel A, Malyszczak K, Pyszel K, et al. Disability, psychological distress and quality of life in breast cancer survivors with arm lymphedema. Lymphology 2006; 39:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/102\">",
"      Todd M. Understanding lymphoedema in advanced disease in a palliative care setting. Int J Palliat Nurs 2009; 15:474, 476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/103\">",
"      Frid M, Strang P, Friedrichsen MJ, Johansson K. Lower limb lymphedema: experiences and perceptions of cancer patients in the late palliative stage. J Palliat Care 2006; 22:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/104\">",
"      Mystakidou K, Tsilika E, Parpa E, et al. Psychological distress of patients with advanced cancer: influence and contribution of pain severity and pain interference. Cancer Nurs 2006; 29:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/105\">",
"      Block SD. Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine. Ann Intern Med 2000; 132:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/106\">",
"      Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011; 12:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/107\">",
"      ZUNG WW. A SELF-RATING DEPRESSION SCALE. Arch Gen Psychiatry 1965; 12:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/108\">",
"      Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009; 115:5349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/109\">",
"      Coyle N, Sculco L. Expressed desire for hastened death in seven patients living with advanced cancer: a phenomenologic inquiry. Oncol Nurs Forum 2004; 31:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/110\">",
"      Chochinov HM, Wilson KG, Enns M, Lander S. \"Are you depressed?\" Screening for depression in the terminally ill. Am J Psychiatry 1997; 154:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/111\">",
"      Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis. Br J Cancer 2008; 98:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/112\">",
"      Akizuki N, Yamawaki S, Akechi T, et al. Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Symptom Manage 2005; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/113\">",
"      Mitchell AJ. Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol 2007; 25:4670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/114\">",
"      Stark D, Kiely M, Smith A, et al. Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002; 20:3137.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association, Diagnostic and Statistical Manual, 4th ed, APA Press, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/116\">",
"      Caraceni A, Nanni O, Maltoni M, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 2000; 89:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/117\">",
"      Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000; 160:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/118\">",
"      Bruera E, Neumann CM. Management of specific symptom complexes in patients receiving palliative care. CMAJ 1998; 158:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/119\">",
"      Casarett DJ, Inouye SK, American College of Physicians-American Society of Internal Medicine End-of-Life Care Consensus Panel. Diagnosis and management of delirium near the end of life. Ann Intern Med 2001; 135:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/120\">",
"      Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990; 113:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/121\">",
"      Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA 2001; 286:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/122\">",
"      Wei LA, Fearing MA, Sternberg EJ, Inouye SK. The Confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc 2008; 56:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/123\">",
"      Breitbart W, Rosenfeld B, Roth A, et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997; 13:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/124\">",
"      Lawlor PG, Nekolaichuk C, Gagnon B, et al. Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: Assessing delirium in advanced cancer. Cancer 2000; 88:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/13/41178/abstract/125\">",
"      Sarhill N, Walsh D, Nelson KA, et al. Assessment of delirium in advanced cancer: the use of the bedside confusion scale. Am J Hosp Palliat Care 2001; 18:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2196 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41178=[""].join("\n");
var outline_f40_13_41178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4277426\">",
"      Dimensions of symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4277550\">",
"      Symptom change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1507215\">",
"      Challenges in symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSESSMENT AND RATING INSTRUMENTS FOR SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192146909\">",
"      PERFORMANCE STATUS, SYMPTOMS, AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      APPROACH TO SPECIFIC SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10693177\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533711386\">",
"      - Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patients with a history of substance abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patients unable to self-report",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88107081\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dry mouth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3315170\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lack of appetite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15069336\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nausea with or without vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Swelling in the arms and legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Psychological and cognitive symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2853694\">",
"      - Sadness, grief, and depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2853905\">",
"      - Anxiety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2861007\">",
"      - Delirium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1508773\">",
"      PHYSICAL EXAMINATION AND INVESTIGATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2196\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2196|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?42/14/43246\" title=\"algorithm 1\">",
"      Healthcare delivery mods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?31/33/32287\" title=\"algorithm 2\">",
"      Diagnosis of dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?16/8/16527\" title=\"algorithm 3\">",
"      Diagnosis esophageal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/24/22912\" title=\"algorithm 4\">",
"      Eval Rx oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2196|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/46/42723\" title=\"figure 1\">",
"      Visual analog scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/30/3567\" title=\"figure 2\">",
"      Edmonton symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/13/23762\" title=\"figure 3\">",
"      Memorial symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/31/44542\" title=\"figure 4\">",
"      The Oxygen Cost Diagram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/60/17352\" title=\"figure 5\">",
"      Pathophysiologic pathways involved in emesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2196|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?12/21/12624\" title=\"form 1\">",
"      Faces pain scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?0/20/328\" title=\"form 2A\">",
"      MDAS I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?19/43/20153\" title=\"form 2B\">",
"      MDAS II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2196|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/27/11710\" title=\"table 1\">",
"      Symptom prevalence in palliative care patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/59/13243\" title=\"table 2\">",
"      MOPQRST mnemonic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/43/26299\" title=\"table 3\">",
"      Domains ESAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 5\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/36/3660\" title=\"table 6\">",
"      Predictors of survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/31/24061\" title=\"table 7\">",
"      Principles of risk management during opioid treatment for pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/45/6878\" title=\"table 8\">",
"      Causes of dyspnea in palliative care and potential treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/10/15532\" title=\"table 9\">",
"      Borg scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/35/11838\" title=\"table 10\">",
"      Clinical COPD Questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/29/9692\" title=\"table 11\">",
"      Brief fatigue inventory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/13/17627\" title=\"table 12\">",
"      Assessment tools for fatigue in patients with serious illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/38/4715\" title=\"table 13\">",
"      Cancer related fatigue initial workup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/45/17117\" title=\"table 14\">",
"      Causes oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/14/22765\" title=\"table 15\">",
"      Common causes nausea and vomiting in palliative care pts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/62/12268\" title=\"table 16\">",
"      Constipation assessment scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/42/33451\" title=\"table 17\">",
"      Physical findings in edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/3/5181\" title=\"table 18\">",
"      Major causes of edema by primary mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/46/36587\" title=\"table 19\">",
"      Characteristic grief depres",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/53/29531\" title=\"table 20\">",
"      Abbrev screen depres cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/48/1804\" title=\"table 21\">",
"      Confusion assessment method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/52/18251\" title=\"table 22\">",
"      Bedside tests of attention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=related_link\">",
"      Assessment and management of dyspnea in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35048?source=related_link\">",
"      Constipation in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24985?source=related_link\">",
"      Diabetic autonomic neuropathy of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=related_link\">",
"      End of life care: Stopping nutrition and hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=related_link\">",
"      End of life considerations for heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24778?source=related_link\">",
"      Euthanasia and physician assisted suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4120?source=related_link\">",
"      Evaluation of health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4707?source=related_link\">",
"      Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=related_link\">",
"      Failure to thrive in elderly adults: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6647?source=related_link\">",
"      Herpes simplex virus infection of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7226?source=related_link\">",
"      Malignancy-associated gastroparesis: Pathophysiology and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/24/38282?source=related_link\">",
"      Normal aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12890?source=related_link\">",
"      Pain assessment and management in the last weeks of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/23/20855?source=related_link\">",
"      Palliative care: Issues specific to geriatric patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=related_link\">",
"      Palliative care: Overview of fatigue, weakness, and asthenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2037?source=related_link\">",
"      Pathogenesis and clinical manifestations of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=related_link\">",
"      Prescription drug abuse and addiction: Prevention, identification, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=related_link\">",
"      Survival estimates in advanced terminal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_13_41179="Reversible cause incontinence A";
var content_f40_13_41179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Identification of reversible conditions that cause or contribute to urinary incontinence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Affecting the lower urinary tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinary tract infection (symptomatic with frequency, urgency, dysuria, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrophic vaginitis/urethritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pregnancy/vaginal delivery/ episiotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postprostatectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stool impaction",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Increased urine production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic (hyperglycemia, hypercalcemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Excess fluid intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Volume overload:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Venous insufficiency with edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Impaired ability or willingness to reach a toilet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Delirium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic illness, injury or restraint that interferes with mobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychological",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Nocturia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nocturnal polyuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sleep disturbance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41179=[""].join("\n");
var outline_f40_13_41179=null;
var title_f40_13_41180="Frequency adverse effects";
var content_f40_13_41180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of adverse drug events by type",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Total adverse drug events (n = 815)",
"        </p>",
"        <p>",
"         N (percent)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Preventable adverse drug events (n = 338)",
"        </p>",
"        <p>",
"         N (percent)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropsychiatric",
"       </td>",
"       <td>",
"        199 (24)",
"       </td>",
"       <td>",
"        97 (29)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhagic",
"       </td>",
"       <td>",
"        159 (20)",
"       </td>",
"       <td>",
"        53 (16)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        140 (17)",
"       </td>",
"       <td>",
"        55 (16)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal/electrolytes",
"       </td>",
"       <td>",
"        80 (10)",
"       </td>",
"       <td>",
"        40 (12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic/endocrine",
"       </td>",
"       <td>",
"        64 (8)",
"       </td>",
"       <td>",
"        35 (10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular",
"       </td>",
"       <td>",
"        36 (4)",
"       </td>",
"       <td>",
"        15 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatologic",
"       </td>",
"       <td>",
"        36 (4)",
"       </td>",
"       <td>",
"        4 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrapyramidal symptoms",
"       </td>",
"       <td>",
"        30 (4)",
"       </td>",
"       <td>",
"        7 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fall with injury",
"       </td>",
"       <td>",
"        21 (3)",
"       </td>",
"       <td>",
"        17 (5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fall without injury",
"       </td>",
"       <td>",
"        21 (3)",
"       </td>",
"       <td>",
"        11 (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"       <td>",
"        19 (2)",
"       </td>",
"       <td>",
"        1 (&lt;1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syncope/dizziness",
"       </td>",
"       <td>",
"        16 (2)",
"       </td>",
"       <td>",
"        8 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergic",
"       </td>",
"       <td>",
"        9 (1)",
"       </td>",
"       <td>",
"        3 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia/difficulty with gait",
"       </td>",
"       <td>",
"        9 (1)",
"       </td>",
"       <td>",
"        5 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematologic",
"       </td>",
"       <td>",
"        8 (1)",
"       </td>",
"       <td>",
"        3 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory",
"       </td>",
"       <td>",
"        6 (1)",
"       </td>",
"       <td>",
"        4 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia",
"       </td>",
"       <td>",
"        3 (&lt;1)",
"       </td>",
"       <td>",
"        2 (&lt;1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional decline",
"       </td>",
"       <td>",
"        3 (&lt;1)",
"       </td>",
"       <td>",
"        2 (&lt;1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic",
"       </td>",
"       <td>",
"        1 (&lt;1)",
"       </td>",
"       <td>",
"        1 (&lt;1)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Adverse drug events could manifest as more than one type. Neuropsychiatric events include oversedation, confusion, hallucinations, and delirium. Anticholinergic effects include dry mouth, dry eyes, urinary retention, and constipation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gurwitz, MD, Field, T, Judge, J, Rochon, P, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118:251. Copyright &copy; 2005 Excerpta Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41180=[""].join("\n");
var outline_f40_13_41180=null;
var title_f40_13_41181="Buffers in metabolic acidosis";
var content_f40_13_41181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Buffering in metabolic acidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mechanisms of buffering of strong acid infused intravenously in the dog. Fifty seven percent is mediated by cell buffers, resulting in the movement of sodium (36 percent) or potassium (15 percent) into the extracellular fluid or in the movement of chloride (6 percent) into the cells. Forty three percent of buffering occurs in the extracellular fluid, almost all by bicarbonate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pitts, RF, Physiology of the Kidney and Body Fluids, 3d ed, Year Book, Chicago, and from Swan, RC, Pitts, RF, J Clin Invest 1955; 34:205.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41181=[""].join("\n");
var outline_f40_13_41181=null;
var title_f40_13_41182="Kwashiorkor dermatos";
var content_f40_13_41182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatosis of Kwashiorkor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The desquamating dermatosis and subcutaneous edema in a young infant with Kwashiorkor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Buford Nichols.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41182=[""].join("\n");
var outline_f40_13_41182=null;
var title_f40_13_41183="Melioidosis acute pneumonia";
var content_f40_13_41183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of acute pulmonary melioidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 286px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEeAWIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKAClpKKACiiigApykim0opoCzE5rQtifWs6FSWGK2bGPa2ZEbp3FaxRlJ2LlucYxW/pSs0ygEjHJPtWdbRgfeAI/PFdHosAEmRIq85IPtW0Uc7Z1mgW8kmCApHUlh0HvXUpBbRszKqmLdlckjdXOaVJcKArNuTqNorUuvtREbQxnfnacISPritlsZMzfH2vLc3dym5UlZVPlg4+X2HbiuX8LXCnUYg46tg89ag8a6XOsMl4xH2gOGCsPnkXkM34cfnWP4anm/tKAGJgVYHIBIrNvUu2h61qdqEtVeJQdwyQrHK81xOsMecLllx1NdxNKYF3DcM9OCa5bVkMyuziJN+RxwT9RVSQos89vx85J5z1rHukA7GuuvLeNQTjr3zzWFqsQIAjAyOp/pWMkaRepzkwAJzVKTrV+5RlJ3DBqhKDx9KyZ0RIjSUppKzZoFFFFIAooooAKKKKACiiigAooooAKU8GkooAKKKKACiiloASiiigApe1GD6UAE9BRYBKXBqRYXPO04p3kuBnaapRFdEFFThSTgjP1qRLZJDgFlJ9RRyi5kVKWtKPSZ35j2P9DimyWEsJxLEyemRxT5GLnRn4PpSkVe+yk9qSO0eSTaqk/Snyhzop7fTpT1jZjwK14dLJyGIAHpyan+yxpwqZqlAl1DPt4guMEZPc1sWvBBJHHvT4IDHl2ARAOTirUVxASA0O4DGe1WlYxlK5ft4NwVgjIOpOMitqwspJMCKWNz/dHBNV4mQsGiUrnqCf61rWIillHm7o5OgJGf171okZm/4cs7nzyNj5H8OCK61Z40nRd7FVG1ue+f8A9VUNBEn2cJKrPCRwV7mn3wc2shMTZU4YjgD1rVaEHn3jq+abV7iVZGdRKyxtk/dwAAP5VhaNcNbXCtHIF+h6fhWVrd9dvcSyGL9xI7FSR159aZo15idSyfL3NYuWprbQ9r1hpZ9PL2zu8JjX5gSecVx9xFcbS7Idn+0etddprf6FFLBn/VBhtHAyBzWNfqoZ3nly2c/N3P0rRkJ2ONvoZ/Mwq5UjOax7qMFMMQSBzjiuwu9hlVgrhT0bGP8A9ZrBvzbxTORCzNzy2KzZVzlbqHIJOOlZE1uc/LXWmaBzjaEJ45WqNzbLn5o+B3FQ43NIzscnIhViCKZXRS6fFJ0JU+/NZs+nyxMcrkDuKzcDaNRMz6KtfZzimmAjtU8pXMitRVp7WRQMqRUTREHBpco7oioqdbaZhnYQPU8U1ownBOT7UrMLoiopT7Uu04zg4osMbRRRSAKKKKACiiigApcVLFGr8HKn1qQQPDJh1yPbv7iq5SXJECxk08REEbgcVtWljvClRuB9O9W59InClhC+PXFaKmZuqc4YSpxz61IsJIGcjPvWslo4PlzxyBR91tvSteHwtqUkYdbRwh5DEcH+tNQE6nc5P7PKrfuy34HFSpNPGfn+b2cZrpZtEuoMkx7sDJ284qmbQPHyvFPlYvaJlGKS2lz5imJj7ZFatjpqSnMbxSjjof6VWh0qSQgxANn14xWrZaNMhXCuznoE45qoruRKS6M0NM0I3MuzayADJY9q2ptKSGJwjM6DjMoGD+FaGiQXloirdOpR2AkLrwPRFPdu5q/5kFxM0kyNBgkRQOcjGerH9cVqkrGTZyh8NWt4gZkeyz/y0X5lJ9l/+vUUnhO4t4mktxFJbDrIGwf++epP0rurpEtkMl1s3KAQpOFUepNcXq/iK1hZmikNxcDo2cIlDSW4JtnP6hc2unKUMTNIOhmG3P8AwDr+ZrnbjWrmRyYz5S+iDbx+FXNV1S4vpma5CzE/31zj2z2rIniVgdoZD6ZyKwlLsbwiupHNqF1K2WnlOP8AaNLHqV0hB89zj1OaqlSM00A1ldm/LE6nSfEMkbBJ0Eie3Br0bw9cQXMClJMow6MM8/0rx2x5fg4Ndt4WvXtrmP8Aut1HYj3renJ9TmqQS2PZtAgeKXzLbcUYkEBuBxW3qsvkac370JKVK4B4G44/xrnPDUxRwIdzxhSWz2yRgH/Perni2ZYNBeXGArA47+tb3MUeZ+MUDPJb5ylvM0SAfq31JBP41jaOsjTeWsjbOu0Hk07W9SjvJz5cUiHOd3qT1PtUvh6JHlDYOc/eB5FZvVl9D1K2jmudCtgXbcIQuNxGKzJrOOIlpT5sucZJyfyrds53bRbRCwZFLZc8Y44z+NYt3E7r5dvknHLk4yfatGQjn9YkiWTLtg9QByx/wrlbq9Z3JhhUHpl/m/SuzutI48x1Z884I4FY91bojFVRQp44rNlo5GZbqTJIA/4DilsWu1PlMQVI+UNjj2rYlhYMRGrEepp9rpVzcTL5SByOT04Gamw7mWI5Fcie03D/AGPlNTGwiuf+PeQpKvSOUYJ9ga7SLw9cOoxbkn13Dp+eaVfDcuQt1JGmf4T8xquUVzzq50zLbXQxSepHB+oqr/ZdyJlVIXeQnKlF3An616tHpdhbuouYZrxP9ptuPpWibLdaMtpsNoeqINpH1755pcg1No8/03wo15as13MluTwYR877uPTp/SsmTT4LfctvASwP3n5YfX0r0u30MxJcSW5ZgrK2zPzL15HqKqa1pcdwpuomjEzD95FuClz/AHl9Se4o5Rcx5VdQSSHD7vpWY9sF3Buo7V2GpRSsSiwlQP8Anrhfyrn7nT5JGO5x9McfnWcomsZGNKyrwi5PrULbmOW5rVlsSiD7p9eaZDYtMzA9V64GTUOJopJGXiitptNiX/WFw393uf8ACq8unEqWibpyVNS4MpVEzMpcVfj0926uuKJrJkTPBHqKOQOdGfRUhUZPIopcpVy/ZwHIIBzW1DaeZFg4PcD0pbOyYDcF4rpNDtBNMqSDKnrx+ldEYnJOZV8M2nkXAWVfkc/KT2rsH0gYClcoRxmrEekH5CoBLDr6V22nWEEmhRy3rYkVirKi88e//wBatlEycrnn2neGZDdqzA4LfKuePXNSm2miXcjyZJ6g816ho1rFK0K26FztG0Mp459fWpda1bRdGncmGBL7OWe2iUsT+P3frTtYNTzyz8Paxdq0qQO6D/nonUfl0rBv9CnguZvPhiA3MBkYJyfTNdH4i8d6lfrJFZXdzFEOM7yM564Ax+dcXL5k6gyOzOzZJZicn1NJ2GaVnp8aDdJFbxKRjc9wM/XaMmtW1axgVjFKZ5VHQLsUD8eT+lYlrbfLwnAHbjNbmj2JknB2YC8k44FCEy9ZRs9x9pkG+4VGMeekIxkY9/8APWqOqXltoWmiaQ7rlwQpIyR64Hr6ZrpLua20nTLi4uJPLgQHc7Dkt2AHc+1eB+M/Ec+q3h25ihA2qpPzEe5/oKJyUUOEXJjdZ8R3U8jZmaNMn92DnP19/esJr9yT8oye55NUjSVxym2dsaaRM8zOcs7H6mmg81HS1PMVYUnnNKjEHg0mfXFKNvfNMC/ZzorAuCCO/UV2/heSOW5jQCPJ4BI61w9rbq/IcZz09q6fQrd4byNkOPY9DW0LnPUse/eEIle1ilQ7Z9+1gB1XHX+X51oeLLaD+wRvt0bzGZGUDGOOo/Ouf8EamqzWYhbbskOUz2x0/Wu28XRG50xXifeAzHH1FdBzrY8O1PQbcpEYl2blP8XPXjnvVzQdJtjIcRyKIwMlj1Oeldbr2ltBCisP9SFGfTIyf1zR4esZFlJ8oSq5wyNyPr+FLlC5rw24OmW42rHGqgqFHXNMtLVTeRb0+UNgj6VuahbypIsUQ2qqqvHG3Hv7isy0t3mv2E0mdgOUOTz70wIbxbeCV9mZMdCowP1rmb5pZZCbdghxnhAWP4kda7W/04yqRuABAG5hw3v/APXrB1DR2i2N5/zA5yoxQByKQTsSS2T6sK3NKtSlu8pJBI6Z7VajtdO8zY831Ayea0w9pDEY0t5ZOO/FCQXuc1cxsc8Mx3ZPt71BBFPGQYmdT6Z4rfdkwcRRopOMEFv5nFUrlsKwS4lXPOEwAPyosBWnu/KVTdxIVH8X3G/DsaZZapasS9jcGS5AOYgPmx+PBH0zWPqdhuYlXDHpluormJzJb+Y5Ei7ejAdD2walsdj0lbt7xJJrTbbsU2ugOSrfX09DXN6nDhpZ0JFyv317Sj6etP8ABOuR3azw6icuwUC4HU8nhh36dfzre1WwAj+Yqd4JSRTkH3B/pRug2Z57dX9rONs1tsY/8tFOT+I6GsW7QDLQTQD2KlCP5j9a3dVsGhuGDKNucqR0+grCvIAoY9h7VmykQSeYyfvUiP8AtDmtPStPfUIngSb5yfkEeBmsNhhOOmaRWZZAVd1YdCGIpXKtcu3ejXNlOY50K46ZHWrlnpR+zPcSqwTG1cD7ze1a+geNNQgiW11ad7yzHCvJh5ofQqT94f7J/AiuivXeZVnLpcROuRLtHT09R9KpJEtvqcBLppV02qQHGQD29c1l6ynlsLePOf4j7V6RGlpLFJuOyWNCV5yM+n+fWuHazaaeWSQBSxJORSaGnqcx9gb+7n8aK6ExqDgM2PpRUciL9ozpNPsWMR77e4/lXSaFpbIQXHJ59KuWlh8u0Ljtmus02x5jVVAGO4wOldKic7YWlnss1bggcdKfEhMbRDPDHA9Kt3JJKJGTtHyqDzn3qe0tlQKOCDjv+tUIWW7fSNCnli4uJh5cbMPmQH0/DNeV6jI8smC3qWJ7mvRvG8hFtbRJgKSc/pXHpp5ZwcErnrSaHc5+K1OOQSSc9KtRWOWBUA4roItLwwwvPr/WtGDTBgZTkdqFELmZYae0pKIuOPvEcCtqOC306wlubpjFaxD5mA+Zz/dX1Y/oK6Cz0ryomSQgHrIff0rzT4j62J5mhVtsEPypGDwP8TQ3YLHJePden1ZyxzHbICsMQJ2xjv8AU+rd682vSC2cfMK29YvGuDjOEXqT0Fc7LIpPy847muWpK7OqlGxEaSiisGdAUUUUgCnDHc4ptKOtNAW7GRo5BjBHcGu88NbrghlGQP7tedI21sjj3rtPBeovbTMxYKduOnB5rem9bHPWj1PZPCdgHu4fO/d4ySVPIA9e3tXp80LrFHbJNHyvmoGO0tzXnPw/mjurkqX2o0edwGcN6/0ru9YbZOpiBCoojXI7cnPt1NdJzIo6xY3VyGVoI/3jgvnGAaseH9NlFzGZGVI92MhfT0qxhp0iLBG3A9jwa3PD9kWaHBCiJWBVj1z3H+e1JvQaWoXlrEyvMykgDJyPSsOzSKG8Zm2qTnkDk8966HWLgQ2h2Ju3cAVwGrahtfMfJ9icZpR1G9DV1J5T5jvtMIH3/urXL61exSokcU24fdPlrkt9Paq979qnkiYzuyyAkLkkcHHTtWjplpNGjTTRh2jyY2fAwx44FVaxN7mL9l+wMrrFIzlg+045+v8AhWxbyDY2YAA+dwZyduP/ANVWJ4WlQCQxjcvLDORz1qvNbSW4URSFlJzuUfe7YNMRhz3pMnywKyZOcuQcVA19bb9rRPjHJVv61Y1iGMRu8UijJywAP61z8YmkcK4zuyVKnJ+n4UmNF+5FpcwMscxUgZIcbf16VyutoYbZlIIDjI29CPr3rX8mRNyL8p5+Y+tYstteQu5EwWNuGVvuv7c/WoZS0K/h23KzIoJQyfeHt24/Ou70+5mhj8iVVkiY5Mbfdb8ex9657S5IDdxMVSGYcYJJjPtnqK3Li6aCUpKgDHBz/wDX9PpTSExmp2kcq+ZCfOtnOwk/eQ4+63ofT16iuR1bSpIpGU4IIyPRhXfWRjabz4hvgceXPEf7v/1uoNSalo4eN4QN2AXhbv06fj/PFDiCZ45c2bAHAxjrVQxMucjp7V2eo6fh24+lZ8lgpDdCcdMVDRdznEBBAx7dK63w7cSm2kgLAxlc4P5VkS2Xlk4GOM4rT8PZSVhgkFefzpIGTyZy4AAAIAJPUVGkJawuCvLLKuT7EH/CtKWMOWJ2ZPBwMZzTbZmt5N2MhgA2Rxn6VQjl2i+Y/K459KK637PankOVHpjpRSsB3SW6wW3myny4FzjI5Y+gFWtI1OOf5CfKAO0Drkf0rj73UbjUroyTuyxr8scQPyovb/8AXWloC4ugMfKw4Hqa3TM3odsqFpC2QR/snoKsW6gkPu9QeM/T+tVYLQsd7E5PXjGKvWqPuKkfKBgYx0oGjI8Qw/aBC3JCkj6cf/WqpFZksFxx3JHSupvLLdjj6gU23tQ4J4yq0XBoxktuOAFHv1rY0bTvNuEcDlBvAIz06fqRU0doZJFOCAeuB0/+vXV2VoLW2YlQHYc+wHaplKw0jjPGt4mgeG5pN4E852KT24yxH+NfNHiTUA8he4ZgW5WL+Ij1PoP517D8b9ZCFoVKyS25yiEZCg9WYdz6D059q+e7sSTM0krMxJ3F25JrObsrFRV2Zd9cNPKS2AB0VeAKqVNcAbjtGBUJrlkdkdhKKKKgoKKKKAClBwaSigCRW5z3rp/CES3TzRAfvdu5cd/WuVzWv4Zu3tNVglQ8qenqO4NawlqZ1FeJ9C/DS1eFwJt4JA2k8A/Q16HeqJJpimXZZMke1YvwwZLuNZostFtBO4Zxk/oe1dpBZQPcyPJFhG+bK5Byf89K627HGtSvaQFo7YGNV4JOF7Guk02ML5jDJAG30/CpFhgC/KgOMEYOO2K1ILdI7cBVALDdzWUpXNEjmb3TZLqGRJG288cfzrlbvw9H5qeYx2d2b+gr014yRk5asO+SJZZHkkC7ulOMhOJxN7YQ2/liBo0VgF3r1P4+lUZgkdm5fakgwp9G9+aueJtUhgVxaK0jDhc/4d68v1XxPfTXskD3AMZOCAo4Na37kM7bUZRHbLFGwLkY256c8H6GsS7eeRXUXaHjgq+MD2rBtr0SMVllG/GQSOCP/rcVBLfotwVGD6sMEf560XQjXhifdIJ2jkQgEFXHBB+vtVNLeU3DyJGUOcgkcAHv/wDWqO6ljKJwAC2C5HXP+FJbzLaArBO5xk7s8mgDprWwFyFa8iAUYwNuD9R6Vmaxo0Yl2ROq/Lu2MMj8Kba+IpYXxMxlgz1bAIPsR+XNWorm31JpfJn2XDDiOQ4A+jdM/WjRgclfaf8AZ5VQgr0OP71W4JJLb5JY/Pt+pTPK9/kPY/pXR22niOLF7GXZmyTIOuKtaxpEQs4prJVVwDmI/wAX40rBczNJDxPFKjGWCQ9VHQdwR2NdzcWSyoksQBOxWwPYDkfpmuC0i4eCRhKhSJzsde4HrXpmltDNZo0Lho1GAw54pjR5t4j07ZcMyj5CcgfUf/rrCktVC8gfh6V6d4jsFaRXC/u3XAx2IrjbuzaJnDA5HfFK1wvY5SW03OAw9806zs/LDt6/rW2bbAJ5JxT4rUrat3z7UrBcyZFXGc8gnqMU6JY2UfN1H1xTLtcvwOO+PSpordoYiT060hkDeQCfnUf8Boqi8ql26dfX/wCtRSKNK1OZMnI5Ax710+mLtKMODnK1kRwBSHH1IxzXQabF8qlh15zWyRi2d3pCrc2olA56EZ79xV2OAJJ8o3N7jj/PNU/CaAvNG3O5c4z6VviIEAjHAxwKluxa2GPCCADknHXvimQ2xWQn1G3BrUjhBAJ6HrUq2w3semR+dRzFWIrC1C/vGGQvI+v+eam1e7/s3SZ7wjMqgiNT3btWjFCFijXbyRuNct8S7n7PpwhU4IXJ56f5zUr3mN6I+ePGJYzSy3JMsrMSd3r7+przPUEJZ3U4iHUnotel+KnjSNrq6JEbMdkYPzSH29vevLNZunuGDNtVR91FGFX/AD606gqe5j3EoLEJzz949TVansCeSMUyuSR2oKKKKkYUUUUAFFFLQAlWLEObqMICWJ7dar1s+Gbc3F7hAd3AGKuCuyZu0WfUPwLvhb6SzSlmXbsI7FvQV6ykPmxhgO/UdK8H8BSy2axWzRkKOd45BavePD8nnaemQc+pB4NdclZXOKPY0IYtu3OewrbVB5Sjb0FUIIR8uTnj0rVUAxgDtxisJM2ijMuA3CqT07VxWuJK0jrDG8gb7xr0KSLPJA561gX9uGYggYqoSJkjynU7G5YFVTCr/E3GK4nVdByzzZQSHpt5JJ9PSvUtfURTnIJjIO739xXP3NuhhI24UgnIOc8cGujcxeh5Ld2Zt3dWecqOW6YHsKrF1t0ZlYtIPvMe/pXb6vpokj3eZEAOx61z0tpBt/4+IN5XGDn5ufSpaGmQ6eftAhBklILb35+XHbr71fbT5oYGmjmGwfKA4zk06y051SWNZIHkXCqS4FbdratIEikaNo1wrbHDYPcimkK5jXVpxBGke7+LzFOQfbii2twkDOpKu+MD1JrpL+zClChGO6nPetC0gS4dFmWMrGM5weB6U7CuRaGLmLasgWaBVJMb54+h7VsT2q3Ns0tvI0gJy0ePmj7fiPcU6O1SNGO35f4U6ZH+FV4rjyAwgQrJGxIIP3fegZmanbQ4SObYkpw29edvt9K0vCE8lhe/ZLgFYJhlSpyM/wB76eorn7zUA7SkoBfMd2xhgP8A7vv7VraBf+eVEyBCf4em2hgjtLuz81ngYABuFJ6KeoP51xeqWbRs4ZCrDKsPTH/169EMW62hZsHjbuHcdjWD4nslaXzAnEwyf94df6GpTKaOBktAwTaAOeRin3MXlW5HatgW2MBh0HGe5qlqEXB54P41RByhtyJl44yai1lxb2qxj/Wyc+wWt0W538gZHU1y+qnzrqSUn5ScY9hxUvQpanOv99skdf8APairDD5jgDGaKiwztYQCpGDjp9a6DS4+gHSsS1wAmDjPetvTH/ebcjOcV0GR2fh1fKu4SucscGuqSLY7da5HSGAljOP4h1rs4T8569aymaxJYUxx3q5HHkk45xioYhkjHT9a0bVQcA9fWsmy0iYRAMDgHGAK8y+Jk0UUkkt0N8f/ACziz/rT7/7I7n8K9UlwFdjwAOa8O+JzveTm5LEIgKBR3A/p6mqpasVTRHgni+ee+vJp5CS/RsjgDsB6D2rhrsqA3GcfzrtvFB6gAhB0wP8ACuK1DZGNzn5z/B3+vtSqDpGWxyfX0plOdtx4AA9BTK5mzrQUUUVIwooooAKWikoAkdQrAAhs9xW/4WuBaXHmIR5mMD2rnauaeHWeMrnr2rWL1M5q8bH0T8OXdxwwLBMkk9zX0d4bg/4l8BKkFl+avmz4RGZgkpXGOACM7q+nfDqOLBPN+8OAAMAcV0VH7py09zSYBTyDkVJGeBx3xSyLlRjFRDcoIycVzm5Iw+U8c9Diuf1GWNHbd8x9FrdkY7CB14rBvYdzHjrVRJkcD4kuXKSeUgQckHbmvNb+7mjd/OmLLGpJJPGPWvVvEtu/2dv3WRyQR9K8j1qyu5JJfk4xnaBwRXStjB7mQdct8EMS3UYHy5/zxWPc6w13PlIkjWMbhjB/zmlvNNlecLHhATjHTFQ/2RJC9x8u0qM4OcZpNsLWLWm3Uwti87OWYtk85wP610Glh2dHWM5I6A/dHfPr/wDWrl4GFvEsZm3HblgvY+nNbMd3LbK0cokTbg7MfM/5euaaYWOriu5EjYB2byjnDAbR/OtfRNQW4lQXMTQRgfeUcsfdT0HuPyNcTPfXD3kNvboyTKqu27+EHsfU1tWENwgz50m9m59RjkjNVuSd9ebIrSWdNrxY5dSMfT2/GsuLU7WC2ladAf7oCnL/AEx261WiikgImRiZJBlt5zuB9QeKoXMlvN5itGIJ2bhQfkc/X+H6dKVirnIeJo5ZLsXNu5dS27O3BUfT+tdH4VuIbphEZALkAfP03D3/AM9qyNShVZY4XDKVOSc8g+tXNMtFjXfakGTOMA8n/wCvRbUVz2jRT9o0popBhlbjnJXgVV1m2zboHXlW57/56U7wjM1xZoHx5qph/f3rV1iMPaqQMnIyPUdqzvZmm6OBuIQjMCO+cn9Ky9SjAUeh9K6LVISuT1zxWLdINu1uDk4q0yWc3qj/AGeyYgYZgVHH+feuQuNvf0rrvFGQkKg8AsTj2A/xri7/AIHBwBzSkJGUy/MenX0oppY5NFSM7m3H7wcnAGPXNb1huE4cDJA6Cuas3Y3DdeBwAe9ddp0XlhA3LdyfX0rdGR1eixF5FB5GRxnrXYxINxIzzXKaMpBVwCNpHauytl64IwfwwKymaxLNsoLAVp28e1WOPaqlohLDI7dK0oV+U/WsJGqIL1gljKzdMY+teH+OGe4nlMQLFeNo6e4r2nxC5SwCoOSTwK+e/iRrIsxPbWrb3OfOYHB/3R/WtaO1zOoeO+M5ltLlhZ/PLyHccrH7L6/WvP7pmZ/mOT3JrqNbaSYuFBKg546KK5m6jAY4IzWdTU1pWRUpKUikrnZ0hRRRSAKKKKAJoomdcjp0zV0XMclrHA0ShlP3+tWrK2WTSH2uC7Hp3FZ8lvLbyLvUYIyMjhhW1rIyupMd5HLZGF7GtTw7psl1dqqA8c4PFU4JImKo6kEj1r074f6MDJDOpDqzY4POe/FXCN2ZVJ2R7B8ItCe0Tc64VB8u4dTXuelR7LcKO3HSuW8JQRpp8EaoDgZIxyD/ADrsLKPYuck9qdRk01Yte1NdOelSbenPFO25FY3N7FJgctx+lU541fIz83p61rOmQayLxghJPAqokPQ5rxHCyRNhThq4XULISW4DYVwSGwMDnvXU+MddazSFYlQsWOTJXPnVWubZSF2y91CYA9MV0wvYxlY4a+0U/ayyI0kg52gEc+tcn4ile1mkhm8wozYHBGa9J1K6ECGSSSQOARlDg4PrXlPju5v55xL5zsrD5ecCnIhHPXc8cZj+XJbkgnmtDR7i4kuTdB22KcO78knsBXJPqE8Lsk0g3HjJGSBVy31crNGESN41PBOVLe/HFZ8xpys9U0qIyTrub7zcHGfz/wAa72PTo8RlXdSDu9N3ocdK8j0TXv3ihwyKemw5XH+RXpOha550ZDOsgP3Qp6Adq1TuQaGpW86oio4kgDfP8uSD7D2ritdukkMqcBDgluSWxXV6tqRns/3cioOQMcHNcPeoJHTzmRjkFQDjr/npQxFOC+ZpBHNIRGMbHJ+ZB6e49q67QswMrSHaHOUwp5Oevt7Vws0Xk3SuT5yBgxwOnvitjS9bzcmORCInb5STwv49hSTsDPa/DkvlXMU+c7xtlAPb1rrLmPMjxP8AdYFT9a898Jy+UVDPnuCB0r0eQbljcfxKOfcVnPc0jqjk9ThJjYMOVOcVzd3HjkjIHtXd6lF+8kOPvcjj1rktQj2byeccD3q4sTOH8QpuRPbcOK4XVDtDYGDzivQtdXcijjBJPPeuI1OEYJxx9ackSjlC7ZPLfrRV4xEE9P8AvmiosM6/QMSXMjspKIQPxruLBflz3HOfWuP0KPy4E4OW+ZifX0rtdOUbQAOSK2Rn1Or0Vc+/611tnyF4/CuT0k4dQo/D/Guq077oA5/lWMzWJsW4GDjrV6EHYT3JqrCvAx2FXUGOPQVhJmqOe8bXP2TR2kX7+CAfTPevl/xhC5lnkl3HcS23PUep9q+nPGgWS3MbHGE49j6182eNIZZJ5kMQZh2C9/Wt6XwmNTc8n1eYuCp+TsBjrXLXXr0X3rp/E08cDGIbGmb7wUfKntnuf0rkZy7SEyHLVlUZvSWhGxHYYptLRjisGdAlFLSUgCpoYpLiVY4lLOeAAKiAz3qxaStbXMcq9VYEVSXcTemhpR2k1myeY+0ODjnmrkVw0UI8+FZ4VUgI38NUbm5e4umlmbe+ewwCK1tIs5b9AiqQG64Pat49kc0npdmZpds91NuMYxuwMivZvAdlNpwt7qNsxDGEZepHb2qDw7o1rYwr9qtVlkQgqCevvXpOjaVFLEskA3K3IGMY9sdK2hDlMZz5meg+Dbw3Ftkj3613ttIHRCo681x3hXTkit/uBCTkqveu1to9oGBisKj1Nqa0J+euKcDxRgU4CsTYYax7+Iysex9K2iKp3MWTx1qosmSPMvGemGYKsa5ABPSuU02GSG4fCMxI2PwTx3wK9Y1C1DXBLHA2+tY13o0JeRgR86nn0OOK6Yz01Odx1PL9Yga7huCkckmUwAo6+9eU+Jg6PJbyMUOO5yBxX0DBaollJCsjeaWJXGBgj04rivGOg2N5CJGbfeY7gdqt6i2PmnVLKeKTzGBIB5NV7aYpIpHQHkHvXomteH5pXfyWRsA5iPB/CuButOubd3ZYmwpIII5BrnlGzubRldWZuW+p7doQYkz8x7Nx0FbtnrbxJGBjzQf4c5H0rgoLoqBuU57Edq0rG9eP5kVdw+7k9fempEygevWesTXFhPPf+ULeAc44fGOpbv8AT9az5bxLtFmimMikcnG1lGOMjrXApqEu07ZmcsPmXt+PrQdUlgn82PKuO4OOa05yOU74KgkBPKMB069OtO/s4JKZIskDOYz0P096x9F1OO6VUlZYps5xn5T/AIGuptxHM6sihdijdk8r74prUl6Hb+A7wTLHE7EsgwP9of4ivZLP97p0SkDOOPevDdDQwXMVxb4MyEZCZw/v9cV7jpZBtYjGcx4BX6etKoXTKd+mXYe1clrK4Z8/XpXaX6fvZB64xXIa2mJX3cg0QYM4XVRmfDHoMew4rk9UiADcevH9K6zU2PmscKOep9K5nV8nccYx1+laPYzW5yxLAkYbj6UUrDLE4HX2orMo7XS4/wBzHxhgOD/Kuw0peMA8Y/KuVsBt2D04xXWaOo53dMcY71sZrc6fTflmXB9vpXU6ccsMdveuSs3AmPJwOnFdZpPEY3elYzNYnQQjOBVxRlsc1StzwO1XV/U1zs2Ryfis+ZIwXqeK+efidcg3E8OnNicDbJMvt/Cp7fWvePFlz5NrPhgs75WM+gPU184eLomSSdQCWII5PP1rpgvdMJ7nj2rMd7DnIrHdSzEk9OpNdRqtvvchlw3Yen41gXSgYAAPrgYFYTjqdFOWhR+lJT2HPTim1k0biUpBFFKoLEAdaQCqpJ4qZSEcB+npik4jwvX6daOSykD5j39KtKxDdzq9L0ETol7ICLYMAwUjJPau70SytYjGqpKM8kJjcc/0rirC0lsbWMNvy4DbPU16b4Ra1jSMum5yAGU+46/QV1wRxTbZ3Phe10h4pVnS5ExXMWQAM/XtXoPhbT4PsoSNQyHkY7cdq5PwxZ77gSKucN5ZUdMDpz75r0rRLKK1jVYgQo6jPSio7BBXNfTbVIlBUc54OOta8YGBVe1HBwORVtR04rkkzqih1KKU9aKg0sJUMgFTGq8xJzzxTQpGNfRjzmO4A1nzIocsSpUD19av3XzyHOMZx1qGeLfGVHOOw7VsjBo5LxJZC3BlgaJBjeDn9MVyktkb5BMsi+eCSSXB3eld/cWIm3LLjldoB5BB9q5a40f7I0jQxZGDgjkAYraLM2jznXraXzWIs0+0KcvsHUeoxXE6jYq7PPGrpk5ZQeR/9avW59LW6kk81JEdujAEfr0rP1HQhHZFuDIv8Z7j/CrauQeDa5pMW5XgRzLgkjA2/p3rn3IY7GTDrkccY9q9f1DQsFsQ4Qt1Q/eHtXBeJdBaCUsFIJ5X1x71jKJrGXc58SbQApzx3OMfSnecJVYumHXkYGDn+tUCrpIUk+Vs4K0/zigAHzLnuOKzuaWL1ldlGXcDnuevFd/4b1tJLsW12z8keXKWwR7GvNwiyMHhOCfvKT39jW3p0x85UP3xzuP0/WriyJo+ifDIO+GUKAOu30PavYtCA/seJscBjx6DrivC/hxqf2xEtZuHXoSOa920Vdtk0OOiiqqbEwC8HCtzk8frXH+JsqhK8E/LXY3HMSnrg1yWvp5kL+3IogOR53qS4yRyBXLaj8zYwPaul1WULlUyMfrXKXzgtu5BHWtGZLcxypyaKazruOFXrRUXLOy02Tc6noRwK7KxbYigdfrXn2k3O1VHXPrXZaZPkpz7fWtjJaM6bTHxKuVOa7bTQdi5OT71wumOVnUsAVrvdO4Xp15rKoaRNu3PQ1fxhuPpVGz5Iz061cZv3RY+lczN0eW+NGkmu5Ap2xxnbuH9PrXinjdkYOigKnJYZ/nXtPjqULkopO5cHOMAj3rxPxWYlikluCFP8Kg8n6V2R+E5pbnmGporOArZLfw4PFYV8qrI2FLP0YdMH0rb1ss7HcrIM8CsC6U4BMg3AZBFYSNqaM+THJOc56CojVh1AGGPzfyqVLJ2j8wFWUe9Y2udCkkVFXPJ/L1qxaTiGTeEVuOQ3INJJFgnOfwqe1smmkAc7EwW57imk+gm01qUclmPvVqxQNdRKQzAtjAqy9qu4rGfoMck1b0tYobqJ5R8sbAyDODweaajqTKemh3WiaRLdQi4dSArZGTjj0r0zwXofmwKYdrS5KkDqO/+fpXNaTfebFB9nh2xEZ2YySAe1es+CdNaEPOwc7xkbxgAdwfxrsWiuce7Oo0TTY7cW8MADbAC+M8nGPxrrLCEgc53Vk6bFsdCWJAyM1vwkpjA+XjtXPNm0UaMCbRnvipx71FA25M1OO9c7OiK0FopaKksaarz9M1ZNQT5C8VSJkY7AbifxFQkjYwyQxOD61bGMHI/SoDH8+eta3MStDbh3VjwQT/k1Qv7QbXG4hiD0rat0/eE9+vFR38G8cHt1xTTsxW0OLazZFdPMyp6gnr9cVWubPzIDbviRXGGOeV9MGuklsWSXzEPzY6Cq89uQhyoXPtwDWqkRY8i1TT2hkZbVV8pSS4fPHv/ACrltYjG93uItwI+UjqPx7mvYNa0zmSVhu3ffU9z6+9cdqFpHIrRS25cdRkZzWm6M2rHz/4q0htzXFt869scY9vauViIfKs230B7V7brdlGqyAQh1bIkBGcDsD6mvHdeshY3zKOVblTXPUjbU3pyvoQp8ilc4bPBrf0qVWkVHIUggketc7DdHCpKNyrwPVfpWjpuUmDffj6c0olTWh7X8PDJbXkNxk/ujnJ/kf8AGvpHQJ1nVZIzlZEJH+FfL3gbU0DqHIDgbTnktX0J8Orvzra5hUnZEQ6EnkBuo/MfrWsvhMYbnSX42xkdiw/UVy2sMBE3H/166jUGItVY5+9g1yeqPlW3dMdM1MC5bnlmu4SaTnuccdK5i9l3Dnjtj0rq/FKD7SxHBOegritScBcHvWkjJGOzfMcsQc9MUVUeX52+YdaKm5VjpdLuMkc54AGa7fR5iuzOce3WvLdCuxuQnmvQdHvFBQKTkd81rFmTPR9KAkZe5OK76wGFA9q878OOHuIywy3XmvQ7HAHJPPrWdQ0gbdr3P+zirEpxAB6moLPBB6460mqTrBbeZIcIAc1z7s26Hmfjx4oo5fPw2/JRc9cH7xPZR+tfOniy8eW7kW4JLgnJHTA6fQele1fEG98+4NzuIIXA6Hbj/wDXXiuvwC9DvEpFxnCsRwfb2rqtaJzvc4nUPMcjhuf1rNW2ed2+VwoPLdv/ANddFc6ewmYSL8ox0P8AnNF1H5kQFshWEce5/wA+tZONzRSsrGCLKGFN8mZDnqP6+lWrg7hGdqrxyBwOO1Si3KMsZVERsfNnt61TvpFSQxov1P8AKlsUtWNkkjILYGAOhHBFRfbACdinae1QOC4IBJzyOOtSRwShM+Wdo9f6VN2XZIDI7ShkG1l7+lIJ3yVCpycksMkmnraXLOW8k7RjOT+VXY9NmlnjKQtuYZ5ppNg2kenfCmW4u5YHnuJBEBs+TAOfQV7XpOozJKI4nk3OQFDNuNeMeAoJLWVLeRVQsSR/vE17XoFlMzmWSMrtbbkL1rpXw6nN1O10ieWRh5xVs+2K6G2bcxIBrD0yE4VhwdpHA4rfs8cDbg4rmmbRL8KgL6VMBTEHAqQVgzoiLRRRUlhioJ8bDnIqc1SvnCoc9+OKqO5EtijMY1zlmxjjioo5EGSTj6imy/Ngn1qLblCAM5raxjcsQOrEspHBxVi4/hbHtj2qtDEmDk/dpWlBHy9O1IAMKlTtPUVVkgKHj7p698VOGMasxwe2KUuGQnOB0xTAy72yS5iZGRTnoa5PVvDq7srvyDxiu0mIQ5QYPp60xiskJIwM+oqlJohpM8S1/RPLmZwg8z+JccV458QtAcRvOE2kDfj15xX1Tq9j5yyfxDPOehrzPxj4eBSTy2QxkfNH6H69q1dpKxHwu6PloxYxkjnpWhpkzwTBmHQ9D0NW7zSpLe6eCUBWRyOOag2KjkMSzLwPpWCVmb81zuNAuEkImgUI3V4s/dHqPUV9HfB2ZmSYSHl0GQexNfKmgzNBewzRuAUfOff0r6g+Ec0bWUlzGNqyNtxnowGT/Otd4sx2Z6RfA+RIh6j5vy/ya4/VhhD2+n9a7S9UNLu/hIwfxFcZquNpzilAuR5t4nBBB42/zrz/AFmZVGR1B4FegeLWzCWCjrivK9al+83Tk1cjJGQ8rb24J59aKzWuPmPTr6UVF0XZl3RrwqVAOM16J4euxgZOa8h0ycgrz+teh+HbjhS3U9B6VUGTNWPafB8xa4AbknkHHSvT9OYbBjP5V5F4Kk3y54Bx9a9W0xsqM9fQGnUCB0tkcRk9zx0rE8b3Hl2Mca9SefxHFbVscBVPYZNcp40bzIZmc4WNMgepHNYwXvGstjyjxMxuCyMcRjODjO71x615/fwuEIPybz8nOBj1rrtavFmmMhAAzwnXjHH0ridXv440DXErBuSFI6jj8vrXTI51uZGoW++MAY80cY7e5z2rIuSUUqCH6Fn7H6Cu+8O+Eda8TSgxW5gsyTiSQEDGOw7/AI16t4f+EulWIErobq7Jy8swB/IdBUPzKWux86ad4a1TWMywW0iR4yJJBtyvqBW7afDyQ5MwkcEDPGM/Svp2Hwhax84wQu3aAKuf8I7BEnyx5J6ZFK8SrSPm9fA8NqoRocSf8swVzge9M/4QuQRBWh3AnJYDj6V9HSeGoZJfMZB16+tSx+GY9/Ea9ee1PniLkZ4Hb+D1ks2gkhVRvB3FOfoBWz4X8ERqX8yBgNwH4CvcIvD8cYGQv4DOKtJo6bxhBgdOe9HtV0D2bPH7bwqj6gJIt0ah9oQdxnqa9EgtZPPiGxkRFHQ1vppKqSNmMHNXPsfOT1xjIqJVLlKFiOzjART0IFaFunzj19KZFFtGCCPerUSEbR3FYtmyRYXpThTR0p1ZGyFzRSUE0hinpWbqX3cY75rRNUL7qD2qobkT2MxuW2gYIqVFAj6ewNKwJIGB70oXEBK5x1rW5kRKMKQ3frUS9CpqZQ25uMjHUe9VXbaSR25piJSu6PBxkGqrybFJ4KjrgU9XJRmJ4FZ01ysWMkgsc8njFNK4mySe5IUtjI9BUJu1QhT91hkZHFZ91PgAjO084U54qnNeELs3CVQcY6bf8KtRIuXr+VJSPKkCPzyDkGuP8RWuEdnKjKj5jyPel1W8KSB4nfZ0znof61jaj4oVFa2uNj4XPI7VaViWzyHXbZF1q8gWJSN+VJGa5290aQMTEu5RjPHP4etd5q02mTagWEyKw524429s1l6iBFeFxt8pVG0huvvSaQJtHNaZbCKZV47Z44P417v8PtRGlxQLIV8tsBsDpz1/D1ryuGKKSWI+XhVIPTOT6101ldmKUpzsX7oPemkhN9T6bZvMSMg53ICD+HFcX4gYJ5gxgg9a6DQ7k3Ph/TpskssSoT344rm/FjbJZgvA+8D9RWcdHY0kzzHxdMTFIM5J59MYryXW5+CM+vevRPF1ydj5JHBryPV7ncT+VVNkRVzPaYbjyOtFZrTHceT19KKx5jp5SbTpMOtd54dmOVwf/r153Zvtcetdh4fuNrKd2COaqmzOqj3TwPcHzAM9+levaM4fy1GPmwAB9a8K8GXYEg5OTg4zXsvhq4LNF+J/IZreSujGO520T5ErHgdM+1cF471DyVKhghfjPtzn86627uPIsAQwGWyfoBXkXjK8utV1RbXTBm4deGYgrCn94+55IFZ0463Lm9DzrUL6dtTOn2CfatRJPA+7EO2f8/4V2ng34blp477WSbu5J35blVPsK6vwf4JtdLiR0USTOuZZW5aQ+pP516BZWqxIFRQABgCrlJImMbiaVpscEIijUKoHatmG3VOgpsS4Ht+dWV9u3vXPJtmyVhFjCkkgE0GPceBUwXnP608LzU3KsQCAAjp+VSCMAdO9ShfSnYouOxCyUqpgg9KkA9qUDNAWGADNB744qTHpTgvGfWlcLDUyRyBUiiheKcKllpCilopQKkoSloooGIapXhGep4FXjVK4A3nJqokT2Mvz1D4IZcd+tSmTKAbgQBSPaq7Zx1PTNRmyXzTyRnjrWuhkCSZcgjFV3cMD0NW0t9uc4IpVhG0gj9KBWMkL8wwWw3PriszUra4K/JGSmMD2rqxCAcmgxLyCAR2GKalYXKee3VrdFDiHkn1FVYrC8eVg8SpHwMqeTnvmu/mt4mPbd2qu9qBkgHB/zmtOcnlPH9Tsb1pmZIejY+91FeTfEH+19NkcS2siKxJ87GR19ulfU9zYgnIQFh69xWFrPhm3vo3YIA7HJquZSJtbU+OodSLFGzucHkE4B+hrqLfWkmtvLMYDDjr2Ndr4/wDhdHO8lzYwray5J/cqAre5FeQ6vpuoaNcbb2NlVTgSL91qlpxHZPY7EXoGNilcDBYcHb7itOzlUyQ+UPlLAMPT/wCtXAW+o5SJGYbjwH9R6V0Xh26Md0yyjKnKg59aaZLVj6d8BX6z6EkecEA9fXNUfGDFo0kGOhT8ua5/4e6h9ljiiZ884/3lPer3i2ctZ3mGx5cgkx+O0/zp21C+h5D4ulA8wdua8k1SQ5YZ716X4unA3DIPWvLNTfMrc96zqM0prUoFjnrRTKK57nVYfEcMK3tLuNjr9a58cVfsptpFXTZFSNz2DwdfYK8Z59a9u8E3fnXXB+SOMs36CvnDwhdCOUZOB/WvefhxLm2mkJy0w2qfQKf/AK/6V1rWJxbM6/xzqhtNFiwcvMWRFzwWJx+WM1g+DtLULukG5ixZnb7zn1P8q0vFFv8AbrzSYW+7bqzSZ/vNgr+n8629KtljRcYAXt0pL3Ylbs2rNFCAAAYq7Gox/niqsIG0df8ACtCGLoSOPSsWaomiTjkYHpVlVHr0qNBjFSgYPQ4rNloeop2OKaAKkAH5UhgB60oHHWnAYNLj2pFWGhaXbTsD8qXHPSlcLDQMClApeBS0XGIBnpTh60lOxSGgpaKKRQUUUUAIarTpknNWqjYDvTTsTIp+XyPSneXlsnBqfYKXFVcixB5QximtFgHnAqzgd6Y4yKLg0UZeAB2FV5WK59KvNFyefxqvLbZ+93qkSY80ygE5yakgmzjJyBwRUlxpQc5BPPNOjsFi5BY561ehOtxJIg5yO9VZItoJWtURrjGPwNRyRZBHr0pJg0c5qNkk4II+X1rhvEnhOxv4pFuLcMjD5lI6/wD169NuIcEentWPewqynA98VrGRDR8heP8AwDdaBM1xpyvNYMfufxx/41jaRqIkSNZGG5RjPrX1ZrejxT27hl3butfOfxE8Jy6HftfWSfuHbcyjoPWhxtqhXvoztPCmt5sFkXhkPTPb/PNdT4gvvNE4UkmaA7fy3fzFeQeDL/ddJuJKFeh78/5Fela8wihtMHmMlD9Mn+hFWndEbOx5V4muhLuPXNef3bkyGuo1yfDshPK/LXIyndIx9656jOmkhlFFFYG4VNbthwKhp8Rw4qo7iex13h+U+cnXrX0f8PyI5dJiJ+Xyd7fRgcmvm3w2v+kIT0zX0T4Zcxw+YhO6PT0APoSo/wAa7aexwz+I9Dg/0lfNY8mQv07Z/wAP5VuWgUADnHYVi6MwlhUZGGGa6CzjOwFvpUyGi/axjv8AWr6DjmqsA9TwKtLzWLNUiYAH14qRRmo0HvUyj3J9KktEij3pwAwKRRx1pw9allJDgBSgUgGKcPrSGGKXik9KO9IYtFJS0AGM0tJS0hi0UfjSUDFooooAKaaWkb2oExMUYFLikxTFYQikIHrTu9JjpQKwwgetNZRUhU+tNI461QrEDoP6VCydcnmrTDk80xh3poTRVIHrTSAR1PFTsvHaoSPQ0ySpPEOazLmEZyB09K2ZB6mqk0faqTE0c1fQhkPHXjmvP/GGlR3NpJHLHuVhgjHf2r06+iIGV6Vyur24kB44FbRZk0fMzaU+h68qA4hd8Kewzwf8a9A8SNu0yzlyc+YUJPqMH/GpfGukLLGWIG5fmDelReIFJ0fGTmNlm6du/wDOqtYjdniPiSXdfXD4Vd0jHaowBz0A7Vzh5JrZ1s7pGbuTmsWuSpudlPYKKKKzNApyfeFNpV+8Ka3A7Pw4o+U4/WvftBJ/s5iO1pCCfbK14L4ZAOz8K910VtmnOPS3hyfxFd9PY8+e56T4Y/exoCchev09K66MADIOa5Hw0PKtYweS4yf6V1UTHbjuKie5cS/HzjnircY9apQZz+tXU9PQVjI0ROoxzUyj0qFT271KnQYJ/GpLJVFPAxTF4FOFSykOx+VLTR+tLSGOFFIKWkMWikp1AIKWko7Uhi0d6SigAA4paSigAxQaKDQAmKCKKKYhMUYooFACYpCKWkamIYQcGmMvH/16lNMIxTQmQsKiZe9TP39uaibnmqJIGHPWq0g7E/SrbjqfSqsgwR600Iz7tOo9e1c3q0GBnqM11E3SsfUFDxMp6VpEzkeW+JYVlRo8/e4Fc14kfzNDLKefsskZx6r0/kK7LW0wz5+8OB7VwWsSbtPlT/ptx9CMVv0Mup4bq44yOnasWtnWcjg+nWsauKpudlPYKKKKzND/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute melioidosis presenting as a left upper lobe infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bart Currie, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_13_41183=[""].join("\n");
var outline_f40_13_41183=null;
